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 The dystrophin-glycoprotein complex (DGC) is a transmembrane structure that links the 
cytoskeleton of muscle cells to the extracellular matrix. Genetic disruption of this complex in 
muscular dystrophies causes sarcolemmal instability that results in injury and death of the 
muscle cells and causes altered activation of mechanosensitive signaling pathways. These 
features suggest dual structural and signaling roles for the dystrophin-glycoprotein complex. 
While much research has focused on protein-protein interactions that enable the DGC’s 
structural function, less is known about how the complex regulates signaling within muscle 
cells. Therefore, the goal of this thesis was to investigate the mechanisms whereby the 
dystrophin-glycoprotein complex regulates muscle nitric oxide (NO) production, a phenomenon 
that is crucial to normal muscle function and is disrupted in several forms of muscular 
dystrophy. A novel live cell imaging assay was developed to measure the mechanical activation 
of NO production in isolated muscle cells and investigate the biochemical signaling pathways 
involved in this process. This investigation identified dystrophin-dependent mechanoregulation 
of AMP-activated protein kinase (AMPK) as a key component of mechanosensitive NO 
production in striated muscle. Since defective muscle NO production contributes to diminished 
exercise tolerance in muscular dystrophy, subsequent studies investigated the therapeutic 
potential for acute pharmacologic AMPK activation to restore striated muscle NO production 
and improve exercise tolerance in a mouse model of dystrophin-deficient muscular dystrophy. 
Acute AMPK activation stimulated NO production in isolated dystrophin-deficient striated 
muscle cells in vitro, and increased the exercise capacity of dystrophin-deficient mice in vivo. 
These results suggest that acute AMPK activation may be a viable therapeutic strategy to 
improve exercise tolerance in muscular dystrophy patients. Finally, a novel transgenic mouse 
model was generated in order to test the contribution of asymmetric dimethylarginine (ADMA), 
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an endogenous nitric oxide synthase inhibitor, to poor exercise tolerance in muscular 
dystrophy. These experiments suggested that ADMA contributes to exercise-induced fatigue in 
female dystrophin-heterozygous mice, a model for female carriers of Duchenne muscular 
dystrophy mutations. They also indicated that ADMA may affect exercise tolerance via effects 
to promote hypertrophy and impair the contractile function of the dystrophin-heterozygous 
heart. Considered together, the findings of this thesis support the idea that nitric oxide 
production is impaired in dystrophin-deficient muscle due to combined effects of disrupted 
intracellular signaling cascades and increased release of endogenous nitric oxide synthase 
inhibitors from damaged cells. Thus, this research provides evidence for the hypothesis that 
both the structural and signaling functions of the dystrophin-glycoprotein complex are critical 











The dystrophin-glycoprotein complex in muscular dystrophy and the role of nitric oxide 
signaling in striated muscle. 
 
Muscle is a mechanically-active tissue that converts the chemical potential energy of adenosine 
triphosphate (ATP) into mechanical work via muscle contraction, allowing for movement of the 
skeleton and the circulation of blood. In order for this process to occur and to continue over a 
lifetime, muscle must have a robust capacity for metabolism to maintain an adequate supply of 
ATP, as well as an ability to withstand both internal and applied external forces, while at the 
same time transmitting forces generated by actin-myosin cross-bridge cycling between 
sarcomeres and between neighboring cells. Meeting the demand for increased work output by 
both the heart and skeletal muscle during exercise requires a capacity for striated muscle to 
dramatically increase metabolic flux, adapt to increased mechanical stress imposed on the 
plasma membrane, and fine-tune the local delivery of oxygen and nutrients to match increased 
metabolic needs. In muscular dystrophies, primary mutations in components of the 
sarcolemmal dystrophin-glycoprotein complex (DGC) and membrane repair proteins impair the 
ability for striated muscle cells to prevent or heal disruptions in the plasma membrane incurred 
during periods of elevated mechanical stress. Such defects directly contribute to death of the 
muscle cells and the progressive muscle degeneration and wasting seen in these diseases. 
Secondary disruptions in DGC-dependent signaling pathways are also observed in muscular 
dystrophies caused by mutations in DGC components. In particular, loss of dystrophin 
expression in Duchenne muscular dystrophy (DMD) is correlated with disruptions in nitric oxide 
(NO) production by neuronal nitric oxide synthase in both skeletal and cardiac muscle, and a 
consequent disruption of NO-dependent regulation of blood flow within the muscle tissue(1). 
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This observation suggests a critical role for dystrophin and the DGC in the regulation of striated 
muscle NO production. However, the precise mechanisms by which dystrophin affects muscle 
NO signaling, and the contribution of disrupted muscle NO signaling to the pathophysiology of 
the muscular dystrophies, is poorly understood and is the foundation for the research of this 
dissertation. The goal of this work is to understand how striated muscle NO production is 
normally regulated by physiological mechanical stresses imposed on the muscle, and how 
genetic disruption of the DGC disrupts this process. Because mechanical stimulation is a 
primary driver for NO production in striated muscle, initial experiments sought to understand 
the role of dystrophin in the cell-intrinsic molecular signaling pathways coupling cell length 
changes to increased cellular nitric oxide production. These experiments were followed by an in 
vivo study testing whether acute pharmacologic activation of the same signaling pathways 
could bypass the defect caused by loss of dystrophin and improve exercise tolerance in a mouse 
model of Duchenne muscular dystrophy. Finally, a novel genetic mouse model was generated 
to explore the potential impact of endogenous cell-extrinsic factors released following 
mechanical injury of dystrophic muscle cells on NO signaling and exercise performance in DMD. 
In order to understand how dystrophin may participate in the regulation of striated muscle 
nitric oxide production, and the potential contribution of disrupted NO signaling to impaired 
muscle function in DMD, this introduction will first review the clinical phenotype of DMD, then 
summarize the literature supporting  a signaling function of the DGC as well as recent evidence 
for a role of reduced striated muscle NO production  in the impaired ability to perform and 
withstand exercise  observed in dystrophinopathies. 
 
Muscular dystrophy and the dystrophin-glycoprotein complex. 
The group of muscle wasting diseases known as muscular dystrophies were first 
described in the mid-1800s by physicians reporting case studies of patients presenting with 
progressive muscle weakness, muscle atrophy, and eventual loss of ambulation(2, 3). The most 
common of these disorders was first characterized in depth by Meryon(4) and Duchenne de 
Boulogne(5). Their reports describe young boys, and in some cases multiple boys within a given 
family, who demonstrated an early difficulty and excessive fatigue with walking or standing, 
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that eventually degenerated into an apparent paralysis with near-complete loss of voluntary 
muscle movement. Meryon noted a sex-specific predisposition to this disorder, citing one 
family consisting of four affected sons and six unaffected daughters(4). While the limb muscles 
of affected boys generally underwent atrophy, Duchenne and Meryon described a peculiar 
hypertrophy of the calf muscles, leading Duchenne to term the disease “pseudo-hypertrophic 
paralysis.” Microscopic examination of the muscle tissue revealed that this apparent 
hypertrophy was not due to increased muscle fiber size, but rather by increased deposition of 
fibro-fatty tissue that replaced atrophying or necrotic muscle cells(4, 5). Furthermore, Meryon 
reported that the nervous tissue of patients was generally unaffected(4), suggesting a primary 
defect originating within the muscle cells themselves.  
In describing the disease that would come to be named Duchenne muscular dystrophy, 
these early case studies touched on hallmark manifestations that are typical of this disorder 
and are shared by several forms of childhood muscular dystrophy. In DMD, the most common 
and prototypic form of these diseases, muscle weakness first becomes apparent in early 
childhood, with affected boys falling more than others, having difficulty standing up from a 
sitting position, and showing difficulty in everyday physical activity like climbing stairs(2, 3). 
Over time, the ability for patients to withstand exercise gradually declines, and patients report 
exaggerated fatigue following even moderate bouts of physical activity(5, 6). Evidence of these 
impairments can be seen as diminished performance in timed function tests or measurements 
of 6-minute walk distance(7, 8). Progressive muscle atrophy further exacerbates patient 
weakness, ultimately leading to patients losing the ability to walk and being confined to a 
wheelchair by their early teenage years(2-5). In some forms of muscular dystrophy, such as the 
mild version of DMD known as Becker muscular dystrophy (BMD), certain types of limb-girdle 
muscular dystrophy (LGMD), and facioscapulohumeral muscular dystrophy (FSHD), such signs of 
muscle dysfunction do not appear until adulthood(9), implying a wide clinical spectrum of 
disease progression in this group of disorders.  
Historically, patients with DMD have died by their early twenties due to complications 
from respiratory failure associated with damage and degeneration of the diaphragm and other 
respiratory muscles(2, 10). However, over the past 20-30 years advances in respiratory 
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interventions, including the use of surgery to correct scoliosis and the use of nocturnal 
ventilators, has allowed patients to survive in to their thirties and in some cases their 
forties(11). Unfortunately, this increase in lifespan has revealed that in addition to the limb and 
respiratory muscles, the cardiac muscle is also affected to varying degrees in as many as 90% of 
DMD patients(12). Cardiac muscle disease in DMD and related dystrophies ranges from 
subclinical electrocardiographic abnormalities, diastolic dysfunction, and cardiac hypertrophy, 
to overt dilated cardiomyopathy and heart failure(10, 12-15). Female carriers of DMD 
mutations do not typically exhibit the characteristic skeletal muscle disease seen in male DMD 
patients. However, DMD carriers are recognized has having a substantially increased rate 
incidence of cardiomyopathy compared to the population at large, indicating that they share 
some of the same cardiac muscle defects as male DMD patients(16-20).  
 Common pathological signs of the muscular dystrophies support a primary defect in 
muscle cell integrity as a unifying feature of these diseases. Clinically, muscular dystrophy 
patients exhibit elevated serum concentrations of proteins that are enriched in muscle, such as 
creatine kinase, lactate dehydrogenase, and cardiac- and skeletal-muscle specific troponin 
isoforms(21, 22). This observation indicates that there is excessive damage to or permeability of 
the plasma membrane of muscle cells in these diseases, allowing for leak of intracellular 
contents out of the muscle cells. Indeed, Meryon noted a breakdown of the sarcolemma upon 
microscopic evaluation of muscle biopsies taken from muscular dystrophy patients as early as 
1852(4). This finding was later corroborated by electron microscopy studies in the 1970s, which 
showed discontinuities in the plasma membrane of DMD muscle that preceded muscle cell 
necrosis(23, 24). Interestingly, a report by Carpenter and Karpati noted the restoration of the 
plasma membrane in regions of the muscle fibers that appeared to have undergone recent 
sarcolemmal injury, providing evidence for endogenous repair mechanisms that exist to heal 
such breaches in the sarcolemma(24).  
Histologically, evidence for muscle damage can be seen by the presence of necrotic 
muscle fibers and infiltration of the tissue with inflammatory cells(25). Dystrophic skeletal 
muscle also displays an increased proportion of small-diameter, centrally-nucleated muscle 
fibers, indicative of cells that have recently undergone regeneration from satellite cells in order 
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to replace dying fibers. As the regenerative capacity of the satellite cells is depleted, damaged 
skeletal muscle cells are instead replaced by fibrotic or fatty tissue (25). Similar signs of cellular 
injury can be seen in the dystrophic heart, with focal replacement of cardiomyocytes with 
fibrosis and fatty infiltrates(26, 27). Such loss of functional muscle cells is the primary driver of 
the severe skeletal muscle wasting, gradual thinning of the wall of the heart, and eventual 
dilated cardiomyopathy observed in DMD. The observation of plasma membrane breakdown 
and resulting cellular damage in DMD, as well as analogous histological findings in the skeletal 
muscle and/or heart in related diseases, led to the formulation of a “sarcolemmal hypothesis” 
for muscular dystrophy(2). This idea proposes that the underlying genetic defects of muscular 
dystrophies result in a common increase in the susceptibility of the muscle cell plasma 
membrane to lesions, especially when under mechanical stress, or otherwise a diminished 
capacity to repair normal amounts of damage incurred on otherwise healthy membranes. 
 Mutations in the X-linked DMD gene that encodes the 427-kDa, cytoskeletal protein 
dystrophin were identified as the genetic basis for Duchenne and Becker muscular dystrophy in 
1986-1988(28-32). This breakthrough opened the door to a molecular understanding of the 
mechanisms of the muscular dystrophies. Since then, identification of the genetic causes of the 
various limb-girdle and congenital muscular dystrophies revealed a preponderance of genes 
encoding proteins that are functionally clustered at or near the muscle cell plasma membrane, 
in addition to proteins of the extracellular matrix(9). Subsequent biochemical studies revealed 
that dystrophin localizes to the interior of the muscle cell membrane and is concentrated at 
structures called costameres that overlie the z-line(33). There, dystrophin binds to the sub-
sarcolemmal actin cytoskeleton and to an assembly of transmembrane glycoproteins including 
dystroglycan and the sarcoglycans in a complex that came to be known as the dystrophin-
glycoprotein complex, or DGC(34-41) (Fig. 1.1). In muscle, α-dystroglycan binds in a 
glycosylation-dependent manner to extracellular matrix proteins such as laminin(36), agrin(42-
44), and perlecan(45, 46) that contain multiple LamG domains. Thus, the core components of 
the dystrophin-glycoprotein complex form a structural linkage between the interior and 
exterior of the muscle cell. Finally, several additional accessory proteins complete the DGC: α- 
and β-syntrophin and α-dystrobrevin bind to dystrophin on the intracellular side of the DGC(47, 
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48), and the membrane-spanning protein sarcospan associates with the sarcoglycans(49) (Fig. 
1.1). 
 
Structural function of the dystrophin-glycoprotein complex in plasma membrane 
stabilization. 
 Resolution of the primary structure of the components of the dystrophin-glycoprotein 
complex and their protein interactions suggested a putative role for this complex as a molecular 
shock absorber that stabilizes the plasma membrane against the mechanical stresses 
experienced during muscle contraction or stretch(36, 50). Indeed, one recent study 
demonstrated a critical role for dystrophin and the DGC in transmitting the force of contraction 
from the interior of the muscle cell to the extracellular matrix and neighboring fibers(51). The 
authors of this work proposed that this function might help to maintain sarcomeres in register 
and to distribute the forces of muscle contraction evenly along the sarcolemma, preventing the 
development of excessive, injurious forces at any given point of the membrane. Such a force-
dissipating, protective function of the DGC would explain why muscular dystrophies in which 
DGC components are mutated present with compromised integrity of the plasma membrane 
that ultimately leads to death of the muscle fibers. In recent years, the development of genetic 
animal models for these “DGC-opathies” has enabled the direct investigation of this stabilizing 
function of the complex. Given that the primary loss of dystrophin in DMD can result in 
secondary reductions in sarcolemmal expression of the remaining DGC proteins in both skeletal 
and cardiac muscle(52-55), the following paragraphs will focus on animal models of DMD as a 
prototypic example of DGC disruption and its consequences for membrane stability. 
 Like DMD patients, dystrophin-deficient mdx mice  exhibit elevated plasma 
concentrations of creatine kinase (CK), necrotic muscle fiber degeneration, increased muscle 
fiber size variability and central nucleation, and increased muscle fibrosis(56, 57), features that 
are consistent with a defect in sarcolemmal integrity. Early experiments in mdx mice noted a 
particular susceptibility for muscle fiber damage in the diaphragm, and the investigators 
proposed that this increased susceptibility to injury compared to other skeletal muscles 
resulted from the continuous contractile activity of the diaphragm throughout life(58). These 
7 
 
same authors later used membrane-impermeant dyes to demonstrate that dystrophin 
specifically protects the sarcolemma from lesions during the increased mechanical stress 
imposed on it during muscle contraction(59). Consistent with this model, numerous in vitro and 
in situ investigations have reported exceptional susceptibility of dystrophin-deficient muscle to 
damage during “eccentric” or “lengthening” contractions, in which the load against which the 
muscle contracts is greater than the force generated by contraction and results in elongation of 
the muscle. Such eccentric contraction- or lengthening contraction-induced injury in mdx 
muscle is indicated by increased uptake of membrane impermeant dyes as well as a rapid drop 
in force production following repeated contractions(60-62). Delayed signs of eccentric 
contraction-induced injury include an increased incidence of fiber necrosis and IgG infiltration 
into damaged fibers(63). Experiments using intact mdx mice have shown that the stresses of 
eccentric muscle contraction during downhill treadmill running result in excessive CK release 
and increased dye uptake into the skeletal muscles, suggesting that such eccentric contraction-
induced muscle injury is indeed a legitimate component of the muscle damage observed in vivo 
in DMD(64, 65). The phenotype of excessive membrane fragility can also be observed directly in 
isolated dystrophin-deficient muscle fibers. Studies using passive mechanical stretching report 
an exaggerated drop in force production and excessive permeability to extracellular cations, 
notably calcium, following eccentric contractions(66-68), recapitulating  the findings from intact 
muscle. Furthermore, the application of hypo-osmotic stress to swell cells reveals an 
exaggerated sensitivity of dystrophin-deficient muscle fibers to membrane blebbing, 
hypercontracture, and leak of pyruvate kinase, suggesting increased sarcolemmal permeability 
when mechanical stress is placed on the membrane(69). However, the relative contribution of 
abnormal membrane lesions versus excessive activation of stretch-activated ion channels to 
calcium overload and cell death in these models remains a topic of debate(67, 68).  
Dystrophin-deficient cardiac muscle also shows an exaggerated sensitivity to membrane 
injury when under mechanical stress. Aged mdx mice exhibit increased focal cardiomyocyte 
damage compared to wild-type mice(70), a phenotype that is exacerbated when animals are 
subjected to aortic banding and pressure overload(71). Over time, damaged cardiomyocytes 
are replaced by fibrosis and mdx animals develop dilation of the left ventricle, consistent with 
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features of the cardiomyopathy seen in DMD patients(10, 12, 26, 27). When subjected to acute 
β-adrenergic stress, as would be experienced during exercise, mdx hearts rapidly 
decompensate, showing a dramatic reduction in systolic pressure generation within as little as 
30 minutes of administration of a β-agonist(55, 72, 73). This decline in cardiac function is 
associated with increased release of lactate dehydrogenase(74, 75) and increased staining of 
cardiomyocytes with membrane-impermeant Evan’s blue dye(73, 75). These observations 
demonstrate that like dystrophin-deficient skeletal muscle fibers, dystrophin-deficient 
cardiomyocytes are more susceptible than healthy cardiomyocytes to sarcolemmal disruption 
under conditions of increased mechanical stress. Direct investigation of isolated mdx 
cardiomyocytes that are passively stretched in vitro revealed a reduced tolerance for such 
mechanical deformations. Compared to wild-type cardiomyocytes, mdx cardiomyocytes were 
more susceptible to stretch-induced calcium overload that resulted in cell contracture and 
death(72). This study further demonstrated that these defects in mdx cells could be corrected 
by treatment with a poloxamer 188, a polymer that can insert into the lipid bilayer and is 
thought to seal breaches in the plasma membrane. Together with the observations noted in 
isolated skeletal muscle fibers above, these cellular findings support a cell-intrinsic defect in 
sarcolemmal stability as a causative mechanism for the functional impairments and muscle 
damage evident following periods of increased mechanical stress in dystrophin-deficient 
striated muscle. Analogous findings of primary sarcolemmal instability have been observed in 
models of α-dystroglycan glycosylation-deficient muscular dystrophies(76, 77) and 
sarcoglycanopathies(78), suggesting a role not only for dystrophin itself, but rather for the 
function of the DGC as a whole to mechanically couple the interior and exterior of the muscle 
cell, in protecting the sarcolemma. 
 
The dystrophin-glycoprotein complex in cellular signaling.  
Beyond the classically-accepted role for dystrophin and the DGC in supporting the 
sarcolemma, recent work suggests additional, signaling functions of the complex. Several 
groups noted early on that the soleus muscle of dystrophin-deficient mice is specifically 
protected from contraction-induced injury(60, 61, 79), despite the fact that it still exhibits 
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hallmark features of dystrophic muscle pathology such as an increased proportion of recently-
regenerated fibers(80). The soleus muscle of α-dystroglycan glycosylation-deficient mice 
similarly demonstrates an increased resistance to contraction-induced injury compared to other 
skeletal muscles, yet still remain weaker than the wild-type soleus(81). Finally, muscle 
degeneration has been observed in the absence of mechanical muscle injury in mice lacking γ-
sarcoglycan(82). Collectively, these observations indicate that additional mechanisms distinct 
from sarcolemmal instability may contribute to the pathophysiology of the various diseases 
caused by DGC disruption. The inability for the sarcolemmal hypothesis to explain such 
membrane integrity-independent aspects of the DGC-opathies has contributed to the 
development of a complementary, “signaling hypothesis” for muscular dystrophy. 
Initial investigations of a putative signaling function for the DGC compared the response 
of dystrophin-deficient and wild-type muscle cells to applied mechanical stretch, a stimulus that 
has long been known to activate a variety of signaling pathways in striated muscle(83, 84). One 
early study reported excessive activation of MAP kinase signaling upon stretch of fibers from 
the dystrophin-deficient mdx diaphragm, an effect that the authors attributed to excessive 
entry of extracellular calcium(85). However, it was not fully clear from this work whether 
excessive calcium flux and its effects on signaling was a direct consequence of lesions in the 
plasma membrane as would be suggested by the sarcolemmal hypothesis, or rather a 
consequence of increased activity of stretch-activated ion channels consistent with the 
signaling hypothesis. Additional evidence in favor of a signaling function of the DGC in calcium 
homeostasis was provided by the later  finding that blocking mechanosensitive ion channels 
could reduce the incidence of abnormal calcium release events, or “sparks,” from the 
sarcoplasmic reticulum during osmotic challenge of dystrophin-deficient muscle fibers(86). 
Parallel investigations have shown additional pathways, notably PI3K/Akt signaling, to be hyper-
activated by stretch of dystrophin-deficient muscle(87).  
How might the dystrophin-glycoprotein complex exert its effects upon cell signaling? A 
leading hypothesis is that the DGC regulates cell signaling via direct physical interactions with 
signaling proteins. This notion is perhaps most clearly illustrated by the finding that the 
syntrophins mediate direct protein-protein interactions between the DGC and TRPC cation 
10 
 
channels(88, 89). Such a model could help to explain how disruption of the DGC leads to altered 
mechano-activation of these channels and excessive calcium entry upon muscle stretch. Apart 
from ion channels , components of the DGC also bind to a variety of known signaling molecules 
including MEK and ERK(90), archvillin(91),  a Grb2-Sos1 complex(92, 93), and heterotrimeric G 
protein subunits(94, 95). These observations have led to the notion that in addition to direct 
regulation of the activity of signaling proteins, the DGC may play a critical role in scaffolding 
signaling proteins near important interacting partners or sites of action, thus serving a 
permissive function in the transduction of the pathways in which these proteins participate. To 
date, the effects of DGC disruption on many of these proteins, and the contribution of the 
signaling pathways in which they act to the pathophysiology of muscular dystrophy, remain 
uncertain. However, in the last twenty years it has become apparent that the DGC has a clear 
and critical role in the regulation of neuronal nitric oxide synthase (nNOS), an enzyme that is 
essential for normal striated muscle function. 
 
Nitric oxide as a critical regulator of the cardiovascular system and striated muscle. 
Neuronal nitric oxide synthase is one of a family of three mammalian enzymes that 
catalyze the production of nitric oxide from the reduction of molecular oxygen and oxidation of 
the amino acid, L- arginine (Fig. 1.2). Both nNOS and the closely-related isoform, endothelial 
nitric oxide synthase (eNOS), are constitutively expressed in select tissues, whereas the 
expression of inducible nitric oxide synthase (iNOS) is stimulated by cytokines in disease 
states(96). The enzymatic activity of nNOS and eNOS requires the binding of calcium to 
calmodulin, which reversibly associates with homodimers of these isoforms(96). nNOS and 
eNOS activity is further subject to post-translational regulation by phosphorylation of a number 
of stimulatory or inhibitory residues, notably nNOS serine 1412/eNOS serine 1177 (stimulatory) 
and nNOS serine 841/eNOS threonine 495 (inhibitory)(96-98). Finally, all three NOS isoforms 
are subject to endogenous competitive inhibition by methylated arginine species generated by 
the proteolysis of proteins that have been modified by a class of enzymes known as protein 
arginine methyltransferases (PRMTs)(99). The presence of endogenous inhibitors such as 
methylated arginines and active arginase that depletes arginine in cells is thought to explain the 
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“arginine paradox,” where supplemental arginine can increase NOS activity despite circulating 
arginine levels being 25- to 30-fold higher than the Michaelis-Menten constant of isolated 
purified NOS in vitro(100). 
In skeletal muscle, nNOS is found near the sarcolemma, where it binds to the 
dystrophin-glycoprotein complex via direct interactions with α1-syntrophin as well as 
dystrophin itself(101-104) (Fig. 1.3A). This anchoring of nNOS at the sarcolemma and near the 
periphery of the muscle fiber facilitates the diffusion of nitric oxide out of the muscle fiber and 
to local arterioles within the vascular bed of the muscle tissue. Within the arteriolar smooth 
muscle, skeletal muscle-derived NO stimulates soluble guanylyl cyclase to produce cyclic 
guanosine monophosphate (cGMP), which stimulates the activity of protein kinase G (PKG). 
PKG in turn promotes smooth muscle relaxation via the activating phosphorylation of myosin 
light chain phosphatase, the phosphorylation of phospholamban to increase calcium uptake 
into the sarcoplasmic reticulum, and the activation of potassium channels to oppose 
depolarization and contraction of the smooth muscle cell(105-108). Investigations measuring 
blood flow in the rodent hindlimb demonstrated that such skeletal muscle-derived NO is critical 
for the local regulation of muscle blood flow in the face of increased sympathetic tone, as 
occurs during exercise. In this process, known as sympatholysis, contraction of the skeletal 
muscle triggers nNOS to produce NO, which attenuates α-adrenergic vasoconstriction of the 
local arterioles and thus helps to maintain blood flow and the delivery of oxygen and nutrients 
to the contracting skeletal muscle(109, 110). Mechanical stimulation such as contraction or 
stretch also triggers the activation of nNOS and eNOS within cardiomyocytes(111, 112). While 
endothelial cell-derived NO is thought to be a major determinant of coronary artery blood flow, 
it is possible that an analogous mechanism of mechanically-activated cardiomyocyte-derived 
NO production may also contribute to local blood flow regulation within the heart(113-115). 
In addition to paracrine effects on blood flow, there is an increasing body of evidence to 
suggest that nNOS has intrinsic effects on the contractile function of both skeletal and cardiac 
muscle cells. In healthy skeletal muscle, nNOS has been reported to attenuate contractile force, 
thought to occur through activation of cGMP production as in smooth muscle(116). 
Paradoxically, studies using nNOS knockout mice have demonstrated reduced maximal force 
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generating capacity in nNOS-deficient skeletal muscle, although this feature could presumably 
be explained by a decrease in cross-sectional area of the muscles tested, as overall muscle mass 
was reduced in nNOS knockout animals and specific force was not altered(117). This same work 
reported that nNOS-deficient muscles were more susceptible than controls to contraction-
induced fatigue, even though they did not exhibit any increase in susceptibility to eccentric 
contraction-induced injury. In vivo experiments demonstrating that nNOS-null mice exhibit a 
dramatic reduction in voluntary physical activity following an acute bout of treadmill 
running(118) suggest that the muscle fatigue observed in situ in nNOS knockout animals is 
recapitulated as a behavioral phenotype at the  level of the intact animal. Together, these data 
support the contention that nNOS exerts important physiological roles within the muscle, and 
may do so via effects that are independent of plasma membrane stability. Percival et al. also 
later noted localization of an nNOS splice variant in the Golgi apparatus of skeletal muscle, and 
showed it to be critical for the regulation of muscle fatigue resistance and post-exercise force 
generation, distinct from effects on blood flow(119). This observation indicated that skeletal 
muscle NO production may be compartmentalized in discrete functional domains, and that 
additional mechanisms besides vasoregulation may contribute to the physiological control of 
muscle function by nNOS. 
nNOS also regulates the contractility of cardiomyocytes, tending to favor relaxation and 
enhance the diastolic function of the myocardium. These effects are mediated in part by PKG- 
or protein kinase A-dependent phosphorylation of phospholamban serine 16(120-122), leading 
to enhanced SERCA function and calcium uptake into the sarcoplasmic reticulum. Studies of 
nNOS knockout mice suggest that myocardial nNOS also reduces calcium current density and 
calcium transient amplitude, thus attenuating contractile force development(111, 123, 124). 
These effects are likely mediated by direct actions of NO to nitrosylate and inhibit L-type 
calcium channels(125), although evidence also exists supporting inhibitory phosphorylation of 
the L-type calcium channel by PKG(126, 127). Furthermore, as PKG can target the myofilament 
proteins titin(128) and troponin I(129), nNOS- or eNOS-derived cardiomyocyte NO may also 
facilitate diastolic function by increasing the passive distensibility of the myocardium and 




Disruption of nitric oxide signaling and phenotypic consequences in muscular dystrophy. 
In the mid-1990s, immunohistochemical studies of tissue from DMD patients and mdx 
mice noted a striking loss of nNOS from the sarcolemma of dystrophin-deficient skeletal muscle 
cells (Fig. 1.3B). In contrast to wild-type skeletal muscle, nNOS tended to become localized to 
the cytosol of dystrophin-deficient fibers, and total cellular nNOS activity was reduced 
compared to healthy controls(101, 102). This reduction in total nNOS activity was partially 
explained by an overall reduction in nNOS mRNA and protein content, indicating some degree 
of transcriptional silencing of nNOS and possibly increased degradation of the mislocalized 
nNOS protein(101, 102). Similar observations of altered nNOS localization and function were 
later reported in other instances of DGC disruption, including Becker muscular dystrophy(132), 
dystroglycan deficiency(133), sarcoglycan deficiency(134), syntrophin deficiency(135, 136), and 
dystrobrevin deficiency(137). These findings suggest that nNOS dysregulation may be a 
common feature underlying the pathophysiology of multiple forms of muscular dystrophy. 
The functional consequences of disrupted nNOS function in dystrophin-deficient skeletal 
muscle were made clear by studies of vascular function in mdx mice. Thomas et al. reported 
that sympatholysis is attenuated in dystrophin-deficient animals, recapitulating a characteristic 
phenotype of nNOS-null animals(1). These observations suggested that disruption of nNOS 
signaling in dystrophin-deficient muscle specifically contributed to an impaired regulation of 
muscle blood flow. Indeed, whereas wild-type mice respond to exercise with an increase in limb 
muscle blood flow, this phenomenon is abrogated in mdx mice(118). The additional findings of 
abnormal vascular function and reduced contraction-induced skeletal muscle cGMP production 
that paralleled the loss of sarcolemmal nNOS in δ- or β-sarcoglycan(138, 139) or α-dystrobrevin 
deficient mice(137) provided further support for the notion that sarcolemmal NO production is 
critical for the ability of the skeletal muscle to exert regulatory control over the local 
vasculature. Given a demonstrated cell-intrinsic role for nNOS in muscle fatigue resistance(117), 
defective nNOS signaling may also help to explain the increased susceptibility of dystrophin-
deficient muscle fibers to fatigue(140).  
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Recent in vivo investigations indicate that disrupted nNOS signaling contributes to 
impaired exercise tolerance in dystrophin-deficient mdx mice. Compared to wild-type, these 
animals exhibit exaggerated fatigue following treadmill running that closely resembles the 
phenotype of nNOS-null animals(118), as well as reduced endurance during exercise(141). 
Studies by the Campbell lab showed that post-exercise muscle blood flow could be increased 
and exercise-induced fatigue could be prevented in mdx mice treated with a phosphodiesterase 
5 (PDE5) inhibitor to boost cGMP signaling. This intervention failed to correct exercise-induced 
fatigue in nNOS-null mice(118), implying that NO/cGMP-dependent regulation of muscle blood 
flow is critical to the prevention of such fatigue. Impaired nNOS-dependent vasoregulation has 
also been demonstrated in Duchenne and Becker muscular dystrophy patients(142, 143), 
prompting several investigations into whether PDE5 inhibition might also improve blood flow 
regulation and exercise tolerance in these populations(144-146). 
 
Current model of DGC-dependent regulation of nNOS. 
 The work described above supports the notion that misregulation of muscle nNOS 
activity is an important component of the disease phenotype in DMD and suggests that 
enhancement of muscle nNOS signaling may improve exercise tolerance in this disease. 
However, the precise regulatory mechanisms that normally activate nNOS during muscle 
contraction, and the exact pathways by which DGC disruption alters nNOS function, remain 
poorly understood.  
 Collectively, the skeletal muscle investigations described in the preceding paragraphs 
led to the development of a model in which dystrophin or the DGC as a whole is critical for 
scaffolding nNOS near the plasma membrane of the muscle cell, where the NO that it produces 
during muscle contraction can signal in a paracrine fashion to promote the dilation of nearby 
arterioles (Fig. 1.3A). This model also proposes that the binding of nNOS to the DGC is required 
for basal and contraction-induced nNOS enzymatic activity. When the DGC is disrupted, as 
occurs with genetic loss of dystrophin in DMD, nNOS is mislocalized from the sarcolemma to 
the cytosol, where its enzymatic activity is reduced (Fig. 1.3B). Although this model is consistent 
with a requirement for a physical interaction between nNOS and the DGC in the stimulation of 
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muscle nNOS activity, direct evidence for this hypothesis is lacking. Indeed, the observation that 
transgenic over-expression of nNOS in dystrophin-deficient muscle can increase total muscle 
NO production, even without restoration of nNOS-DGC scaffolding interactions(147, 148), 
argues against an absolute necessity for protein-protein interactions with the DGC for nNOS 
activity.  
 This current model also fails to explain recent data regarding nNOS activity in 
dystrophin-deficient cardiac muscle. nNOS activity was first demonstrated to be decreased in 
total homogenates of mdx mouse hearts in 1999(149), and this reduction in cardiac nNOS 
activity was later localized specifically to the dystrophin-deficient cardiomyocytes (150). nNOS 
impairment could explain some of the characteristic functional defects of dystrophin-deficient 
hearts, such as decreased cardiomyocyte compliance(72), impaired relaxation and diastolic 
distensibility(14, 55, 73), and aberrant calcium handling(151). These observations suggest that 
like in skeletal muscle, impaired nNOS signaling is a relevant component of the pathophysiology 
of the dystrophin-deficient heart. They also raise the possibility that cardiac effects of disrupted 
nNOS,  in addition to local effects within the skeletal muscle and skeletal muscle vasculature, 
contribute to the impaired exercise phenotype common to dystrophin-deficient and nNOS-
deficient animals(118). 
 Notably, the study by Ramachandran et al. reported that the total mRNA and protein 
content of nNOS was not altered in mdx versus wild-type cardiomyocytes, indicating that the 
overall decrease in nNOS activity in mdx cells was due to impaired activation of nNOS, rather 
than attributable to a net reduction in total nNOS expression. Immunohistochemical staining of 
nNOS in mouse cardiac tissue revealed that in contrast to skeletal muscle, nNOS was not 
specifically enriched at the sarcolemma of either wild-type or dystrophin-deficient 
cardiomyocytes(150). This finding corroborated results from another group that demonstrated 
that nNOS co-immunoprecipitates with dystrophin and other DGC components in skeletal 
muscle but not cardiac muscle(152). Taken together, these results indicate that in cardiac 
muscle, dystrophin expression does affect the activity of nNOS, but does so via some 
mechanism that is independent of a direct physical scaffolding interaction with nNOS (Fig. 1.3 C 
and D). As nNOS protein levels and localization are not affected by loss of dystrophin, I 
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hypothesized that dystrophin- or DGC-dependent regulation of this enzyme likely occurs at the 
level of post-translational modification of nNOS. Importantly, this alternative model also calls 
into question whether skeletal muscle nNOS activity does in fact rely on direct protein-protein 
interactions between nNOS and the DGC, or rather may be regulated by intermediate 
dystrophin-dependent signaling pathways.  
 
Rationale and Experimental Approach. 
 Studies of skeletal and cardiac muscle have suggested an important role for neuronal 
nitric oxide synthase in striated muscle. Furthermore, evidence from animal models of 
Duchenne muscular dystrophy indicates that impaired muscle nNOS activity contributes to 
impaired skeletal muscle and heart function, and, consequently, a diminished capacity for 
exercise in this disease. These observations point to a critical role for dystrophin in striated 
muscle NO signaling. However, the specific mechanisms by which muscle NO production is 
regulated, and the precise role of dystrophin and the dystrophin-glycoprotein complex in this 
process, are unclear. Therefore, the overall goal of the work in this thesis was to determine the 
mechanistic role of dystrophin in the regulation of striated muscle nitric oxide production. The 
overall hypothesis is that dystrophin regulates biochemical signaling pathways that allow the 
transduction of mechanical cues into the stimulation of nitric oxide synthase activity. This 
hypothesis was tested with the following specific aims: 
 
Specific Aim 1: Determine the direct, cell-intrinsic mechanisms by which dystrophin affects 
striated muscle NO signaling. 
 
The purpose of this set of experiments, described in Chapter 2, was to investigate the 
involvement of dystrophin in mechanosensitive signaling pathways that participate in the post-
translational regulation of nitric oxide synthase activity. A novel live-cell imaging assay was 
developed that used in vitro stretch of adult mouse cardiomyocytes as a model to investigate 
mechanosensitive nitric oxide signaling in fully-differentiated striated muscle. The mechanical 
activation of the upstream nNOS kinase, AMP-activated protein kinase (AMPK), and the 
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subsequent stimulatory phosphorylation of nNOS at serine 1412 and activation of NO 
production was impaired in dystrophin-deficient cardiomyocytes as compared to wild-type. 
These data support a model in which dystrophin-dependent mechanoactivation of AMPK is 
critical for the mechanical stimulation of nNOS activity in striated muscle. This model is 
consistent with a role for dystrophin and the dystrophin-glycoprotein complex as an important 
mechanotransducer within muscle. Finally, this study shows that acute pharmacologic 
activation of AMPK, either with the AMP-analog AICAR or with salicylate, is sufficient to bypass 
defective mechanosignaling and increase nNOS activity in dystrophin-deficient cardiomyocytes 
in vitro, providing proof-of-concept evidence for this approach to increase striated muscle NO 
production in Duchenne muscular dystrophy. 
 
Specific Aim 2: Test pharmacologic activation of AMPK-NO signaling as a strategy to improve 
exercise tolerance in the mdx mouse model of Duchenne muscular dystrophy.  
 
 The experiments performed in this Aim expanded on the findings from Aim 1 and sought 
to determine whether direct pharmacologic AMPK activation could stimulate increased NO 
production in dystrophin-deficient skeletal muscle in vitro, and whether acute pharmacologic 
AMPK activation in vivo could improve exercise tolerance in dystrophin-deficient mice. The 
results, discussed in Chapter 3, demonstrate that acute treatment with AICAR or salicylate 
increases the exercise capacity of dystrophin-deficient mice. This study also shows that like in 
dystrophin-deficient cardiac muscle, acute treatment with the AMPK-activating drug, salicylate, 
is sufficient to stimulate nitric oxide production in isolated dystrophin-deficient skeletal muscle 
fibers. In contrast, treatment with AICAR does not stimulate NO production in dystrophin-
deficient skeletal muscle fibers, suggesting there may be important differences between cardiac 
and skeletal muscle in the subunit composition of AMPK heterotrimers that target nitric oxide 
synthase. Together with the findings from Chapter 2, the results of this investigation suggest 
that acute AMPK activation may a viable therapeutic strategy to improve exercise tolerance in 




Specific Aim 3: Understand the impact of secondary effects of dystrophin-deficiency on striated 
muscle NO signaling and exercise tolerance in Duchenne muscular dystrophy.  
 
The increased degree of muscle damage, cell death, and inflammation within 
dystrophin-deficient striated muscle raises the possibility that the pathologic milieu of this 
tissue may perturb cell signaling, thus affecting cellular nitric oxide production not as a direct 
consequence of the loss of dystrophin, but rather as a secondary consequence of changes in 
the muscle cell microenvironment. Indeed, patients with Duchenne muscular dystrophy and 
dystrophin-deficient mdx mice exhibit elevated circulating concentrations of methylated 
arginines, modified amino acids that can act as endogenous inhibitors of the nitric oxide 
synthases. Chapter 4 describes experiments designed to test the hypothesis that excessive 
asymmetric dimethylarginine inhibits muscle NO production and contributes to exercise 
intolerance in DMD. Injury of otherwise healthy skeletal muscle with cardiotoxin resulted in 
increased circulating methylated arginine levels, supporting the notion that these compounds 
are elevated in DMD as a result of increased damage to the dystrophin-deficient muscle. 
Impairment of exercise performance in wild-type mice infused with exogenous ADMA indicated 
that this compound was sufficient to affect exercise, even in the absence of dystrophy. 
Dystrophin-deficient and dystrophin-heterozygous mice expressing a transgene encoding 
dimethylarginine dimethylaminohydrolase 1 (DDAH), an enzyme that degrades ADMA, were 
generated and assessed on treadmill running assays in order to examine the contribution of 
ADMA to exercise tolerance in DMD. Surprisingly, DDAH transgene expression attenuated 
exercise-induced fatigue in female dystrophin-heterozygous animals, but not in male 
dystrophin-deficient animals. This improvement in exercise tolerance was associated with 
reduced heart weight, improved cardiac contractile function, and improved chronotropic 
responsiveness to β-adrenergic stimulation in transgenic female dystrophin-heterozygous mice. 
Collectively, these observations support a model in which methylated arginines diminish 
resistance to exercise-induced fatigue in DMD carriers, potentially by promoting the 




Chapter 5 will summarize the principle findings of this thesis and describe how they fit 
into a new integrated model for the DGC’s structural and signaling roles in the regulation of 
striated muscle nitric oxide signaling. The chapter concludes by discussing some unanswered 
questions regarding the mechanisms of AMPK regulation by the dystrophin-glycoprotein 
complex, the potential contribution of ADMA to cardiac remodeling in muscular dystrophy, and 
the potential applications of this thesis work given the current state of therapies targeting 
















Figure 1.1. The structure of the dystrophin-glycoprotein complex. The dystrophin-
glycoprotein-complex (DGC) is found at the plasma membrane of muscle cells, where it 
forms a functional linkage between the cytoskeleton and the extracellular matrix. This 
linkage is formed by binding of dystrophin to sub-sarcolemmal actin and to the 
transmembrane protein, β-dystroglycan. β-dystroglycan in turn associates with the α-
dystroglycan, which is heavily glycosylated and mediates binding of the complex to matrix 
proteins such as laminin. β-dystroglycan also binds to a sub-complex comprised of the 
sarcoglycans and sarcospan. Additional accessory proteins including α- and β-syntrophin 
and α-dystrobrevin bind near the C-terminus of dystrophin to complete the DGC. (Adapted 


















Figure 1.2. The production of nitric oxide by nitric oxide synthases. The three mammalian 
forms of nitric oxide synthase (NOS) (neuronal nitric oxide synthase, endothelial nitric oxide 
synthase, and inducible nitric oxide synthase) catalyze the production of nitric oxide (NO). In 
this reaction, NADPH provides electrons for the reduction of molecular oxygen, which is 


















Figure 1.3. Functional relationships between nNOS and the dystrophin-glycoprotein 
complex in striated muscle. (A) The current model for dystrophin-dependent regulation of 
nNOS activity relies on a direct physical interaction between nNOS and the dystrophin-
glycoprotein complex (DGC), as is observed in healthy wild-type (WT) skeletal muscle. (B) 
When dystrophin is lost, as occurs in Duchenne muscular dystrophy (DMD), nNOS-DGC 
binding is disrupted and nNOS is mislocalized to the cytosol. Mislocalization of nNOS is 
correlated with diminished nNOS enzymatic activity. (C) In healthy cardiac muscle, nNOS is 
expressed but does not bind to the DGC. (D) Diminished cardiac muscle nNOS activity in 
DMD supports an alternative model in which dystrophin is required for the appropriate 
regulation of nNOS activity, but does so via a mechanism that does not depend on direct 
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Dystrophin-glycoprotein complex regulates muscle nitric oxide production through 




Patients deficient in dystrophin, a protein that links the cytoskeleton to the extracellular matrix 
via the dystrophin-glycoprotein complex (DGC), exhibit muscular dystrophy, cardiomyopathy, 
and impaired muscle nitric oxide (NO) production. We used live-cell nitric oxide imaging and in 
vitro cyclic stretch of isolated adult mouse cardiomyocytes as a model system to investigate if 
and how the DGC directly regulates the mechanical activation of muscle NO signaling. Acute 
activation of NO synthesis by mechanical stretch was impaired in dystrophin-deficient mdx 
cardiomyocytes, accompanied by loss of stretch-induced neuronal nitric oxide synthase (nNOS) 
S1412 phosphorylation. Intriguingly, stretch induced the acute activation of AMP-activated 
protein kinase (AMPK) in normal cardiomyocytes but not in mdx cardiomyocytes, and specific 
inhibition of AMPK was sufficient to attenuate mechanoactivation of NO production. Therefore, 
we tested whether direct pharmacologic activation of AMPK could bypass defective mechanical 
signaling in order to restore nNOS activity in dystrophin-deficient cardiomyocytes. Indeed, 
activation of AMPK with 5-aminoimidazole-4-carboxamide riboside or salicylate increased nNOS 
S1412 phosphorylation and was sufficient to enhance NO production in mdx cardiomyocytes. 
We conclude that the DGC promotes the mechanical activation of cardiac nNOS by acting as a 
mechanosensor to regulate AMPK activity, and that pharmacologic AMPK activation may be a 







The muscular dystrophies are a group of muscle wasting disorders characterized by progressive 
weakening and degeneration of striated muscle. The most common form is Duchenne muscular 
dystrophy (DMD), an X-linked disorder caused by genetic disruption of dystrophin(1) that 
affects 1 in 3500-5000 males(2, 3). DMD and several other types of muscular dystrophy result 
from disruption of the dystrophin-glycoprotein complex (DGC), a structure that spans the 
sarcolemma and forms a mechanical linkage between the cytoskeleton and the extracellular 
matrix via the association of dystrophin with subsarcolemmal γ-actin and the binding of α-
dystroglycan to laminin(4). The generally accepted role for this complex is to act as a molecular 
shock absorber and stabilize the plasma membrane during muscle contraction. Disruption of 
the DGC’s linkage between the cytoskeleton and extracellular matrix, such as occurs in DMD(1, 
5-7) or with the disruption of α-dystroglycan-laminin binding in glycosylation-deficient muscular 
dystrophies(8, 9), leads to destabilization of the plasma membrane, rendering skeletal muscle 
fibers and cardiomyocytes susceptible to stretch- or contraction-induced injury and cell 
death(10-14).   
In addition to this structural role, a signaling function for the DGC has been proposed 
based on its association with several signaling proteins including Grb2-Sos1(15), MEK and 
ERK(16), heterotrimeric G-protein subunits(17, 18), archvillin(19), and neuronal nitric oxide 
synthase (nNOS)(20-22). The current dogma is that the DGC serves as a passive scaffold for 
these molecules, anchoring them near sites of action or important partners, with genetic 
disruption of the DGC leading to mislocalization, destabilization, or ineffective recruitment of 
these molecules to the complex(23). In healthy skeletal muscle, nNOS binds to the DGC via 
direct physical interactions with dystrophin and α-1 syntrophin(20, 22, 24) and is thus anchored 
near the sarcolemma. During muscle contraction, nitric oxide (NO) produced from nNOS  is 
thought to signal in a paracrine fashion to the vascular smooth muscle of arterioles that supply 
the skeletal muscle with blood, thereby locally counteracting vasoconstriction induced by 
increased sympathetic tone during exercise(25, 26). In DMD, genetic loss of dystrophin results 
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in secondary mislocalization of nNOS from the skeletal muscle sarcolemma(20, 21) and 
impaired muscle NO production is observed. Disrupted muscle NO signaling impairs muscle 
blood flow regulation in dystrophin-deficient mice(27) and results in markedly exaggerated 
fatigue following exercise(28). Severe muscle fatigue is also a prominent feature of human 
DMD, and its improvement is considered an important clinical outcome for therapies, such that 
the six minute walk test is an important endpoint for clinical trials in DMD(29). Despite growing 
appreciation of the physiological implications of disrupted muscle NO production, it remains 
unclear whether impaired nNOS activation in dystrophin-deficient skeletal muscle is a 
consequence of disrupted scaffolding of nNOS to the DGC, or whether the DGC acts as a 
mechanosensor in a mechanosignaling pathway that regulates nNOS activity. Furthermore, 
mechanical stimulation enhances nNOS and endothelial nitric oxide synthase (eNOS) activity in 
cardiac muscle(30, 31), but whether such mechanosensitive cardiac NOS signaling occurs via 
one of these two possible mechanisms or depends on dystrophin is unknown. 
 Two reports have suggested that dystrophin-deficient hearts(32) and 
cardiomyocytes(33) exhibit impaired nNOS activity. Despite this apparent similarity of the effect 
of dystrophin-deficiency on cardiac and skeletal muscle NOS signaling, another recent study 
demonstrated that in contrast to skeletal muscle, nNOS is not physically associated with the 
DGC in cardiac muscle(34). These interesting observations suggest that dystrophin and the 
DGC’s impact on NO signaling may not result from a purely scaffolding function of the DGC for 
nNOS in striated muscle. Therefore, we hypothesized that dystrophin and the DGC act as a 
mechanosensor to couple the muscle cell’s mechanical activity to a biochemical signaling 
pathway leading to NO production, independent of a direct physical interaction between NOS 
and the DGC.  
We used cardiomyocytes as a model for striated muscle, and performed in vitro 
mechanical stretching to investigate the direct involvement of dystrophin in mechanically-
activated muscle NO signaling and the potential role of the DGC as a mechanosensor. Here we 
report that acute mechanical activation of NO production is impaired in dystrophin-deficient 
mouse cardiomyocytes, and identify disrupted mechano-AMPK-nNOS signaling as a key 
component of altered NO production in these cells. These findings suggest that dystrophin and 
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the DGC play more than a passive structural role in striated muscle, and rather may be active 
participants in mechanotransduction. Finally, we demonstrate that acute pharmacologic 
activation of AMPK is sufficient to restore nNOS activity and NO production in dystrophin-
deficient cardiomyocytes, and propose that this may be a suitable strategy to bypass disrupted 
mechanical signaling and restore NO production in dystrophin-deficient striated muscle. 
 
MATERIALS AND METHODS 
 
Mice: Control wild-type (WT) C57 and dystrophin-deficient mdx mice were used at 8-25 weeks, 
before the development of dystrophic cardiomyopathy(35). All animals were housed at the 
University of Michigan’s Unit for Laboratory Medicine and all procedures were approved by the 
University of Michigan Committee for the Use and Care of Animals.  
Cardiomyocyte isolation and general plating conditions: Cardiomyocytes were isolated 
from adult mouse hearts using methods we have described previously(36). After isolation, 
cardiomyocytes were resuspended in plating medium (Table 2.1) and plated for 2 hours as 
described below.  
In vitro cardiomyocyte nitric oxide imaging: Cardiomyocytes were plated on individual 
35mm-diameter FlexCell membranes (FlexCell International) coated with 50ug/mL mouse 
laminin (Invitrogen; 23017-015) at 30,000 cells/membrane. Following plating, cardiomyocytes 
were switched to culture medium (plating medium without serum), and then loaded with the 
nitric oxide-sensitive dye, 4-Amino-5-Methylamino-2’,7’-Difluorofluorescein Diacetate (DAF-
FM-DA) (Molecular Probes; D-23842). Cardiomyocytes on FlexCell membranes were incubated 
in imaging buffer (Table 2.2) containing 20µM DAF-FM-DA for 40 minutes in the dark at 37oC. 
Cardiomyocytes were then washed in fresh imaging buffer without DAF-FM-DA for 20 minutes 
in the dark at 37oC, then washed again for 5 minutes at room temperature. In experiments 
using enzyme inhibitors, inhibitors or appropriate vehicle controls were first added to buffer 
during this 5-minute wash. Membranes were then loaded into a StageFlexer Jr. stretch chamber 
connected to a FX-4000T Flexercell Tension Plus system (FlexCell International) and covered 
with fresh imaging buffer. The stretch chamber was secured on the stage of an Olympus BX51 
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upright epifluorescence microscope and a 10x field of view was visualized under the FITC 
channel using a 6% neutral density filter. Images of the same field of view were recorded at 0, 
10, 30, and 60 minutes of 12% 1Hz stretch or drug treatment. After imaging, the fluorescence of 
all rod-shaped, non-fibrillatory cardiomyocytes was quantified using ImageJ, with background 
fluorescence subtracted. Changes in cellular DAF-FM fluorescence intensity over the 1-hour 
imaging period were expressed as the change in fluorescence over initial (0-minute) 
fluorescence (ΔF/F0). Inhibitors and other reagents used in these studies were as follows:  NG-
Nitro-L-arginine-methyl ester hydrochloride (L-NAME) (100µM) (Enzo; ALX-105-003), S-Nitroso-
N-acetylpenicillamine (SNAP) (100µM) (Calbiochem; 487910), vinyl-L-NIO hydrochloride (VLNIO) 
(100µM) (Cayman Chemical; 80330), Compound C  (10µM) (Cayman Chemical; 11967), 5-
aminoimidazole-4-carboxamide riboside (AICAR) (2mM) (Cayman Chemical; 10010241), and 
sodium salicylate (10mM) (Sigma; S2679). 
In vitro stretch protocol: Cardiomyocytes were plated on 6-well BioFlex culture plates 
(FlexCell International) coated with laminin at 30,000 cells/well in plating medium 
supplemented with 25µM blebbistatin (Toronto Research Chemicals; B592500).  
Stretch for western blotting: Following plating, cardiomyocytes were changed to 
culture medium containing 25µM blebbistatin and serum-starved for 4 hours. BioFlex plates 
were loaded into a baseplate housed within a tissue culture incubator and connected to a FX-
4000T Flexercell Tension Plus system (FlexCell International). Cardiomyocytes were subjected to 
15% cyclic stretch at 1Hz for 0-60 minutes based on methods we have described previously(14).  
Stretch for cGMP analysis: Cardiomyocytes were stretched for 60 minutes as described 
above. Stretched cardiomyocytes and non-stretched controls were then washed in DPBS and 
lysed in 0.1M HCl for 20 minutes. Lysates were centrifuged for 10 minutes at 1000 x g, and the 
supernatants were stored at -80oC until use. cGMP concentration in cardiomyocyte lysates was 
analyzed using a cyclic GMP EIA kit (Cayman Chemical; 581021) according to the manufacturer’s 
instructions, and was normalized to protein concentration based on the DC Protein Assay (Bio-
Rad; 500-0116).  
Drug treatments for western blot analysis: Cardiomyocytes were plated on 60mm 
tissue cultures dishes coated with laminin in plating medium supplemented with 25 µM 
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blebbistatin. After plating, cardiomyocytes were switched to culture medium containing 25µM 
blebbistatin and serum-starved for 4 hours. Cardiomyocytes were treated with AICAR or sodium 
salicylate for 0-60 minutes. 
Cardiomyocyte lysis for western blot analysis: After stretch or drug treatment, 
cardiomyocytes were washed in DPBS and then lysed in ice-cold Triton-X lysis buffer 
supplemented with protease and phosphatase inhibitors (Table 2.3). Lysates were sonicated for 
10 seconds and then centrifuged for 2 minutes at 14000 x g at 4oC. Lysate supernatants were 
collected and stored at -80oC until use. 
Heart collection and tissue preparation for western blot analysis: Hearts were 
collected from anesthetized mice. The atria and large vessels were removed, then the ventricles 
were drained of blood, snap frozen in liquid nitrogen, and stored at -80oC. Approximately 50mg 
of tissue per heart was added to ice-cold Triton-X lysis buffer containing protease and 
phosphatase inhibitors, minced with scissors, homogenized, and then sonicated twice for 10 
seconds. Heart lysates were centrifuged at 14000 x g for 10 minutes at 4oC. Lysate supernatants 
were collected and stored at -80oC until use. 
Western blot analysis: Protein concentration in lysates was quantified using a DC 
Protein Assay. 100 µg protein of each sample was separated on 3-15% (wt/vol) gradient 
polyacrylamide gels and then transferred to polyvinylidene fluoride membranes (Millipore; 
IPVH00010). Membranes were then blocked in 5% (wt/vol) nonfat dry milk (NFDM) or 5% 
(wt/vol) BSA (Fisher; BP1600) in Tris-buffered saline + 0.05% Tween 20 (TBST) for 1 hour. 
Following blocking, membranes were incubated overnight at room temperature with the 
appropriate primary antibody. Primary antibodies included the following rabbit polyclonal 
antibodies: dystrophin (Abcam; ab15277), phospho-nNOS-serine 1412 (Abcam; ab5583), nNOS 
(Cell Signaling; 4234), and AMPKα (Cell Signaling; 2532); and the following rabbit monoclonal 
antibodies: phospho-AMPKα-threonine 172 (Cell Signaling; 2535), phospho-acetyl-CoA 
carboxylase-serine 79 (Cell Signaling; 11818), and acetyl-CoA carboxylase (Cell Signaling; 3676). 
After incubation with primary antibodies, blots were washed 3 times for 10 minutes each in 
TBST and then incubated for 1 hour at room temperature with horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories; 111-
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035-144). Membranes were washed 3 times for 10 minutes each in TBST, then exposed using 
SuperSignal West Pico or Dura chemiluminescent substrate (ThermoFisher; 34080 and 34075). 
Images of blots were recorded with an Alpha Innotech western blot documentation system, 
and band intensities quantified with AlphaEaseFC software.  
Cardiomyocyte Immunofluorescence: WT and mdx cardiomyocytes were plated on 6-
well BioFlex culture plates and stretched for 0-10 minutes as described for Western blot 
analysis. After stretching, the cells were fixed for 15 minutes in 3% paraformaldehyde, washed 
three times for 5 minutes each in PBS, and then incubated overnight at 4oC in block solution 
consisting of 1x PBS, 5% BSA, 0.5% Triton-X, and 50mM ammonium chloride. After blocking, the 
FlexCell membranes with attached cardiomyocytes were excised from wells of the BioFlex 
culture plates with a scalpel and placed on glass slides. The excised membranes were then 
incubated for 1.5 hours at room temperature with the appropriate primary antibodies diluted 
in block solution without ammonium chloride. Primary antibodies included the following rabbit 
polyclonal antibodies: nNOS (Cell Signaling; 4234) and AMPKα (Cell Signaling; 2532); and mouse 
monoclonal MANDRA1 dystrophin (Sigma-Aldrich; D8043). After incubation with primary 
antibodies, membranes were washed three times for 5 minutes each in PBS and then incubated 
for 1 hour at room temperature with secondary antibodies diluted in block solution without 
ammonium chloride containing DAPI (Sigma-Aldrich; D9564). Secondary antibodies were as 
follows: Alexa Fluor 488-conjugated goat anti-rabbit (Invitrogen; A-11034), Cy3-conjugated rat 
anti-mouse (Jackson ImmunoResearch Laboratories; 415-165-166), Cy3-conjugated goat anti-
rabbit (Jackson ImmunoResearch Laboratories; 111-165-144), and Alexa Fluor 488-conjugated 
goat anti-mouse (Jackson ImmunoResearch Laboratories; 115-546-062). Membranes were then 
washed three times for 5 minutes each in PBS, and a glass coverslip was mounted on top of 
each membrane using PermaFluor (Thermo Scientific; TA-030-FM). Images were captured using 
a 60x objective on a Nikon A-1 Spectral confocal microscope. 
Statistics: All data are presented as mean ± SE. Significance was determined by the 






Mechanical stretch activates NO production in adult mouse cardiomyocytes.  
To investigate mechanically-activated muscle NO signaling, we established an assay 
using the NO-sensitive dye, DAF-FM-DA, to monitor cellular NO production during in vitro cyclic 
stretch of isolated adult mouse cardiomyocytes. Upon entering cells, DAF-FM-DA is cleaved to 
form 4-amino-5-methylamino-2’,7’-difluorofluorescein (DAF-FM), which increases in 
fluorescence upon irreversible binding with nitric oxide(37) and thus can be used to assess 
cumulative cellular NO production over time. 1Hz cyclic stretch of wild-type cardiomyocytes 
elicited a significant increase in DAF-FM dye fluorescence over the course of an hour compared 
to non-stretched cells (Fig. 2.1 A and B). This stretch-induced increase in DAF-FM fluorescence 
was abolished by incubation of the cardiomyocytes with the general nitric oxide synthase 
inhibitor, L-NAME, verifying that the stretch-induced increase in dye fluorescence was due to 
increased NO production (Fig. 2.1B). DAF-FM fluorescence was also increased by treating cells 
with the exogenous NO donor, SNAP (Fig. 2.1B).  
 
Stretch-dependent NO signaling is disrupted in dystrophin-deficient cardiomyocytes.  
We then used this assay to test whether dystrophin is required for mechanically-
activated NO signaling in cardiac muscle. Under resting conditions, we detected no difference in 
changes in DAF-FM dye fluorescence between WT and dystrophin-deficient mdx 
cardiomyocytes (Fig. 2.1C). However, the increase in DAF-FM dye fluorescence during stretch 
was significantly attenuated in mdx cardiomyocytes compared to WT cardiomyocytes (Fig. 
2.1C), suggesting that dystrophin is required for appropriate mechanical activation of NO 
production in cardiac muscle. Treatment with SNAP after the stretch period produced a 
significant increase in DAF-FM fluorescence in both WT and mdx cardiomyocytes (Fig. 2.1D). 
This finding verifies that mdx cardiomyocytes did effectively retain the dye, and that the 
diminished increase in dye fluorescence during stretch of these cells was indeed attributable to 
impaired NO production, rather than an artifact of the dye leaking out of the excessively 
permeable or damaged plasma membranes that are characteristic of dystrophic 
cardiomyocytes(14, 38). Measurement of cellular cGMP content downstream of NO production 
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revealed no differences between WT and mdx cardiomyocytes at rest (Fig. 2.1E). One hour of 
1Hz stretch increased cGMP content in WT cardiomyocytes, but this effect was abrogated in 
mdx cardiomyocytes (Fig. 2.1F). These data further support the idea that the loss of dystrophin 
disrupts mechanically-activated cardiac NO production and may have physiologically-relevant 
consequences on downstream signaling.  
 
Stretch-induced nNOS phosphorylation is impaired in dystrophin-deficient cardiomyocytes.  
This defect in mechanically-activated NO signaling prompted us to investigate the 
mechanism coupling dystrophin to cardiac NOS activity. Given that mRNA and protein content 
of the constitutively-expressed nitric oxide synthases, nNOS and eNOS, are not reduced in mdx 
hearts(33), we hypothesized that impaired mechano-NO production in dystrophin-deficient 
cardiomyocytes was related to misregulation of post-translational modification required for 
NOS activity. The enzymatic activity of both nNOS and eNOS is under multiple levels of 
regulatory control that include phosphorylation of several stimulatory or inhibitory residues(39, 
40). Biochemical analysis revealed a significantly reduced ratio of serine 1412-phosphorylated 
to total nNOS in mdx versus WT heart lysates (Fig. 2.2). Interestingly, phosphorylation at this 
site increases nNOS activity(41).  
To investigate whether decreased nNOS phosphorylation in dystrophin-deficient hearts 
in vivo was due to disrupted mechanical signaling, we compared the impact of stretch on nNOS-
serine 1412 phosphorylation state in WT and mdx cardiomyocytes in vitro. Phosphorylation of 
this residue increased significantly over basal levels within 10 minutes of 1Hz stretch in WT 
cardiomyocytes (Fig. 2.3A). Incubation of WT cardiomyocytes with the nNOS-specific inhibitor 
vinyl-L-NIO attenuated the stretch-induced increase in NO production (Fig. 2.3B), verifying that 
increased nNOS-serine 1412 phosphorylation during stretch was indeed associated with 
increased nNOS activity. Intriguingly, stretch failed to elicit an increase in nNOS-serine 1412 
phosphorylation in mdx cardiomyocytes (Fig. 2.3A). Immunofluorescence labeling revealed that 
nNOS was localized in the cytoplasm, in a striated pattern, and in the nucleus and was not 
specifically enriched at the sarcolemma of WT or mdx cardiomyocytes at rest (Fig. 2.4), in 
agreement with previous reports (33, 34). Moreover, stretch did not lead to membrane 
42 
 
recruitment of nNOS or otherwise discernibly alter nNOS localization in either WT or mdx cells 
(Fig. 2.4). Collectively, these results suggest that the loss of dystrophin impairs the mechanical 
activation of cardiac nNOS not by disrupting a physical interaction between nNOS and the DGC, 
but rather by disrupting mechanical signaling that regulates nNOS phosphorylation state and 
activity.  
 
Stretch-induced AMPK phosphorylation is impaired in dystrophin-deficient cardiomyocytes.  
We next sought to determine the mechanosensitive signaling pathway that couples 
dystrophin to stretch-induced activation of nNOS. AMP-activated protein kinase (AMPK) 
phosphorylates nNOS-serine 1412 in multiple cell types including skeletal muscle(42-45), and 
can be activated by mechanical stimulation of cardiac muscle(46, 47). Therefore, we 
investigated the involvement of AMPK in dystrophin-dependent mechano-nNOS signaling in 
cardiomyocytes. Western blot analysis demonstrated that stretch of WT cardiomyocytes 
increased phosphorylation of the catalytic alpha subunit of AMPK at threonine 172 (Fig. 2.3A), a 
modification that reflects increased AMPK activity(48). Stretch of WT cardiomyocytes also 
increased phosphorylation of the classical AMPK substrate acetyl-CoA carboxylase (ACC) at 
serine 79 (Fig. 2.3A), reinforcing the idea that stretch activates AMPK. Incubation with the 
AMPK inhibitor Compound C attenuated the stretch-induced increase in DAF-FM fluorescence 
in WT cardiomyocytes (Fig. 2.3C), confirming that AMPK activation contributes to mechanically-
induced NO production in these cells. Notably, 1Hz stretch of mdx cardiomyocytes failed to 
increase phosphorylation of AMPKα-threonine 172 and ACC-serine 79 (Fig. 2.3A), indicating 
that dystrophin is required for appropriate mechanical activation of AMPK. These findings 
further imply that impaired mechanoactivation of AMPK contributes to impaired 
mechanoactivation of nNOS in dystrophin-deficient muscle. Similar to nNOS, AMPK displayed 
striated cytoplasmic and nuclear staining and was not associated with the sarcolemma in WT or 
mdx cardiomyocytes either at rest or after stretch (Fig. 2.5), raising the possibility that 




Pharmacologic AMPK activation restores nNOS activity in dystrophin-deficient 
cardiomyocytes. 
There is increasing interest in using AMPK activation as a therapeutic strategy to 
improve muscle pathology in Duchenne muscular dystrophy. Chronic activation of AMPK with 
administration of the AMP analog AICAR(49) in mdx mice has been shown to promote a slow, 
oxidative muscle phenotype, increase utrophin expression, and enhance sarcolemmal stability 
in skeletal muscle(50), and to reduce ongoing muscle damage and increase skeletal muscle 
strength(51, 52). Whether any of these effects depend on increased NO production, and 
whether AMPK activation can enhance NO production in the dystrophic heart, are unclear. 
Therefore, we tested whether acute pharmacologic activation of AMPK is sufficient to restore 
nNOS activity in dystrophin-deficient cardiomyocytes. Indeed, treatment with AICAR or with the 
AMPK-activating drug salicylate(53) significantly increased DAF-FM dye fluorescence in mdx 
cardiomyocytes compared with vehicle controls and at levels similar to treated WT 
cardiomyocytes (Fig. 2.6 A and C). Inhibition of nNOS with vinyl-L-NIO attenuated AICAR- and 
salicylate-induced increases in DAF-FM fluorescence in mdx cardiomyocytes (Fig. 2.6 B and D). 
Consistent with these data, acute 60-minute treatment with AICAR or salicylate increased the 
activating phosphorylation of AMPKα-threonine 172, and increased stimulatory 
phosphorylation of nNOS-serine 1412, in both WT and mdx cardiomyocytes (Fig. 2.7 A and B). 
Together, these results indicate that AMPK stimulates NO production in cardiomyocytes, and 
that acute pharmacologic AMPK activation is sufficient to restore nNOS activity in dystrophin-




Thirty years of research into the molecular mechanisms of the muscular dystrophies have 
supported an important structural role for the dystrophin-glycoprotein complex in stabilizing 
the plasma membrane of striated muscle cells. Increasing evidence suggests that the integrity 
of the DGC also has important consequences for cell signaling(15-22); however, the passive 
effects of the DGC to scaffold signaling proteins(23) have not yet been distinguished from the 
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potential for the DGC to participate actively as a mechanosensor to regulate cellular signaling. 
This question is particularly pertinent to elucidating the mechanisms of muscle NO signaling, 
considering that whether impaired nNOS function in DMD is a direct structural consequence of 
disrupted localization of nNOS to the sarcolemma by the DGC, or whether disruption of the 
DGC leads to altered post-translational regulation of nNOS activity, has remained unclear.  
 Here, we used adult cardiomyocytes as a model of differentiated striated muscle to 
address the hypothesis that the DGC functions directly as a mechanosensor to regulate nitric 
oxide signaling in muscle. Our observation of impaired mechanically-stimulated nNOS-serine 
1412 phosphorylation in dystrophin-deficient cardiomyocytes provides direct mechanistic 
evidence of why nNOS activity is impaired in dystrophin-deficient cardiac muscle. It is also 
consistent with an earlier report of reduced nNOS activity in total lysates from mdx mouse 
hearts(32), given that the heart is stimulated mechanically by contraction in vivo. Moreover, the 
fact that such dystrophin-dependent mechanical nNOS signaling is independent of a physical 
interaction between nNOS and the cardiac DGC suggests that the DGC is not merely a passive 
scaffold for nNOS, but rather is an active regulator of a signaling pathway that controls nNOS 
activity in cardiac muscle, and possibly in skeletal muscle as well. A model in which dystrophin 
loss results in loss of AMPK-dependent regulation of nNOS would also help to explain why 
deletion of nNOS does not dramatically worsen muscle pathology in mdx mice(54, 55), because 
the activation of any nNOS expressed in dystrophin-deficient muscle would already be 
impaired.  
 One potential candidate kinase for regulating nNOS phosphorylation was AMPK. Our 
finding that mechanical activation of AMPK contributed to NO production in WT 
cardiomyocytes and was impaired in mdx cardiomyocytes suggests that impaired stretch-
induced activation of nNOS with loss of dystrophin is due to impaired mechanical activation of 
AMPK. The identification of a dystrophin-AMPK-nNOS mechanical signaling axis in adult striated 
muscle is particularly interesting given the finding that the activation of AMPK by stretch of 
alveolar epithelial cells depends on dystroglycan(56), a core component of the muscle DGC. 
Together, these observations indicate that DGC-AMPK signaling may be an important 
component of mechano-sensing across multiple cell and tissue types. AMPK expressed in 
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cardiac muscle did not appear to colocalize with dystrophin at the sarcolemma. Thus, in future 
studies it will be important to determine the mechanism by which the DGC regulates AMPK 
activity, such as through regulation of the putative AMPK kinases liver kinase B1 (LKB1) or 
calcium-calmodulin-activated protein kinase kinase-β (CaMKKβ), or perhaps by preventing the 
excessive production of reactive oxygen species during stretch(57).   
 AMPK has been identified as an important therapeutic target in a variety of disorders, 
including diabetes and aging, and plays an important role in long-term adaptation of muscle to 
exercise. We demonstrate that acute, direct pharmacologic AMPK activation by either AICAR or 
salicylate mechanistically targets altered nNOS regulation and is sufficient to restore nNOS 
activity in dystrophin-deficient cardiac muscle. Several other strategies to boost NO and 
downstream cGMP signaling in the dystrophin-deficient heart have been tested, including 
transgenic myocardial expression of an nNOS transgene(58) and chronic administration of 
phosphodiesterase 5 inhibitors(35). Such studies have yielded mixed results in animal models, 
with modest improvements in cardiac function and pathology. Furthermore, human trials have 
offered little evidence of a beneficial cardiac effect of sildenafil treatment in adults with 
Duchenne or Becker muscular dystrophy(59, 60). In light of our findings, it is possible that the 
shortcomings of these previous studies reflect the existence of other functional targets of 
muscle-derived NO, or additional targets of altered AMPK regulation, that contribute to 
dysfunction in dystrophic muscle(45, 61, 62). This possibility warrants further investigation into 
whether acute AMPK activation can yield therapeutic benefit to dystrophic patients through the 
restoration of heart or skeletal muscle NO signaling.  
Together, our data support a model in which dystrophin or an intact DGC is required as 
a mechanosensor for the appropriate activation of AMPK by mechanical stimulation in cardiac 
muscle. Dystrophin-dependent mechanical activation of AMPK then triggers stimulatory 
phosphorylation of nNOS-serine 1412, leading to increased cellular NO production. Loss of 
dystrophin expression in DMD uncouples mechanical stimulation from the activation of AMPK, 
ultimately leading to a failure to appropriately activate nNOS and resulting in impaired 
mechano-NO production. Further study is needed to clarify the contributions of disrupted 
mechano-AMPK-NO signaling to cardiac dysfunction in DMD and to determine whether 
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disrupted mechano-AMPK signaling similarly contributes to the disease phenotype, including 
nNOS impairment, in dystrophin-deficient skeletal muscle. Importantly, AMPK signaling may 
provide a new pharmacological target for restoring defective NO regulation in striated muscle 
and for improving cardiac and skeletal muscle blood flow in muscular dystrophy and other 
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Figure 2.1. Stretch-dependent NO signaling is impaired in dystrophin-deficient 
cardiomyocytes. (A) Experimental setup. Adult mouse cardiomyocytes loaded with DAF-FM are 
visualized under 10x magnification using an epifluorescence microscope throughout 1 hour of 
1Hz stretch. (Scale bars = 100 µm). DAF-FM fluorescence in each rod-shaped, non-fibrillatory 
cardiomyocyte is quantified throughout the protocol. (B) Validation of NO imaging assay. 
Stretch of WT cardiomyocytes induces a significant increase in DAF-FM fluorescence (*P<0.05, 
**P<0.01, ****P<0.0001 stretch vs. no stretch + vehicle). Incubation with the NOS inhibitor L-
NAME abolishes the stretch-induced increase in DAF-FM fluorescence (^P<0.001, ^^P<0.0001 
stretch + vehicle vs. L-NAME). Treatment with the NO donor SNAP yields a significant increase 
in DAF-FM fluorescence (‡P<0.01, ‡‡‡P<0.0001 SNAP vs. no stretch + vehicle). (C) The increase 
in DAF-FM fluorescence during stretch is significantly lower in mdx cardiomyocytes compared 
to WT cardiomyocytes (*P<0.05, **P<0.01 WT vs. mdx stretch). (D) Treatment with SNAP after 
stretch yields similar increases in DAF-FM fluorescence in WT and mdx cardiomyocytes. (E) 
There is no significant difference in cGMP concentration between WT and mdx cardiomyocytes 
before stretch (n=8 mice). (F) The change in cGMP concentration downstream of NO in 







Figure 2.2. Stimulatory nNOS phosphorylation is impaired in dystrophin-deficient hearts in 
vivo. The ratio of phospho-Ser1412-nNOS to total nNOS is significantly reduced in mdx hearts 













Figure 2.3. Stretch-induced nNOS and AMPK activation are impaired in dystrophin-deficient 
cardiomyocytes. (A) Acute stretch of WT cardiomyocytes elicits increased phosphorylation of 
nNOS at the stimulatory residue serine 1412, increased activating phosphorylation of AMPKα at 
threonine 172, and increased phosphorylation of ACC at serine 79 (*P<0.05 vs. WT control). 
These effects are attenuated in mdx cardiomyocytes (#P<0.05 vs. WT stretch) (n=6 mice). (B) 
The increase in DAF-FM fluorescence during stretch of WT cardiomyocytes is significantly 
reduced in cells incubated with the nNOS-selective inhibitor vinyl-L-NIO (*P<0.05, **P<0.01 
stretch + vehicle vs. vinyl-L-NIO). (C) The increase in DAF-FM fluorescence during stretch of WT 
cardiomyocytes is significantly reduced in cells incubated with the AMPK inhibitor Compound C 






Figure 2.4. nNOS localization in adult mouse cardiomyocytes is not altered by acute stretch or 
dystrophin deficiency. WT and mdx cardiomyocytes exhibit cytoplasmic and nuclear 
localization of nNOS (green) at rest. nNOS is not specifically enriched at the sarcolemma and 
does not co-localize with dystrophin (red). 1Hz cyclic stretch does not lead to a discernible 






Figure 2.5. AMPKα localization in adult mouse cardiomyocytes is not altered by acute stretch 
or dystrophin deficiency. WT and mdx cardiomyocytes exhibit cytoplasmic and nuclear 
localization of AMPKα (red) at rest. AMPKα is not specifically enriched at the sarcolemma and 
does not co-localize with dystrophin (green). 1Hz cyclic stretch does not lead to a discernible 








Figure 2.6. Pharmacologic AMPK activation increases nNOS activity in dystrophin-deficient 
cardiomyocytes. (A) Treatment with AICAR elicits a significant increase in DAF-FM fluorescence 
in both WT and mdx cardiomyocytes (*P<0.01 WT AICAR vs. vehicle; ^P<0.01, ^^P<0.001 mdx 
AICAR vs. vehicle). (B) nNOS inhibition with vinyl-L-NIO attenuates the increase in DAF-FM 
fluorescence induced by AICAR in mdx cardiomyocytes (*P<0.001, **P<0.0001 AICAR + vehicle 
vs. AICAR + vinyl-L-NIO). (C) Treatment with salicylate elicits a significant increase in DAF-FM 
fluorescence in both WT and mdx cardiomyocytes (*P<0.0001 WT salicylate vs. vehicle; 
^P<0.0001 mdx salicylate vs. vehicle). (D) nNOS inhibition with vinyl-L-NIO attenuates the 
increase in DAF-FM fluorescence induced by salicylate in mdx cardiomyocytes (*P<0.0001 







Figure 2.7. Pharmacologic AMPK activation increases stimulatory nNOS phosphorylation in 
dystrophin-deficient cardiomyocytes. (A) Acute treatment of WT and mdx cardiomyocytes with 
the AMPK activator AICAR increases activating phosphorylation of AMPKα at threonine 172, 
and increases stimulatory phosphorylation of nNOS at serine 1412 (*P<0.05, **P<0.01 vs. 
control) (n=6 mice). (B) Acute treatment of WT and mdx cardiomyocytes with the AMPK 
activator salicylate increases activating phosphorylation of  AMPKα at threonine 172, and 












Table 2.1. Plating Medium Composition. 
Reagent Final Concentration 
MEM (Gibco 1157-032)  
Fetal bovine serum 5% 
Penicillin G sodium salt  100U/mL 
Glutamine 2mM 
Bovine serum albumin  0.2% 
NaHCO3  4mM 



















Table 2.2. Imaging Buffer Composition. 











L-arginine HCl 0.01 















Table 2.3. Triton-X Lysis Buffer Composition. 
Reagent Final Concentration 
NaCl 150mM 
Tris pH 7.5 50mM 





Aprotinin 2 KIU/mL 
Leupeptin 1ug/mL 
NaF 50mM 
Sodium orthovanadate 1mM 
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Acute pharmacologic activation of AMPK improves exercise tolerance in a mouse model of 




Duchenne muscular dystrophy (DMD) results from mutations in dystrophin and causes 
progressive muscle wasting and excessive fatigue upon exercising. Exercise intolerance in DMD 
has been attributed to impaired neuronal nitric oxide synthase (nNOS)-dependent nitric oxide 
(NO) production in the striated muscle, which leads to misregulation of local blood flow and 
inadequate perfusion of the muscles during exercise. We previously demonstrated that in 
dystrophin-deficient cardiomyocytes, impaired activation of AMP-activated protein kinase 
(AMPK) contributes to diminished activation of nNOS in response to mechanical stress, and that 
acute activation of AMPK with 5-aminoimidazole-4-carboxamideriboside (AICAR) or salicylate 
restores nNOS-dependent NO production. Therefore, we hypothesized that by increasing 
striated muscle nNOS activity, acute pharmacologic activation of AMPK would improve muscle 
blood flow and the exercise phenotype of dystrophin-deficient mice. Here, we used live-cell NO 
imaging and treadmill running assays to investigate whether acute pharmacologic AMPK 
activation stimulates NO production in dystrophin-deficient skeletal muscle in vitro, and 
whether acute pharmacologic AMPK activation improves exercise tolerance in vivo in the mdx 
mouse model of DMD. Incubation with an AMPK-activating drug, salicylate, caused a rapid 
increase in cellular fluorescence in isolated mdx flexor digitorum brevis fibers loaded with the 
NO-sensitive dye, DAF-FM-DA. In treadmill running assays, acute treatment with salicylate or 
AICAR increased the time and distance that mdx mice were able to run before reaching 
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exhaustion. We conclude that acute pharmacologic AMPK activation stimulates NO production 
in dystrophin-deficient skeletal muscle like it does in cardiac muscle, and that AMPK activation 
in vivo is sufficient to improve exercise tolerance in dystrophin-deficient animals. This work 
extends upon our previous findings in cardiomyocytes and provides proof-of-concept evidence 
for acute pharmacologic AMPK activation as a therapy to restore striated muscle NO signaling 




Duchenne muscular dystrophy (DMD) is a fatal, X-linked muscle wasting disease caused by 
mutations in the gene encoding the cytoskeletal protein, dystrophin(1, 2). Loss of dystrophin 
and disruption of the associated transmembrane dystrophin-glycoprotein complex (DGC) is 
thought to destabilize the sarcolemma of striated muscle cells, rendering these cells susceptible 
to contraction- or stretch-induced injury and cell death(3-8). Beyond playing an important 
structural function to protect striated muscle cells against mechanical injury, growing evidence 
suggests that the DGC also regulates biochemical signaling pathways, often by scaffolding 
signaling proteins at critical sites of action or near important interacting proteins, as has been 
recently reviewed by Constanin(9). The most widely-studied role of dystrophin and the DGC in 
cell signaling is their impact on nitric oxide (NO) production induced by the mechanical activity 
of striated muscle. In healthy skeletal muscle, this phenomenon of contraction-induced NO 
production is critical for sympatholysis, the process by which skeletal muscle contraction 
attenuates sympathetic vasoconstriction of the arterioles supplying the skeletal muscle with 
blood(10). In the heart, local NO production is similarly stimulated by stretch or contraction, 
and is thought to contribute to the regulation of coronary blood flow as well as the intrinsic 
systolic and diastolic properties of the myocardium(11-19).  
When dystrophin expression is disrupted in DMD, NO signaling becomes disrupted in 
both skeletal muscle fibers and cardiomyocytes(20-23). In dystrophin-deficient skeletal muscle, 
such impaired NO signaling is associated with the loss of scaffolding interactions between nNOS 
and the DGC and consequent mislocalization of nNOS away from the sarcolemma and into the 
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cytoplasm(20, 24). Disruption of sympatholysis secondary to impaired nNOS activation during 
exercise has been demonstrated to contribute to excessive exercise-induced fatigue in the 
dystrophin-deficient mdx mouse model of DMD(25, 26), and may help to explain impaired 
sympatholysis in boys with this disease(27). It has also been proposed that transient ischemia 
resulting from impaired muscle NO signaling contributes to muscle cell injury and necrosis in 
DMD(28), and that disruption of local NO production contributes to impaired function and 
excessive fatigability of dystrophin-deficient hearts and skeletal muscle in a manner distinct 
from the vascular effects of NO(21, 29, 30). Thus, the restoration of striated muscle NO 
production has gained considerable attention as a therapeutic goal to help maintain skeletal 
muscle and cardiac function and to alleviate exercise intolerance in DMD patients.  
Early reports demonstrating the ability for transgenic approaches that boost nNOS 
expression in the dystrophin-deficient striated muscle of mdx mice to improve neuromuscular 
junction architecture, reduce membrane damage, reduce cardiac fibrosis, and correct 
electrocardiographic abnormalities(31-33) provided foundational evidence for the potential for 
augmentation of nNOS signaling to ameliorate dystrophic muscle pathology in DMD. 
Translational studies over the past ten years have focused on the use of phosphodiesterase 5 
(PDE5) inhibitors to attenuate the breakdown of cyclic guanosine monophosphate (cGMP), 
which is normally produced by guanylyl cyclase in response to NO production, and thereby 
enhance downstream effects of NO signaling in order to improve blood flow to dystrophin-
deficient muscle during exercise. In dystrophin-deficient mdx mice, this strategy has been 
shown to alleviate exercise-induced fatigue and ischemic muscle fiber damage(26, 34, 35), 
improve cardiac function and the ability of the myocardium to withstand mechanical stress, and 
slow the progression of dystrophic cardiomyopathy(36-38). Unfortunately, human clinical trials 
of the PDE5 inhibitors sildenafil and tadalafil have produced mixed results at best, with 
different groups reporting alleviated skeletal muscle ischemia during exercise(39, 40), no effect 
on muscle blood flow during exercise or on heart function(41), and no to worsening effects on 
the progression of cardiomyopathy(42) in DMD or in Becker muscular dystrophy (BMD), the 
milder form of this disease. Thus, alternative approaches to correct defects in striated muscle 
NO signaling in dystrophinopathies remain a subject of substantial interest.  
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 We recently demonstrated that in cardiomyocytes, the activation of nNOS is 
mechanically regulated via phosphorylation by the upstream kinase, AMP-activated protein 
kinase (AMPK), and that the mechanical activation of AMPK by muscle stretch depends in turn 
on the expression of dystrophin ((23), described above in Chapter 2). These findings suggested 
that defective NO production in dystrophin-deficient cardiac muscle is due in part to the 
impaired mechanical activation of AMPK. We further showed that direct pharmacologic 
activation of AMPK in dystrophin-deficient cardiomyocytes in vitro could be used to bypass 
defective mechanosignaling and restore nNOS-dependent NO production within these cells(23). 
While it remains to be determined whether nNOS activity is similarly regulated by dystrophin-
dependent mechano-AMPK signaling in skeletal muscle, our work in cardiomyocytes prompted 
us to investigate whether the same pharmacologic approach could be used to augment NO 
production in dystrophin-deficient skeletal muscle fibers, and whether a strategy of acute 
AMPK activation could improve exercise tolerance at the integrated, in vivo level in a mouse 
model of DMD.  
 Here, we used fluorescence imaging of nitric oxide production and treadmill running 
assays in order to test the hypothesis that acute pharmacologic activation of AMPK restores 
skeletal muscle NO production and improves exercise tolerance in dystrophin-deficient animals. 
We report that acute pharmacologic stimulation of AMPK increases NO production in 
dystrophin-deficient skeletal muscle fibers in vitro, and increases exercise capacity in vivo in 
dystrophin-deficient mice. Together with our previous work, these findings indicate that acute 
pharmacologic activation of AMPK in vivo is sufficient to modulate exercise performance in 
dystrophin-deficient subjects, and may do so via NO-dependent effects at the heart and/or 
skeletal muscle. We therefore propose acute pharmacologic targeting of AMPK-NO signaling as 
a novel approach to improve exercise tolerance in DMD. 
 
MATERIALS AND METHODS 
 
Mice: Male control wild-type (WT) C57BL/10SnJ mice (The Jackson Laboratory, Bar Harbor, ME, 
USA, stock number: 000666) and dystrophin-deficient mdx mice (The Jackson Laboratory, Bar 
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Harbor, ME, USA, stock number: 001801) were used at 8-12 weeks of age. Mice were housed at 
the University of Michigan’s Unit for Laboratory Animal Medicine, and all procedures were 
approved by the University of Michigan’s Institutional Animal Care and Use Committee. 
Skeletal muscle fiber isolation and general plating conditions: Fibers were isolated 
from the mouse flexor digitorum brevis (FDB) muscle as described previously(43, 44). FDB fibers 
were plated in MEM (Gibco, Grand Island, NY, USA, #1157-032) + 10% fetal bovine serum 
(Gibco, Grand Island, NY, USA, #16000-044) on 35-mm tissue culture dishes coated with 10% 
phenol red-free, growth factor-reduced matrigel (BD Biosciences, Franklin Lakes, NJ, USA, 
#356231). Plated fibers were allowed to adhere to tissue culture dishes for 1 hour before use in 
imaging experiments. 
In vitro FDB fiber nitric oxide imaging: Nitric oxide production was assessed in isolated 
adult mouse FDB fibers following a protocol modified from that which we have used to 
measure cardiomyocyte NO production(23). Briefly, fibers were incubated in imaging buffer 
(Chapter 2, Table 2.2) containing 10 μM of the nitric oxide-sensitive dye, 4-amino-5-
methylamino-2’,7’-difluorofluorescein diacetate (DAF-FM-DA) (Cayman Chemical, Ann Arbor, 
MI, USA, #18767), for 40 minutes in the dark at 37oC. Fibers were then washed in fresh imaging 
buffer without DAF-FM-DA for 20 minutes in the dark at 37oC to allow complete de-
esterification of the dye. Next, fibers were acclimated to room temperature for 5 minutes 
before being covered in fresh room temperature imaging buffer containing AMPK-activating 
drugs or appropriate vehicle controls. Tissue culture plates were then immediately placed on 
the stage of an Olympus BX51 upright epifluorescence microscope and FDB fibers were imaged 
under the FITC channel at 4x magnification using a 25% neutral density filter. Images of the 
same field of view were recorded at 0, 10, 30, and 60 minutes of drug or vehicle treatment. 
Following imaging, fluorescence of all FDB fibers that retained their elongated, rod-shaped 
morphology throughout the imaging period was quantified using ImageJ as described 
previously(23). Drugs and other reagents used in these studies were as follows: 5-
aminoimidazole-4-carboxamide riboside (AICAR) (2mM; Cayman Chemical, Ann Arbor, MI, USA, 
#10010241), and sodium salicylate (30mM; Sigma-Aldrich, St. Louis, MO, USA, #S2679).   
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Treadmill exercise: Assessment of exercise-induced fatigue and exercise capacity was 
performed in the University of Michigan Physiology Phenotyping Core. Mice were subjected to 
running exercise on variable speed belt treadmills (Columbus Instruments, Columbus, OH, USA, 
#0257-901M) with the shock grid at the back of the treadmill lanes set to deliver shocks at an 
intensity setting of 0.50, about 0.4 milliamps, in 200ms pulses at maximum rate of 11 shocks 
per 10 seconds. In preliminary experiments, naïve mdx mice that were run on treadmills for the 
first time had difficulty avoiding the shock grid even at moderate running speeds. Therefore, in 
order to minimize behavioral effects due to the stress of being shocked on our functional 
analyses, mice were first acclimated to the treadmills by exercising them on a low intensity 
running paradigm on each of the two days immediately preceding the days of functional 
assessment. These training sessions consisted of exercise for 2 minutes at 4 m/min, followed by 
5 minutes at 8 m/min, and then 5 minutes at 12 m/min, with the treadmill set at 0o inclination. 
For all experiments, the treadmill operator was blinded to mouse genotype and treatment 
condition.  
Fatigue assay: The pre-exercise voluntary ambulatory activity of mice was assessed by 
using an ANY-maze automated video tracking system (Stoelting, Wood Dale, IL, USA, version 
5.11) to measure the total distance that each animal walked within individual 44.6cm x 44.6cm 
Plexiglass open field chambers during a 6-minute monitoring session. Mice were then exercised 
on treadmills set at 0o inclination for a total of 15 minutes, starting at a speed of 8 m/min for 
the first 5 minutes, followed by 10 minutes at a speed of 12 m/min. This intensity of exercise 
was moderate enough that mdx mice, as well as wild-type mice, were generally able to 
complete the running protocol without being shocked. Immediately following the completion of 
treadmill running, mice were returned to their respective open field chambers for 
measurement of their post-exercise voluntary ambulatory activity. For mock exercise groups, 
mice were placed in individual empty cages for 15 minutes instead of being run on the 
treadmills in between the first and second open field monitoring sessions. To compare changes 
in the voluntary ambulatory activity between mice of different genotypes or treatment groups, 
the raw open field activity for each animal was normalized by expressing the distance that it 
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walked during each open field session as a percentage of the distance that it walked during the 
first open field session. 
Exhaustion assay: The day following assessment of fatigue, mice were run on treadmills 
at a 0o inclination starting at a speed of 3 m/min, and the treadmill belt speed was increased by 
3 m/min every 2 minutes up to a maximum speed of 21 m/min. Mice were exercised in this 
manner until reaching exhaustion, defined as the point at which they could no longer avoid the 
shock grid at the back of the treadmill lanes despite 3 successive manual boosts from the 
treadmill operator.  
Power analyses: The statistical power of the exercise assays described above to detect 
changes in the exercise phenotype of dystrophin-deficient mice was assessed using DSS 
Research Statistical Power Calculator software (Decision Support Systems, Fort Worth, TX, USA, 
https://www.dssresearch.com/knowledgecenter/toolkitcalculators/statisticalpowercalculators.
aspx). Two-sample power calculations were performed assuming a two-tailed test with the 
significance level set to α = 0.05. 
In vivo drug treatments: Pharmaceutical grade sildenafil citrate (Greenstone, Peapack, 
NJ, USA, #F000154334) was administered to mice in the drinking water at a concentration of 
400mg/L(35, 38) starting 2 days prior to exercise testing and continuing through completion of 
the exhaustion assay. In acute assays, mice were given intraperitoneal (IP) injections of 0-
500mg/kg AICAR (Toronto Research Chemicals, Toronto, Ontario, ON, Canada, #A611700) or 0-
50mg/kg veterinary-grade sodium salicylate (HorsePreRace.com, Tyler, TX, USA) prepared in 
sterile pharmaceutical grade saline. AICAR or saline as a vehicle control was administered 8 
minutes prior to the start of treadmill running (i.e., 2 minutes before the start of the first open 
field session in fatigue assays), and salicylate or control saline was administered 1 hour prior to 
the start of treadmill running (54 minutes before the start of the first open field session in 
fatigue assays).  
Statistics: All data are presented as mean ± SE, and significance for all analyses was set 
at P<0.05. Direct comparisons between two groups were assessed by the Student t test. For 
exercise-induced fatigue assays, data were analyzed by two-way repeated measures ANOVA 






Acute pharmacologic AMPK activation increases nitric oxide production in dystrophin-
deficient skeletal muscle fibers in vitro. 
 In order to investigate the effects of acute AMPK activation on nitric oxide production in 
skeletal muscle, we modified the assay we previously developed for measuring NO production 
in isolated mouse cardiomyocytes(23) for use in isolated mouse flexor digitorum brevis fibers 
(Fig. 3.1A). In contrast to our previous findings in cardiomyocytes, treatment with the AMP 
analog, AICAR, at a concentration of up to 2mM did not significantly increase DAF-FM dye 
fluorescence compared to vehicle controls in either wild-type or dystrophin-deficient mdx FDB 
fibers (Fig. 3.1 B and C). These results are inconsistent with previous observations of AICAR-
induced NO production in L6 myotubes(45), although it is possible that the lack of AICAR 
responsiveness in our study reflects developmental differences between myotubes and adult 
muscle cells. Additionally, we did observe a decrease in the baseline cellular fluorescence of 
both WT and mdx FDB fibers over the course of the 1 hour imaging period (Fig. 3.1 B and C), 
possibly due to photobleaching of fiber autofluorescence. This overall decrease in basal cell 
fluorescence may have obscured detection of any small effects of AICAR to stimulate NO 
production in adult fibers. Unlike AICAR, salicylate, a drug that activates AMPK via the β1 
subunit(46), did yield a significant increase in DAF-FM fluorescence in both WT and mdx fibers 
(Fig. 3.1 D and E). This finding indicates that similar to cardiomyocytes, direct pharmacologic 
activation of AMPK by salicylate is sufficient to restore nitric oxide production in skeletal muscle 
fibers regardless of their dystrophin expression. 
 
Exaggerated exercise-induced fatigue and diminished exercise capacity in mdx mice can be 
detected with treadmill running assays.  
 Our finding that acute pharmacologic AMPK activation can stimulate NO production in 
dystrophin-deficient striated muscle cells suggests that this treatment has the potential to 
increase blood flow to dystrophic muscle during exercise, and prompted us to investigate 
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whether this strategy could affect exercise tolerance in DMD. Various testing paradigms 
involving measurement of voluntary exercise on running wheels, exhaustive forced running on 
treadmills, or analysis of voluntary activity immediately following acute exercise have been put 
forward as strategies to evaluate integrated skeletal and cardiac muscle function in mouse 
models of muscular dystrophy(26, 47-51). However, the translatability of pre-clinical findings 
from these assays to human muscular dystrophy patients is debated, and even the power of 
analogous clinical assessments such as the six-minute walk test is limited by potential subjective 
influences on the part of both participants and investigators(52-56). Furthermore, few of the 
studies that rely on behavioral parameters such as the animals’ voluntary activity in order to 
assess effects of dystrophy on exercise, and the ability of therapeutic interventions to modulate 
exercise phenotypes, have published appropriate control data to demonstrate that any 
observed effects are due to changes specifically in exercise performance or tolerance, rather 
than simple behavioral adaptations throughout the course of the experiments. Therefore, 
before testing effects of pharmacologic AMPK activation in vivo, we first set out to validate the 
use of two common treadmill running assays to measure exercise intolerance in dystrophin-
deficient mdx mice. 
 To compare exercise-induced fatigue in healthy versus dystrophin-deficient mice, we 
measured the animals’ voluntary open field ambulatory activity immediately before and again 
immediately following 15 minutes of moderate intensity treadmill running, similar to the 
approach used by Kobayashi et al.(26, 51). Both wild-type BL10 and mdx mice that were 
exercised on treadmills walked a shorter distance during the second open field monitoring 
session than they did during the first open field session (Fig. 3.2A). However, mice of both 
genotypes that were mock exercised did not exhibit a significant decrease in voluntary 
ambulatory activity between the first and second open field monitoring sessions (Fig 3.2A). 
These data indicate that the decrease in activity of exercised mice was indeed an effect of 
treadmill running, rather than an effect of behavioral acclimation to a second exposure to the 
open field chambers. As WT mice had approximately twice the basal level of open field activity 
than mdx mice, we normalized each animal’s post-exercise voluntary activity to its pre-exercise 
voluntary activity in order to more directly compare the effects of exercise between these two 
70 
 
strains of mice. This analysis revealed that whereas the open field activity of WT mice drops 
about 35% following exercise, the open field activity of mdx mice decreases by up to 80% 
following exercise (Fig. 3.2B). The slight decrease in activity of mock exercised mice in the 
second versus first open field session did not differ between genotypes (Fig. 3.2B). These 
findings substantiate previous reports that dystrophin-deficient animals exhibit excessive post-
exercise fatigue(26, 51, 57), and demonstrate that the minimal behavioral effects of acclimation 
due to repeat exposure to the open field chambers are not altered by the dystrophic phenotype 
of mdx mice. 
 In the second assay we performed, mice were exercised on treadmills at progressively 
increasing speeds until they reached exhaustion and could no longer remain on the treadmill 
belt. As expected, mdx mice were able to run on treadmills for a shorter time and therefore 
distance before reaching exhaustion compared to WT mice (Fig. 3.2 C and D). Moreover, unlike 
WT, most mdx mice failed to achieve the maximum running velocity in this assay (21m/min 
starting at minute 12 of the protocol), suggesting that the maximal exercise capacity or work 
rate is impaired in dystrophin-deficient animals. 
To evaluate the relative sensitivity and potential statistical power of each of these 
exercise assays to detect changes in the exercise tolerance of mdx mice, post hoc power 
analyses were conducted using the observed mean and standard deviation for mdx normalized 
post-voluntary activity (Fig. 3.2B, mean ± S.D. = 17.85 ± 26.36 % of pre-exercise) and mdx time 
to exhaustion (Fig. 3.2C, mean ± S.D. = 11.51 ± 1.899 minutes). These calculations suggest that 
the fatigue assay has sufficient 60-80% power to detect only relatively large changes in post-
exercise fatigue (approximately 85-100% change compared to control group) at a sample size of 
20-30 animals per group (Fig. 3.2E). In contrast, the power analysis indicates that exhaustion 
assay is more sensitive to changes in exercise performance, as with the same sample size of 20-
30 animals per group it can detect as small as a 10-15% change in the time to exhaustion at a 
power of 60-80% (Fig. 3.2F). 
 
Phosphodiesterase 5 inhibition improves exercise-induced fatigue, but not exercise capacity, 
in dystrophin-deficient mice.  
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 We next set out to determine whether these two exercise assays were sensitive enough 
to detect an improvement in mdx exercise tolerance upon pharmacologic intervention by using 
them to assess the exercise phenotype of mdx mice treated with the phosphodiesterase 5 
inhibitor, sildenafil citrate. This drug has been reported to alleviate exercise-induced fatigue in 
dystrophin-deficient mice and is presumed to do so by inhibiting the degradation of cGMP that 
is produced by vascular smooth muscle cells in response to a local increase in NO levels, thus 
improving vasodilatory function and helping to improve sympatholysis in dystrophic skeletal 
muscle(26). Chronic sildenafil treatment has also been shown to improve the function of 
dystrophin-deficient hearts(36, 38), suggesting that some of its effects on exercise tolerance 
may be related to changes in cardiac performance. In our hands, administration of sildenafil for 
two days was sufficient to increase both the pre- and post-exercise voluntary ambulatory open 
field activity of mdx mice (Fig 3.3A). Sildenafil also attenuated the animals’ decrease in 
ambulatory activity following exercise (Fig. 3.3B), demonstrating that it was effective at 
alleviating exercise-induced fatigue. These results also confirm that this exercise-induced 
fatigue assay is indeed sensitive enough to detect effects of pharmacologic intervention on 
exercise tolerance of mdx mice, despite having less statistical power than the exhaustion assay. 
We did not observe any significant effect of sildenafil treatment on the time or distance that 
mdx mice were able to run prior to reaching exhaustion (Fig. 3.3 C and D).  
 
Acute pharmacologic AMPK activation improves exercise capacity in dystrophin-deficient 
mice. 
 Having validated our exercise assays, we tested whether acute pharmacologic AMPK 
activation could improve the exercise phenotype of dystrophin-deficient mdx mice. Earlier 
studies reported that chronic administration of AICAR at 500mg/kg/day improved skeletal 
muscle function and pathology in mdx animals(58, 59). Therefore, in pilot experiments we used 
a dose of 500mg/kg for acute AICAR treatment. Unexpectedly, several WT mice that were given 
this dose of AICAR experienced seizures soon after completing treadmill exercise, raising 
important concerns about the safety of high doses of this compound. The seizure activity we 
observed may have been due to post-exercise hypoglycemia, as AICAR, like muscle contraction 
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itself, is known to stimulate glucose uptake(60, 61), and hypoglycemia has been reported as a 
consequence of overdose with AICAR or metformin, another AMPK-activating drug(62, 63). To 
avoid such deleterious effects of AICAR, we reduced the dose of AICAR given to animals in all 
subsequent experiments. 
A single, acute IP injection of a low, 50mg/kg dose of AICAR did not significantly 
attenuate the exercise-induced drop in voluntary ambulatory activity in mdx mice (Fig. 3.4 A 
and B). However, acute AICAR administration did increase the time and distance mdx mice were 
able to run before reaching exhaustion (Fig. 3.4 C and D). Acute injection with salicylate 
revealed that this drug tended to attenuate the exercise-induced drop in voluntary ambulatory 
activity in mdx mice, though this effect fell short of statistical significance (Fig. 3.5 A and B). 
Similar to AICAR, acute salicylate administration increased the time and distance that mdx mice 
ran prior to exhaustion (Fig 3.5 C and D). Together, these results suggest that acute 
pharmacologic AMPK activation is sufficient to improve exercise capacity in dystrophin-
deficient animals. The rapidity of the effect of the AMPK activators on treadmill running 
capacity, which occurred within the first half hour following AICAR administration or the first 
hour and 15 minutes following salicylate administration, suggests that it is mediated by acute 
changes in AMPK-dependent signaling pathways rather than by changes in the expression of 
metabolic genes, upregulation of utrophin, or increased mitochondrial biogenesis within the 
dystrophic striated muscle, as has been observed in studies of chronic pharmacologic AMPK 




Research from multiple groups supports the idea that restoration of nNOS signaling is beneficial 
to the function and pathology of dystrophin-deficient striated muscle and can ameliorate 
exercise deficits in dystrophin-deficient mice. However, translation of these findings from 
animal models to human Duchenne muscular dystrophy patients has proved challenging. 
Phosphodiesterase 5 inhibition, the only pharmacologic approach currently available for 
modulating downstream NO signaling, has rapidly advanced to clinical trials, but has had only 
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limited success in improving muscle blood flow, striated muscle function, and overall exercise 
capacity in DMD and Becker muscular dystrophy patients(39-42). These shortcomings may 
reflect the inability of PDE5 inhibition to restore essential, direct effects of nitric oxide on 
striated muscle physiology that are independent of changes in cGMP. One recent clinical study 
demonstrated a down regulation of PDE5A in dystrophic muscle(41), suggesting that the very 
enzyme that the PDE5 inhibitor approach aims to target may also be disrupted in dystrophin-
deficient subjects.  
A growing understanding of the physiological mechanisms that regulate nNOS activity in 
striated muscle opens up the possibility of targeting the endogenous pathways that control 
nNOS function as an alternative approach to increase muscle NO production in 
dystrophinopathies. Here, we used a combination of in vitro nitric oxide imaging and in vivo 
exercise assays to address the hypothesis that acute pharmacologic stimulation of AMPK, an 
endogenous upstream kinase for nNOS, rescues skeletal muscle NO production and improves 
exercise tolerance in dystrophin-deficient mice. Our observation that acute treatment with 
salicylate increases NO production in in dystrophin-deficient skeletal muscle fibers, as it does in 
dystrophin-deficient cardiomyocytes(23), provides direct evidence that nitric oxide synthase 
activity is still targetable in these cells, despite the loss of physical binding between nNOS and 
the dystrophin-glycoprotein complex. This argues against the current model for nNOS 
regulation in skeletal muscle, which proposes that direct scaffolding interactions between nNOS 
and dystrophin or the DGC are required for stimulation of nNOS activity. Indeed, work 
demonstrating that increased muscle NO content and improvement of muscle pathology by 
expression of an nNOS transgene in dystrophin/utrophin double knockout mice do not require 
the localization of nNOS to the sarcolemma(66) provides further support for the idea that direct 
NOS-DGC interactions are not absolutely critical for nNOS activity within skeletal muscle.  
Thus, rather than directly modulating the enzymatic activity of nNOS, the scaffolding 
interaction between nNOS and the DGC in healthy skeletal muscle may be important primarily 
for the appropriate targeting of a portion of the skeletal muscle’s NO production to the 
periphery of the muscle cell. Such targeting of NO production to the sarcolemma would 
minimize the diffusion distance between skeletal muscle nNOS and the smooth muscle cells of 
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local resistance arterioles, the main target of regulation for skeletal muscle-derived NO in 
mediating sympatholysis(10, 25). Minimizing this diffusion distance is especially important for 
nitric oxide-mediated signaling, as NO is highly reactive(67) and has a half-life of only a few 
microseconds in muscle tissue due to rapid reaction with myoglobin(68-70). Mathematical 
modeling predicts that in muscle tissue, NO concentration declines sharply with increasing 
distance from its site of production, and that nanomolar concentrations sufficient to activate 
smooth muscle guanylyl cyclase may be reached only within a few micrometers of the source of 
NO production(71, 72). The limitation to the diffusion of NO may have minimal consequences 
for vasoregulation by cytosolic nNOS within cardiomyocytes, which have a diameter of about 
20μm(73), because even nNOS located in the middle of a cardiomyocyte would be only about 
10μm from the nearest neighboring cell. However, in larger skeletal muscle fibers that have a 
diameter of 40-60 μm(74, 75), scaffolding of nNOS at the DGC near the edge of the cell would 
be critical for allowing nNOS-derived NO to reach nearby arterioles in order to promote 
vasodilation. The idea that the specific targeting of nNOS near the skeletal muscle sarcolemma 
is critical for local vasoregulation by the skeletal muscle fibers is supported by experiments 
showing that only those transgenic dystrophin constructs that restore nNOS sarcolemmal 
localization are sufficient to restore functional sympatholysis in mdx mice(76), and that 
sympatholysis is disrupted in syntrophin-deficient mice that exhibit reduced sarcolemmal nNOS 
localization(77). The data in the present study showing that pharmacologic activation of AMPK 
was able to restore skeletal muscle NO production suggests that this may be a viable approach 
to increase skeletal muscle NO signaling in DMD patients. However, because acute AMPK 
activation presumably did not restore nNOS sarcolemmal localization, any beneficial effects of 
increased skeletal muscle NO production on exercise performance with this treatment may 
reflect targets of NO within the skeletal muscle fibers rather than a dramatic improvement in 
muscle blood flow. This notion also raises the possibility that a combined therapeutic approach 
restoring both sarcolemmal nNOS localization and acute pharmacologic nNOS activation 
through AMPK in DMD may be more effective at improving sympatholysis and improving 
exercise tolerance than either approach alone. 
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 In contrast to the effects of salicylate and unlike our previous findings in 
cardiomyocytes(23), we did not observe a significant effect of AICAR to activate NO production 
in dystrophin-deficient skeletal muscle fibers. We also failed to observe any effect of AICAR on 
NO production in wild-type fibers, indicating that the lack of AICAR-induced NO production was 
not merely a consequence of dystrophin deficiency. The discrepancy between the effects of 
AICAR on NO production in cardiac versus skeletal muscle may reflect differences in the 
nucleotide-sensing, γ-subunit isoform composition of AMPK heterotrimers between these two 
tissues. Whereas cardiac muscle expresses γ2 AMPK subunits, skeletal muscle exhibits tissue-
specific expression of γ3 AMPK(63). Fitting with this idea of tissue-specific differences in AICAR 
sensitivity, AMPK trimeric complexes containing γ2 subunits have been shown to be the most 
sensitive to activation by AMP, while complexes containing γ3 subunits are the least sensitive to 
activation by AMP(78). As there is correlative evidence for the activating phosphorylation of 
nNOS by AMPK in skeletal muscle(79), it is likely that in our experiments any subset of skeletal 
muscle AMPK heterotrimers that may have been effectively activated by AICAR, or that may 
have already been activated by any metabolic stress imposed by the fiber isolation, is simply 
distinct from the subset of AMPK heterotrimers that normally regulate nNOS. Our observation 
that salicylate, which specifically activates β1-subunit-containing AMPK heterotrimers(46), does 
activate NO production in FDB fibers provides further support for the notion that a specific 
fraction of the total population of AMPK trimeric complexes within skeletal muscle functionally 
targets nitric oxide synthases. 
The effect of chronic pharmacologic activation of AMPK with AICAR on the pathology of 
dystrophin-deficient muscle has been the subject of several recent investigations(49, 58, 59, 64, 
65). Although such studies have demonstrated a shift toward a more oxidative muscle 
phenotype and improved contractile function of the skeletal muscle after weeks of AICAR 
treatment, the ability for AMPK activation to affect integrated exercise phenotypes in animal 
models of DMD has so far received little attention. Our finding that acute treatment with the 
AMPK activators AICAR or salicylate increases the time and distance that dystrophin-deficient 
mdx mice are able to run on treadmills is the first demonstration that pharmacologic AMPK 
activation can indeed improve exercise performance in dystrophin-deficient subjects. 
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Moreover, that the improvement in exercise occurred on the timescale of minutes to hours 
following administration of these drugs suggests that this beneficial effect is mediated by 
rapidly-acting mechanisms. The one group that measured endurance running in mdx mice 
following 30 days of AICAR treatment did not observe any effect of the treatment on total 
running capacity despite upregulation of the dystrophin homolog, utrophin, and improvements 
in skeletal muscle integrity with this treatment paradigm(49, 58). This result provides further 
evidence that the exercise capacity of mdx mice is specifically affected by the immediate rather 
than long-term effects of increased AMPK activity. Both AICAR and salicylate can acutely 
regulate other proteins besides AMPK, such as the ryanodine receptor(80), cyclooxygenase(81), 
and IKKβ(82), and therefore may alter AMPK-independent signaling pathways that could have 
affected performance on the exhaustion assay we used in this investigation. However, the fact 
that we observed improved exercise capacity in mdx mice treated with either drug supports the 
idea that this improvement was due to AMPK itself, rather than some other unintended target 
of the drugs.  
 The disparate effects of AMPK activators compared to a PDE5 inhibitor that we 
observed in our two different exercise assays raises the intriguing possibility that these 
different classes of drugs affect distinct components of the exercise intolerance phenotype of 
dystrophin-deficient mice. Sildenafil treatment increases post-exercise skeletal muscle blood 
flow in mdx mice and attenuates the decrease in their voluntary activity following exercise(26), 
a phenomenon that we were able to reproduce. We found a similar trend toward attenuated 
post-exercise fatigue in mdx mice treated with salicylate, but not in animals treated with AICAR. 
In light of our in vitro data demonstrating that salicylate, but not AICAR, stimulates nitric oxide 
production in dystrophin-deficient skeletal muscle, it is likely that amelioration of post-exercise 
fatigue in mdx mice specifically depends on increasing NO/cGMP-dependent signaling, and 
possibly local blood flow, within the skeletal muscle tissue. On the other hand, the increase in 
total treadmill running capacity in mdx mice treated with AICAR or salicylate was not 
recapitulated in mice treated with sildenafil, suggesting that increased cGMP levels and any 
associated changes in sympatholysis are not sufficient to elicit this effect. Rather, the 
improvement in exercise capacity may reflect direct, cGMP-independent effects of NO to alter 
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calcium handling and increase the contractile function of the heart and, in salicylate-treated 
animals, the skeletal muscle(83, 84). Any such effects to improve cardiac function or increase 
muscle strength could increase the animals’ maximum work output, enabling them to run at a 
greater maximal speed and therefore remain on the treadmills for a longer time over the 
course of our exhaustion assay. Because AICAR was able to improve the exercise capacity of 
mdx mice even without stimulating FDB fiber NO production, it is also possible that the benefits 
of AMPK activation on exercise capacity are attributable to increased NO signaling specifically 
within the cardiac rather than skeletal muscle, or else are due to NO-independent effects of 
AMPK, such as on metabolism, within either type of muscle or in even non-muscle tissue. It will 
be interesting for future studies to clarify the relative cardiac and skeletal muscle contributions 
to the improved exercise capacity in mdx mice treated with AMPK activators, and to determine 
the necessity of heart or skeletal muscle nNOS for this effect.  
Together with our work in cardiomyocytes discussed in Chapter 2 of this thesis, our data 
support a model in which acute pharmacologic stimulation of AMPK is sufficient to enhance 
nitric oxide production in dystrophin-deficient striated muscle, regardless of any scaffolding 
interactions between nNOS and the dystrophin-glycoprotein complex. Further study will be 
required to identify the precise subunit composition of the AMPK heterotrimers that are 
targeted by this approach, as well as the specific nNOS splice variants that are regulated by 
AMPK. Our in vivo findings demonstrate the physiological relevance of modulating AMPK 
signaling in dystrophin-deficient animals and provide proof-of-concept evidence for acute 
pharmacologic AMPK activation as a novel approach to improve exercise tolerance in Duchenne 
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Figure 3.1. Acute pharmacologic AMPK activation with salicylate increases nitric oxide 
production in dystrophin-deficient skeletal muscle fibers in vitro. (A) Epifluorescence imaging 
of isolated mdx flexor digitorum brevis(FDB) fibers loaded with the nitric oxide sensitive dye, 
DAF-FM-DA, at 4x magnification under a FITC filter (left panel) or brightfield (right panel). (Scale 
bars = 1mm.) (B) Treatment of wild-type C57BL10 (BL10) FDB fibers with 2mM AICAR does not 
significantly increase cellular DAF-FM fluorescence compared to vehicle-treated cells. (C) 
Treatment of dystrophin-deficient mdx FDB fibers does not significantly increase cellular DAF-
FM fluorescence compared to vehicle-treated cells. Cellular DAF-FM fluorescence is increased 
in BL10 (D) and mdx (E) FDB fibers treated with 30mM salicylate compared to vehicle control 







Figure 3.2. Exercise-induced fatigue is exaggerated and exercise capacity is diminished in 
dystrophin-deficient mice. (A) Wild-type BL10 and dystrophin-deficient mdx mice exhibit a 
decrease in voluntary ambulatory open field activity following a single bout of treadmill 
exercise, while voluntary open field activity is not affected in mice that are mock exercised 
(****P<0.0001 vs. same genotype, pre-exercise; ^^P<0.01, ^^^^P<0.0001 vs. same genotype, 
mock post-exercise). (B) The relative decrease in voluntary ambulatory open field activity 
following exercise is greater in mdx mice than in WT mice (*P<0.01, ***P<0.001 vs. mock post-
exercise for same genotype; ^^^^P<0.0001 vs. BL10 post-exercise). mdx mice subjected to 
treadmill exercise run a shorter time (C) and distance (D) before reaching exhaustion than WT 
mice (****P<0.0001) (n=16). Surface plots representing the results of statistical power analyses 
for the measurement of the exercise phenotype of mdx mice in the fatigue assay (E) and 
exhaustion assay (F) reveal a greater sensitivity for the exhaustion assay in detecting small 







Figure 3.3. Phosphodiesterase 5 inhibition improves exercise-induced fatigue but not exercise 
capacity in dystrophin-deficient mdx mice. (A) Treatment with sildenafil increases the pre-and 
post-exercise voluntary ambulatory activity of dystrophin-deficient mdx mice (****P<0.0001 vs. 
pre-exercise for same treatment condition; ^P<0.05, ^^P<0.01 vs. H2O within same open field 
session). (B) The drop in voluntary open field activity following exercise is attenuated in mdx 
mice treated with sildenafil (***P<0.001 vs. H2O post-exercise). Sildenafil does not affect the 












Figure 3.4. Acute treatment with AICAR improves exercise capacity in dystrophin-deficient 
mice. (A) Acute treatment with AICAR does not significantly alter pre- or post-exercise 
voluntary ambulatory activity in mdx mice (****P<0.0001, saline post- vs. pre-exercise; 
^^^^P<0.0001, AICAR post- vs. pre-exercise). (B) The decrease in voluntary ambulatory activity 
following treadmill running is not significantly attenuated in mdx mice acutely treated with 
AICAR compared to saline control. Acute AICAR treatment increases the time (C) and distance 












Figure 3.5. Acute treatment with salicylate improves exercise capacity in dystrophin-deficient 
mice. (A) Acute treatment with salicylate tends to increase the post-exercise voluntary 
ambulatory activity of mdx mice (****P<0.0001, saline post- vs. pre-exercise; ^^^^P<0.0001, 
salicylate post- vs. pre-exercise). (B) The decrease in voluntary ambulatory activity following 
treadmill running tends to be attenuated in mdx mice acutely treated with salicylate compared 
to saline control. Acute salicylate treatment increases the time (C) and distance (D) that mdx 
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Transgenic expression of dimethylarginine dimethylaminohydrolase attenuates exercise-




Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in dystrophin 
and characterized by muscle degeneration, cardiomyopathy, and impaired muscle nitric oxide 
(NO) production that disrupts muscle blood flow regulation and leads to excessive post-exercise 
fatigue. We show here that circulating levels of endogenous methylated arginines that act as 
NO synthase inhibitors, such as asymmetric dimethylarginine (ADMA), are elevated both by 
acute necrotic muscle damage and in chronically-necrotic dystrophin-deficient mice. Therefore, 
we hypothesized that excessive circulating ADMA impairs muscle NO production and thus 
negatively impacts exercise tolerance in DMD. We used transgenic expression of 
dimethylarginine dimethylaminohydrolase 1 (DDAH), the enzyme that degrades ADMA, to 
investigate the contribution of ADMA to exaggerated exercise-induced fatigue in DMD. 
Although infusion of exogenous ADMA was sufficient to impair exercise performance in healthy 
wild-type mice, transgenic DDAH expression aimed at reducing methylated arginine levels was 
not sufficient to affect exercise-induced fatigue in dystrophin-deficient male mdx mice. 
Surprisingly, DDAH transgene expression did attenuate exercise-induced fatigue in dystrophin-
heterozygous female mdx carrier mice. This improvement in exercise tolerance was associated 
with reduced heart weight, improved cardiac contractile function, and improved chronotropic 
responsiveness to beta-adrenergic stimulation in DDAH-transgenic female mdx carriers. We 
conclude that DDAH transgene expression improves exercise tolerance in dystrophin-
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heterozygous females, possibly by limiting pathological cardiac remodeling and preserving 
heart performance. These findings emphasize the importance of methylated arginines to 
cardiac function in dystrophinopathies and reveal a new therapeutic target to mitigate the risk 




Mutations in the genes encoding the proteins of the sarcolemmal dystrophin-glycoprotein 
complex (DGC) lead to muscle wasting diseases known as muscular dystrophies. One of the 
most common forms, Duchenne muscular dystrophy (DMD), is caused by mutations in the X-
linked DMD gene that encodes dystrophin(1, 2). This protein normally links the muscle cell’s 
cytoskeleton and plasma membrane via its interactions with subsarcolemmal γ-actin and the 
transmembrane protein β-dystroglycan(3-5). Loss of dystrophin destabilizes the sarcolemma 
and contributes to excessive sarcolemmal permeability that can lead to calcium overload and 
death of the muscle cell, particularly during the mechanical stresses that occur with eccentric 
contractions or increased workloads(6-9). Evidence of striated muscle cell injury can be seen by 
leak of intracellular proteins such as creatine kinase and lactate dehydrogenase into the 
blood(10), and by an increased prevalence of regenerating skeletal muscle fibers and 
replacement of damaged cardiomyocytes by fibrosis. Over time, accumulated damage to the 
muscle cells results in debilitating muscle weakness and, in older DMD patients, compromised 
cardiac function and cardiomyopathy(11, 12). Cardiomyocyte damage likely also contributes to 
the elevated risk for cardiomyopathy observed in female carriers of DMD mutations, who 
display mosaic dystrophin expression in the heart due to random X-inactivation(13-15). 
 In addition to structural defects, dystrophin-deficient striated muscle cells exhibit 
impaired nitric oxide (NO) signaling(16-19). Production of NO by neuronal nitric oxide synthase 
(nNOS) in contracting skeletal muscle is critical for sympatholysis, the process by which muscle 
contraction locally attenuates sympathetic vasoconstriction and helps to maintain blood flow to 
exercising skeletal muscles(20). In the absence of dystrophin, the disruption of muscle NO 
production and resulting misregulation of muscle blood flow(21-24) is thought to contribute to 
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exaggerated exercise-induced fatigue observed in dystrophin-deficient mice and patients(25, 
26). Given the importance of  nitric oxide for regulating coronary blood flow(27) and the 
intrinsic contractile properties of the myocardium(28-33), it is also probable that disrupted 
cardiac muscle NO production contributes to cardiac dysfunction and, consequently, poor 
exercise tolerance in DMD.  
 Several mechanisms have been proposed to explain how the loss of dystrophin 
negatively affects striated muscle nitric oxide signaling. Various groups have suggested that a 
direct physical interaction between nNOS and the DGC or dystrophin itself is required for 
appropriate activation of nNOS(16, 25, 34), or alternatively that dystrophin is required for the 
normal regulation of biochemical signaling cascades that control the phosphorylation state and 
enzymatic activity of nNOS(19). However, understanding of the endogenous regulation of 
muscle NO production, and the mechanisms by which the loss of dystrophin impairs this 
phenomenon, remains incomplete. Reports from as early as the 1970s suggest that elevated 
concentrations of asymmetric dimethylarginine (ADMA) are present in the urine of DMD 
patients(35, 36), perhaps reflecting changes in circulating levels of ADMA. ADMA is generated 
via methylation of arginine residues within intact proteins, and following release during 
proteolysis can act as an endogenous competitive inhibitor of the nitric oxide synthases(37, 38). 
Therefore, we reasoned that excessive ADMA released from damaged, degenerating muscle 
cells may impair nNOS function and thus contribute to impaired muscle blood flow regulation 
and increased susceptibility to exercise-induced fatigue in dystrophin-deficient subjects.  
 We used transgenic expression of dimethylarginine dimethylaminohydrolase 1 (DDAH), 
an enzyme that degrades ADMA, to test the hypothesis that excessive circulating ADMA 
contributes to exaggerated exercise-induced fatigue in the mdx mouse model of Duchenne 
muscular dystrophy. Here, we report that administration of exogenous ADMA negatively affects 
exercise performance in otherwise healthy mice, and that transgenic DDAH expression 
improves resistance to exercise-induced fatigue in female dystrophin-heterozygous mdx carrier 
mice, but not in male dystrophin-deficient mdx mice. We further demonstrate that DDAH 
transgene expression improves the cardiac performance of female mdx carrier mice, suggesting 
that improved fatigue resistance in these animals is related to altered heart function. These 
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surprising results reveal a new role for methylated arginine metabolism in the regulation of 
cardiac function in DMD carriers and point to the manipulation of methylated arginine 
metabolism as new therapeutic strategy to target the development of cardiomyopathy in this 
population. 
  
MATERIALS AND METHODS 
 
Mice: Control wild-type (WT) C57BL/10SnJ (strain #000666) and dystrophin-deficient mdx mice 
(C57BL/10ScSn-DMDmdx/J, strain #001801) were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA). Dystrophin-deficient female mdx mice were crossed to wild-type males 
expressing a transgene encoding human dimethylarginine dimethylaminohydrolase 1 (DDAH) 
under the control of a β-actin promoter(39) (The Jackson Laboratory, Bar Harbor, ME, USA, 
strain #005863, C57BL/6J-Tg(ACTB-DDAH1)1Jpck/J) to generate DDAH-transgenic (TG) and non-
transgenic (ntg) dystrophin-deficient male mdx mice, and TG and ntg dystrophin-heterozygous 
female mice (“mdx carriers” or “mdxhets”). DDAH-genotype was confirmed by polymerase 
chain reaction as has been described elsewhere(39). Primer sequences for the DDAH transgene 
were 5′-AGCACCAGCTCTACGTG-3′ and 3′-GCCCTTTGTTGGGGATATT-5′. Internal control primers 
were 5’-CAAATGTTGCTTGTCTGGTG-3’ and 5’-GTCAGTCGAGTGCACAGTTT-3’. For initial 
assessments of plasma methylated arginine concentrations, cardiotoxin injury experiments, and 
ADMA infusion experiments, WT and mdx mice were used at 3-4 months of age. All subsequent 
experiments involving DDAH-transgenic mice were performed in mice 11-12 months of age. All 
animals were housed in the University of Michigan’s Unit for Laboratory Animal Medicine, and 
all procedures were approved by the University of Michigan’s Institutional Animal Care and Use 
Committee.  
 Plasma collection: Blood was collected via the saphenous vein of restrained animals into 
ethylenediaminetetraacetic acid (EDTA)-coated tubes and then centrifuged at 1,000 x g for 5 
minutes. Plasma was removed from cells and stored at -80oC until analysis. 
 Serum collection: Mice were anesthetized with 250mg/kg tribromoethanol (Sigma-
Aldrich, St. Louis, MO, USA, #T48402) dissolved in tert-amyl alcohol. Trunk blood was collected 
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following decapitation, allowed to clot for 15 minutes, and then centrifuged at 1,000 x g for 15 
minutes at 4oC. The serum was removed from the clot and stored at -80oC until use. 
Measurement of circulating methylated arginines: Concentrations of asymmetric 
dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-N-monomethylarginine 
(L-NMMA) in plasma and serum samples were determined by high-performance liquid 
chromatography (HPLC) using methods described previously(40-42). 
Cardiotoxin injury: To induce acute muscle injury, 100uL of 10mM cardiotoxin (Sigma-
Aldrich, St. Louis, MO, USA, #C3987) was injected into the gastrocnemius and quadriceps 
muscles of a single leg of wild-type C57BL/10 mice. Plasma was collected via the saphenous 
vein six hours following cardiotoxin injection and analyzed for methylated arginine 
concentration, as well as for creatine kinase (CK) concentration to confirm the efficacy of 
muscle injury.  
Plasma creatine kinase analysis: Plasma was assessed for CK concentration using CK 
NADP Reagent (Cliniqa, San Marcos, CA, USA, #R85119) according to the manufacturer’s 
instructions.  
ADMA infusion: Osmotic minipumps (ALZET, Cupertino, CA, USA, model #1002) were 
surgically implanted in wild-type C57BL/10 mice and set to continuously deliver 60mg/kg/day of 
ADMA (Cayman Chemical, Ann Arbor, MI, USA, #80230) dissolved in saline, or saline alone as a 
vehicle control. 
Voluntary running wheel activity: Three days following osmotic minipump 
implantation, mice were placed in cages with voluntary running wheels (Columbus Instruments, 
Columbus, OH, USA, #0297-0521) to measure exercise performance. Voluntary running wheel 
exercise was monitored for five consecutive nights using a DSI telemetry system (Data Sciences 
International, St. Paul, MN, USA) to record running wheel revolutions and total distance run per 
24 hours. Bouts of running wheel exercise were defined as any length of time greater than 10 
consecutive seconds that a mouse continued to run on the wheel without getting off. 
Tissue collection and western blotting: Mice were anesthetized and the gastrocnemius 
muscle and heart were rapidly dissected and snap frozen in liquid nitrogen. Tissue samples 
were homogenized in Triton-X lysis buffer containing protease and phosphatase inhibitors(19). 
95 
 
Protein concentrations in tissue lysates were quantified using the DC protein assay (Bio-Rad, 
Hercules, CA, USA, #500-0116) and 100ug protein of each sample was separated on 
polyacrylamide gels, transferred to polyvinyldiene fluoride membranes (Millipore, Billerica, MA, 
USA, #IPVH00010), and subjected to quantitative Western blotting as we have described 
elsewhere (19). Primary antibodies included the following rabbit polyclonal antibodies: DDAH1 
(Abcam, Cambridge, MA, USA, #ab82908) and dystrophin (Abcam, Cambridge, MA, USA, 
#ab14277), and rat monoclonal antibody against tubulin (Abcam, Cambridge, MA, USA, 
#ab61610). Secondary antibodies were horseradish peroxidase-conjugated goat anti-rabbit 
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA, #111-035-144), and horseradish 
peroxidase-conjugated donkey anti-rat (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA, #712-035-153).  
Treadmill exercise: Mice were exercised on an Exer-3/6 adjustable variable speed belt 
treadmill (Columbus Instruments, Columbus, OH, USA, #0257-901M) with the shock grid at the 
back of the treadmill set to deliver shocks at an intensity of approximately 0.4 milliamps in 
200ms pulses separated at a maximum rate of 11 shocks per 10 seconds. For all experiments, 
the treadmill operator was blinded to mouse genotype. Before functional testing, mice were 
first acclimated to treadmill running by being exercised for a total of 15 minutes, starting at a 
speed of 8m/min for 5 minutes, followed by 5 minutes at 12m/min, and 5 minutes at 15m/min.  
Fatigue assay: The day after treadmill acclimation, the animals’ voluntary ambulatory 
open field activity was measured before and immediately following repeated bouts of treadmill 
exercise of increasing intensity in order to assess exercise-induced fatigue. For these open field 
measurements, individual mice were placed in the center of 44.6cm x 44.6cm Plexiglass cubes 
and the distance they walked during a 6 minute period was recorded using a ceiling-mounted 
camera with ANY-maze automated video tracking software (Stoelting, Wood Dale, IL, USA, 
version 5.11). In between open field measurement sessions, mice were exercised in 15-minute 
treadmill running sessions with the treadmill incline set at -15o. The first treadmill running 
session consisted of 15 minutes of running at 8m/min. The second treadmill running session 
consisted of 5 minutes of running at 8m/min, followed by 10 minutes of running at 12m/min. 
Finally, the third treadmill running session consisted of 5 minutes of running at 8/min, followed 
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by 10 minutes of running at 15m/min. Mice in mock exercise groups were placed individually in 
empty cages for 15 minutes during these treadmill sessions instead of performing exercise. For 
direct comparisons of changes in voluntary ambulatory open field activity between mice of 
different genotypes or different exercise groups, the raw open field activity data for each 
mouse was normalized by expressing the distance each animal walked during each open field 
session as a percentage of the distance it walked during the first open field session. 
Exhaustion assay: The day after assessment on the fatigue assay described above, mice 
were run on treadmills at a -15o decline starting at a speed of 3m/min. Every two minutes, the 
treadmill belt speed was increased by 3m/min up to a maximum speed of 21m/min. Mice were 
exercised until they reached exhaustion, defined as the point at which they could no longer 
avoid the shock grid at the back of the treadmill despite 3 successive manual boosts from the 
treadmill operator.  
Measurement of urine nitrite + nitrate: Mouse urine was collected on clean strips of 
parafilm and then stored at -80oC until use. Total urine nitrite + nitrate (NOx) concentration was 
measured using a nitrate/nitrite colorimetric assay kit (Cayman Chemical, Ann Arbor, MI, USA, 
#780001) according to the manufacturer’s instructions.  
Histology and immunofluorescence: The heart and the soleus and gastrocnemius 
muscles were collected from anesthetized mice, mounted in Tissue-Plus OCT (Fisher 
HealthCare, Houston, TX, USA, #23-730-571), frozen in isopentane-cooled liquid nitrogen, and 
cut into 8-micron cross sections as described previously(43). To quantify fibrosis, slides were 
stained with 0.1% sirius red in picric acid following the procedure described by Hadi et al.(44). 
Images of the heart or gastrocnemius and soleus muscles were captured using an Olympus BX-
51 fluorescence microscope and the collagen area fraction (CAF), the percentage of the total 
area of each section that stained positively with picosirius red, was measured using ImageJ. To 
quantify the percentage of centrally-nucleated skeletal muscle fibers as well as fiber cross-
sectional area (CSA), slides containing gastrocnemius and soleus sections were washed in 
phosphate-buffered saline (PBS), blocked for 1 hour in PBS containing 5% bovine serum 
albumin (Fisher Scientific, Fair Lawn, NJ, USA, #BP1600), and then incubated with a rabbit 
polyclonal antibody against laminin (Sigma-Aldrich, St. Louis, MO, USA, #L9393) for 1.5 hours. 
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Slides were washed 3 times for 5 minutes each in PBS, and then incubated with an AlexaFluor 
488-conjugated goat-anti rabbit secondary antibody (Invitrogen, Carlsbad, CA, USA,  #A-11034) 
and 4’,6-diamino-2-phenyindole, dilactate (DAPI) (Sigma-Aldrich, S. Louis, MO, USA, #D9564) for 
1.5 hours. Finally, slides were washed 3 times for 5 minutes each and mounted using 
PermaFluor (Thermo Fisher Scientific, Fremont, CA, USA, #TA-030-FM). Laminin staining 
outlining the muscle fiber boundaries was used to measure the dimensions of individual fibers 
in ImageJ. The variance coefficient of the fiber CSA was calculated as: (standard deviation of 
muscle fiber CSA / mean muscle fiber CSA) x 100(45). All assessments of fibrosis, central 
nucleation, and muscle fiber size were performed blinded to mouse genotype.   
Echocardiography: Echocardiography was performed in mice under isoflurane 
anesthesia as described previously(46). Measurements of stroke volume and cardiac output 
were made in the 2-dimensional long axis view, and pulsed-wave Doppler imaging was used to 
assess the left-ventricular myocardial performance index (LVMPI), defined as: (isovolumic 
relaxation time + isovolumic contraction time)/aortic ejection time. To assess beta-adrenergic 
responsiveness, after baseline measurements of cardiac function, a subset of mice was injected 
intraperitoneally with 2mg/kg isoproterenol (Sigma-Aldrich, St. Louis, MO, USA, #I6504) and 
measurements were immediately repeated.  
General statistical methods: All data are presented as mean ± SE. For simple 
comparisons between two groups, significance was determined by the Student t test. Direct 
comparisons between three or more groups were made by one-way or two-way ANOVA, as 
appropriate, followed by Tukey’s multiple comparisons tests. For exercise-induced fatigue 
assays, data were analyzed by two-way repeated measures ANOVA followed by Fisher’s least 
significant difference test for comparison of groups at each of multiple successive open field 




Asymmetric dimethylarginine is elevated in dystrophin-deficiency or following acute necrotic 
muscle injury, and is sufficient to impair exercise performance in healthy mice. 
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We first sought to determine whether methylated arginine levels are elevated in 
dystrophin-deficient mdx mice as they are in human DMD patients. Compared to WT C57BL/10 
controls, mdx mice exhibited elevated circulating concentrations of ADMA and the related 
endogenous nitric oxide synthase inhibitor, monomethylarginine (L-NMMA) (Fig. 4.1A). In 
contrast, circulating symmetric dimethylarginine (SDMA) concentrations did not differ between 
genotypes (Fig. 4.1A). Induction of degenerative  muscle injury in WT mice using cardiotoxin 
injection triggered an increase in plasma creatine kinase (CK) concentration along with a 
concurrent increase in circulating L-NMMA and a tendency towards increased circulating ADMA 
(Fig. 4.1 B and C). These data demonstrate that methylated arginines are elevated following 
acute muscle injury, and support the idea that circulating methylated arginine concentrations 
are elevated in DMD because these compounds are released from dystrophic muscle cells as a 
direct result of muscle injury.   
To investigate the potential for excessive circulating ADMA to impact exercise 
performance, we infused ADMA into healthy, WT mice and assessed their voluntary running 
wheel activity. Infusion of exogenous ADMA resulted in circulating ADMA levels approximately 
3-fold higher than in control mice infused with saline (Fig. 4.1D). This elevation in circulating 
ADMA levels was associated with a reduction in the total distance that ADMA-infused WT mice 
ran on voluntary running wheels per 24 hours (Fig. 4.1E). Mice infused with ADMA also ran less 
total distance per individual bout on the running wheels compared to saline-infused mice (Fig. 
4.1F), consistent with the notion that elevated circulating ADMA causes mice to become more 
easily fatigued following the onset of exercise. 
 
DDAH transgene expression reduces circulating ADMA concentration in dystrophin-deficient 
male mdx mice.  
 To investigate whether elevated circulating ADMA contributes to exaggerated exercise-
induced fatigue in Duchenne muscular dystrophy, we crossed dystrophin-deficient female mdx 
mice to wild-type males expressing a transgene encoding human dimethylarginine 
dimethylaminohydrolase 1 (DDAH), an enzyme that degrades ADMA. This cross produced 
transgenic (TG) and non-transgenic (ntg) dystrophin-deficient mdx male offspring, as well as TG 
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and ntg dystrophin-heterozygous mdx carrier female offspring (Fig. 4.2A). Western blot analysis 
showed robust DDAH transgene expression in the skeletal muscle (Fig. 4.2B) and hearts (Fig. 
4.2C) of TG mdx males and mdx carrier females. Interestingly, transgenic DDAH expression was 
lower in the skeletal muscle of TG mdx males compared to TG WT males and TG mdx carrier 
females (Fig. 4.2B). In contrast, transgenic DDAH expression was reduced in the hearts of TG 
mdx carrier females compared to TG WT males and TG mdx males (Fig. 4.2C). We also observed 
low levels of endogenous DDAH expression in the skeletal muscle and hearts of ntg animals 
(Fig. 4.2 B and C), although expression of endogenous DDAH did not differ between ntg WT 
males, ntg mdx males, and ntg mdx carrier females in either tissue. Dystrophin protein was not 
detected in the skeletal muscle or hearts of mdx male mice (Fig. 4.2 B and C). As expected 
based on the typical expression of dystrophin at relatively normal levels  in multinucleated 
skeletal muscle cells, but mosaic expression pattern due to random-X inactivation in 
cardiomyocytes(47, 48), dystrophin expression was significantly reduced compared to WT in 
the hearts but not skeletal muscle of female mdx carriers (Fig. 4.2 B and C).   
 HPLC analysis revealed that steady-state circulating ADMA concentration was reduced in 
TG versus ntg male mdx mice, while serum concentrations of L-NMMA and SDMA were not 
significantly altered (Fig. 4.3 A-C). In contrast, initial results indicated that DDAH transgene 
expression did not significantly alter basal serum methylated arginine concentrations in female 
mdx carriers (Fig. 4.3 D-F).    
 
DDAH transgene expression improves resistance to exercise-induced fatigue in dystrophin-
heterozygous mdx carrier female, but not in fully dystrophin-deficient mdx male mice. 
 We next established a strategy to assess the effects of DDAH transgene expression on 
exercise-induced fatigue and overall exercise capacity in dystrophin-deficient mice. To assess 
exercise-induced fatigue, the animals’ voluntary ambulatory activity was measured in 6-minute 
open field sessions before and immediately after successive bouts of treadmill running at 
progressively increased speeds (Fig. 4.4A). To assess total exercise capacity, mice were run on a 
single treadmill session, with velocity increased every 2 minutes up to a maximum velocity of 21 
m/min until they could no longer stay on the treadmill belt (Fig. 4.4B). Successive bouts of 
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treadmill running in the fatigue assay led to an exaggerated drop in voluntary ambulatory open 
field activity in both WT C57 and mdx males compared to animals that were mock exercised 
(Fig. 4.4 C and D). These observations established that the drop in activity following successive 
bouts of treadmill running was not due merely to acclimation effects during repeat exposure to 
the open field measurement chambers, suggesting that both WT and mdx male mice exhibit 
exercise-induced fatigue. Normalization of each animal’s post-exercise voluntary activity to its 
own pre-exercise voluntary activity revealed that the drop in voluntary activity following 
treadmill exercise was greater in mdx than WT males (Fig. 4.4E) , in agreement with previous 
reports that exercise-induced fatigue is exaggerated in dystrophin-deficient animals(25, 49). In 
contrast, the drop in activity over repeated open field monitoring sessions in mock-exercised 
animals did not differ between wild-type and mdx males, indicating that these genotypes did 
not differ in their acclimation to the testing chambers (Fig. 4.4F). This control experiment 
verified that any differences between genotypes in the open field activity of exercised mice was 
indeed attributable to differential effects of  or responses to exercise, rather than underlying 
differences in behavioral responses to repeat exposures to the open field chambers. Finally, 
male mdx mice were able to run for a shorter total time and distance prior to reaching 
exhaustion than WT males (Fig. 4.4 G and H), confirming that their total exercise capacity was 
diminished compared to healthy animals.  
 These same assays revealed that like male mice, WT, dystrophin-heterozygous mdx 
carrier, and fully dystrophin-deficient mdx females that were run on treadmills exhibited a 
greater drop in voluntary ambulatory open field activity compared to females that were mock 
exercised (Fig. 4.5 A-C), suggesting that females of all three genotypes are also susceptible to 
exercise-induced fatigue. However, in contrast to fully dystrophin-deficient mdx females, this 
exercise-induced fatigue was not exaggerated beyond wild-type levels in mdx carrier females 
(Fig. 4.5D). The drop in voluntary activity over repeated open field sessions was similar among 
mock exercised wild-type, mdx carrier, and mdx female mice (Fig. 4.5E), indicating that all three 
genotypes had similar behavioral responses to acclimate to the open field chambers. Finally, 
the time and distance that mdx carriers were able to run before reaching exhaustion was 
reduced compared to WT females but was still significantly greater than mdx females (Fig. 4.5 F 
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and G). The observation that mdx carrier performance on both exercise assays was significantly 
better than that of fully dystrophin-deficient mdx females is in agreement with reports that 
human DMD carriers suffer only relatively mild impairments in muscle function compared to 
male DMD patients(13, 15, 50) .   
Following validation of these two exercise assays, we used them to test the effect of 
DDAH transgene expression on exercise tolerance in dystrophic animals. Comparison of TG and 
ntg mdx male littermates revealed no effect of the DDAH transgene on the absolute (Fig. 4.6A) 
or relative (Fig. 4.6B) drop in voluntary ambulatory open field activity following exercise. 
Similarly, we observed no significant effect of the DDAH transgene on time or distance that mdx 
males were able to run before reaching exhaustion (Fig. 4.6 C and D). Together, these data 
indicate that expression of the DDAH transgene was not sufficient to impact exercise-induced 
fatigue or exercise capacity in fully dystrophin-deficient males.  
Surprisingly, the drop in voluntary activity following exercise was significantly 
attenuated in DDAH-transgenic female mdx carriers compared to non-transgenic female mdx 
carrier littermates (Fig. 4.7 A and B). This observation demonstrated that unlike in fully 
dystrophin-deficient mdx males, DDAH transgene expression did have a beneficial effect to 
alleviate exercise-induced fatigue in dystrophin-heterozygous animals. This positive influence 
was limited to exercise-induced fatigue, as DDAH transgene expression did not affect the time 
or distance that mdx carrier females were able to run before reaching exhaustion (Fig. 4.7 C and 
D). This discrepancy would indicate that while DDAH transgene expression in mdx carriers can 
influence functional responses immediately following moderate-intensity exercise, it does not 
change the overall total exercise capacity or endurance of these mice.   
 
DDAH transgene expression alters heart size, but not skeletal muscle pathology, in 
female dystrophin-heterozygous mdx carriers.  
We next sought to understand the mechanisms underlying the beneficial effect of the 
DDAH transgene on exercise-induced fatigue in female dystrophin-heterozygous mdx carrier 
mice. Analysis of total nitrite + nitrate (NOx) concentration in the urine as an estimate of basal 
whole-body nitric oxide production revealed a slight but non-significant effect of the DDAH 
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transgene to increase urine NOx concentration in mdx males (Fig. 4.8A), and no significant 
effect of the DDAH transgene on urine NOx concentration in mdx carrier females (Fig. 4.8B). 
These data argue against any effect of the DDAH transgene to significantly modulate systemic 
NO levels in either mdx males or mdx carrier females. However, it remains possible that any 
local effects of the DDAH transgene on methylated arginine levels within specific tissues may in 
turn alter local NO production, any changes in which could be too small or too locally 
constrained to dramatically alter whole-body NOx levels. Unexpectedly, our data indicated that 
urine NOx concentration already tended to be elevated in ntg mdx males compared to WT  
males (Fig. 4.8A), and was already significantly elevated in ntg female mdx carriers compared to 
WT females (Fig. 4.8B). These finding provides further support to the notion that any small 
changes in NO production in TG animals may have been masked by an already elevated level of 
basal NO production in dystrophin-deficient and dystrophin-heterozygous animals. The 
elevated NOx concentration we observed likely represents NO produced by inducible NOS 
(iNOS), the expression of which is elevated in both dystrophic skeletal and cardiac muscle(17, 
51), as well as in inflammatory cells typically recruited to dystrophic muscle tissue(52). 
 Similar to urine NOx levels, steady-state plasma creatine kinase concentration was also 
elevated in non-transgenic male dystrophin-deficient mdx mice compared to WT controls, 
suggesting that dystrophin-deficient mice still exhibit muscle necrosis or sarcolemmal damage 
even at advanced ages (Fig. 4.8C). However, CK concentration was not significantly altered by 
DDAH transgene expression (Fig. 4.8C). Plasma CK concentration also tended to be elevated in 
ntg mdx carrier females compared to WT females (Fig. 4.8D). Although this difference did not 
reach statistical significance, it would support the idea that like fully dystrophin-deficient males, 
dystrophin-heterozygous animals exhibit a greater degree of muscle damage than healthy 
controls. As for mdx males, DDAH transgene expression did not significantly affect plasma CK 
concentration in female mdx carriers (Fig. 4.8D).  
To distinguish any tissue-specific effects of DDAH transgene expression, we examined 
the overall pathology of the heart and skeletal muscle. Although we saw no effect of DDAH 
transgene expression on heart weight in male mdx mice (Fig. 4.9 A and B), DDAH transgene 
expression resulted in a significantly lower heart weight in female mdx carriers (Fig. 4.9 C and 
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D). The specificity of this effect to female mdx carriers raises the intriguing possibility that the 
attenuation of exercise-induced fatigue in female TG mdx carriers and not male TG mdx mice is 
due to effects of the transgene that are unique to the dystrophin-heterozygous heart. We 
further assessed the effects of DDAH transgene expression on cardiac pathology by using Sirius 
red staining to quantify cardiac fibrosis. However, we did not observe any significant effect of 
transgene expression on this parameter in either mdx males or mdx carrier females (Fig. 4.9 E 
and F).  
Examination of skeletal muscle histology showed a reduction in the percentage of 
centrally-nucleated fibers in the gastrocnemius of TG versus ntg mdx males (Fig. 4.10A), but no 
other significant effects of DDAH transgene expression on fiber size, fiber size variability, or 
fibrosis in the gastrocnemius or soleus muscles of mdx males (Fig. 4.10 B-G). Similarly, DDAH 
transgene expression did not significantly affect central nucleation, fiber size, fiber size 
variability, or fibrosis in the gastrocnemius or soleus muscles of mdx carrier females (Fig. 4.10 
H-N). These data support the idea that DDAH transgene expression improves resistance to 
exercise-induced fatigue in mdx carrier females by exerting specific beneficial effects on the 
heart rather than in the skeletal muscle of these animals.  
 
DDAH transgene expression improves cardiac function in mdx carriers.  
Finally, we investigated whether DDAH transgene expression had any direct impact on 
cardiac function in female dystrophin-heterozygous mdx carriers. Echocardiography revealed 
that stroke volume was greater in DDAH-transgenic than non-transgenic female mdx carriers 
(Fig. 4.11A). This increase in stroke volume was associated with a reduction in basal heart rate 
in TG mdx carriers (Fig. 4.11B), resulting in similar cardiac output between the two genotypes 
(Fig. 4.11C). The left ventricular myocardial performance index, an integrated measure of both 
systolic and diastolic function, was also reduced in TG mdx carriers (Fig. 4.11D), lending 
additional support to the notion that contractile function is improved by DDAH transgene 
expression in these mice. The observation that an elevated heart rate seemed to compensate 
for diminished contractile performance in ntg mdx carriers prompted us to test the effects of 
DDAH transgene expression functional cardiac reserve in mdx carriers. Acute injection of 
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isoproterenol increased heart rate in TG mdx carriers, but failed to increase heart rate in ntg 
mdx carriers (Fig. 4.11E). This finding, coupled with the observation that resting heart rate is 
already elevated in ntg versus TG mdx carriers, indicates that much of the cardiac functional 
reserve is already used up in ntg mdx carriers under basal conditions, and therefore cardiac 
function cannot increase further in response to increased physiological demand. Furthermore, 
these results suggest that by improving contractile performance and lowering resting heart 
rates, DDAH transgene expression restores the functional reserve available for mdx carrier mice 




A growing body of evidence suggests that deficient striated muscle nitric oxide signaling and 
consequent disruption of sympatholysis represents a considerable component of the exercise-
induced fatigue phenotype in Duchenne muscular dystrophy. Recent reports demonstrating 
that deletion of nNOS worsens the phenotype of dystrophin-deficient mice(49, 53) and that 
restoration of  nNOS expression or signaling downstream of NO production can improve the 
function of dystrophin-deficient muscle(25, 54-57) further support the idea that the regulation 
of striated muscle NO production plays an important role in modulating disease progression in 
DMD. While a number of studies have investigated how changes in muscle cell-intrinsic 
processes affecting nNOS expression and its activity may alter NO signaling in DMD(18, 19, 58), 
the potential effects of cell-extrinsic factors such as circulating endogenous NOS inhibitors, and 
their ultimate functional consequences for dystrophin-deficient patients, have received little 
attention. This question is particularly relevant given increasing interest in increasing nNOS 
expression(54, 55), restoring nNOS sarcolemmal localization(34),  or activating upstream 
regulators of nNOS activity(19) as therapeutic strategies to  increase muscle nNOS activity in 
this disease, because endogenous NOS inhibitors may limit the efficacy of these interventions.  
 Here, we used an in vivo approach to address the hypothesis that excessive circulating 
levels of the endogenous NO synthase inhibitor, ADMA, contributes to exaggerated exercise-
induced fatigue in the mdx mouse model of Duchenne muscular dystrophy. Our findings that 
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methylated arginines are released to the circulation following muscle injury and are sufficient 
to impair exercise performance even in healthy mice with an intact dystrophin-glycoprotein 
complex support a causal role for these compounds in the exercise intolerance observed in 
DMD. They also emphasize the notion that secondary consequences of dystrophic muscle 
pathology, subsequent to the primary disruption of the DGC and destabilization of the 
sarcolemma, can have a substantial impact on the dystrophic phenotype. 
 Unexpectedly, transgenic expression of dimethylarginine dimethylaminohydrolase 1 
(DDAH) in an attempt to increase the degradation of ADMA improved resistance to exercise-
induced fatigue in female mdx carrier mice, but not male mdx mice. The discrepancy in the 
transgene’s effects between the dystrophin-deficient mdx background and the dystrophin-
heterozygous mdx carrier background raises interesting questions as to the mechanism by 
which changes in ADMA metabolism may affect exercise tolerance. We did not observe any 
effect of DDAH transgene expression on steady-state circulating methylated arginine 
concentrations in female mdx carriers. If changes in methylated arginine metabolism are in fact 
responsible for the alleviation of exercise-induced fatigue in female mdx carriers, these data 
suggest that the effects of transgenic DDAH expression on circulating methylated arginine levels 
may be appreciable only with acute elevation of these compounds during or immediately 
following a bout of exercise, and therefore would have been missed by our approach. 
Alternatively, any substantial effects of transgenic DDAH expression on ADMA or possibly L-
NMMA concentrations may occur locally within specific tissues. The idea of local rather than 
generalized effects of DDAH expression on methylated arginines and NO production is 
consistent with our observation that total urine NOx levels were not altered by TG expression. 
Indeed, the finding that total urine NOx concentration was elevated compared to WT in mdx 
carriers and also tended to be elevated in mdx males argues against a generalized, systemic 
inhibition of the nitric oxide synthases by excessive circulating methylarginines in dystrophic 
animals.  
Our findings that DDAH transgene expression reduced the mass and improved the 
contractile performance of the hearts of female mdx carriers indicate that local manipulation of 
ADMA metabolism can have consequential beneficial effects within dystrophin-heterozygous 
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cardiac muscle. This specific improvement in heart function may explain the efficacy of DDAH 
transgene expression in attenuating exercise-induced fatigue in mdx carriers, as we did not 
observe any changes in the skeletal muscle pathology with DDAH transgene expression in these 
animals. A cardiac-specific benefit of the DDAH transgene to affect exercise tolerance also 
makes sense in light of the phenotype of human DMD carriers, who generally suffer from little 
skeletal muscle pathology but are at increased risk for developing cardiomyopathy as they 
age(12-14). Fitting with this notion, the improvement in cardiac function and fatigue resistance 
that we observed with DDAH transgene expression occurred in relatively old (11-12 month) 
female mdx carriers. Although overt dilated cardiomyopathy has been reported to be absent in 
female mdx carrier mice up to 21 months of age(59), our observations that the extent of cardiac 
fibrosis is nearly the same in 11- to 12-month-old female mdx carriers as in 11-to 12-month-old 
mdx males, and that chronotropic responses to isoproterenol are lost in female mdx carriers, 
indicate that dystrophin heterozygosity has already started  to affect cardiac structure and 
function at this age. Furthermore, our finding that improved cardiac performance was 
associated with improved resistance to exercise-induced fatigue but not with increased 
maximal exercise capacity in TG female mdx carriers suggests that fatigue resistance is the 
phenotype that is more sensitive to changes in cardiac function in dystrophin-heterozygous 
animals. 
It will be interesting for future studies to determine the precise molecular mechanisms 
by which DDAH transgene expression improves heart function in female mdx carriers. Although 
the impact of mosaic dystrophin expression on cardiac NOS activity has not been reported, our 
data are consistent with a model in which ADMA released during necrosis of damaged, 
dystrophin-deficient cardiomyocytes has local effects to inhibit NO production in neighboring 
dystrophin-positive and dystrophin-null cells. As both nNOS and endothelial NOS are critical 
regulators of contractile function(30-33, 60, 61), relief of their inhibition with DDAH transgene 
expression and local reductions in ADMA concentration may contribute to improved contractile 
performance in TG mdx carriers. Locally-elevated ADMA may also exert either NO-dependent or 
NO-independent effects to promote expression of hypertrophic gene programs, and these 
effects may be attenuated in DDAH-transgenic carriers(62, 63).  
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 Why we did not see an impact of DDAH expression on the susceptibility to exercise-
induced fatigue despite a significant reduction in circulating ADMA concentration in fully 
dystrophin-deficient mdx males remains unanswered. The failure of DDAH transgene 
expression to affect heart size in male mdx mice may reflect that local reductions in ADMA 
concentration or subsequent effects on NO signaling within the heart are simply too small to 
significantly alter the progression of cardiac disease or dysfunction in the setting of total 
dystrophin deficiency. The findings presented in Chapter 2 of this thesis support the alternative 
hypothesis that NO production in dystrophin-deficient striated muscle cells is impaired due to 
distinct defects in mechanosignaling that are independent of methylated arginine metabolism.  
Thus, transgenic DDAH expression alone may in fact do little to improve muscle NO production 
in fully dystrophin-deficient males. Nevertheless, our work raises the interesting possibility that 
manipulating ADMA metabolism may have therapeutic implications not only for heterozygous 
DMD carriers, but also for instances in which exon-skipping or viral gene-delivery approaches 
result in only partial restoration of dystrophin expression in the hearts of male DMD patients. 
Given that exercise-induced fatigue was similar between aged mdx carriers and WT females, 
and that transgenic DDAH expression improved cardiac performance and fatigue resistance of 
mdx carriers, an intriguing question for future investigations is whether altered ADMA 
metabolism may also have beneficial effects on cardiac function or exercise tolerance as 
otherwise healthy individuals age.  
 Together, our findings support a model in which ADMA that is released from damaged 
cells contributes to dysfunction of the aged dystrophin-heterozygous heart. Impaired 
contractile function results in a compensatory increase in heart rate and a diminished 
functional cardiac reserve available for dystrophin-heterozygous subjects to respond to 
adrenergic stress, negatively affecting their ability to tolerate exercise. We demonstrate that 
DDAH transgene expression is sufficient to reduce heart size, improve contractile function, and 
restore chronotropic reserve in female dystrophin-heterozygous mice, possibly improving their 
immediate physiological responses to exercise. While additional studies will be required to 
uncover the pathways by which DDAH transgene expression modifies cardiac function in mdx 
carriers , this work places a new emphasis on the relevance of the regulation of methylated 
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arginine signaling to cardiac function in dystrophinopathies, and its potential to improve 
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Figure 4.1. Circulating methylated arginines are elevated by dystrophin-deficiency or acute 
muscle injury, and are sufficient to impair exercise performance. (A) Plasma concentrations of 
asymmetric dimethylargine (ADMA) and monomethylarginine (L-NMMA) are increased in mdx 
versus wild-type (WT) C57BL/10 mice (n=4-7) (*P<0.05 vs. WT control). (B) Acute single leg 
muscle injury with cardiotoxin (CTX) leads to an elevation in plasma creatine kinase (CK) 
concentration in WT mice (n=3-7) (*P<0.05). (C) Acute cardiotoxin injury elevates circulating L-
NMMA concentration and tends to elevate circulating ADMA concentration in WT mice (n=6-
10) (*P<0.05 vs. non-injured control). (D) In WT mice, infusion of exogenous ADMA elevates 
steady-state circulating ADMA concentration compared to infusion of saline (n=5) 
(****P<0.0001). ADMA-infused WT mice run less total distance per day (E) and per bout (F) on 






Figure 4.2. DDAH1 protein is robustly expressed in DDAH-transgenic mice. (A) Breeding 
scheme. Male DDAH-transgenic mice were crossed to female mdx mice, generating DDAH-
transgenic (TG) and non-transgenic (ntg) dystrophin-deficient mdx male and dystrophin-
heterozygous female offspring. (B)  DDAH1 protein expression is increased in the gastrocnemius 
muscle of TG wild-type (WT) males, mdx males, and heterozygous mdx carrier females 
(”mdxhet”) compared to ntg controls (n=3) (**P<0.01, ***P<0.001, ****P<0.0001). Dystrophin 
protein is not detected in gastrocnemius muscle of male mdx mice (n=6) (**P<0.01, 
***P<0.001). Low levels of endogenous DDAH1 are detected in the gastrocnemius muscle of 
ntg animals, but do not significantly vary between ntg WT males, ntg mdx males, and ntg mdx 
carrier females (n=3). (C) DDAH1 protein expression is increased in the heart of TG WT males, 
mdx males, and mdx carrier females compared to ntg controls (n=3) (*P<0.05. ****P<0.0001). 
Dystrophin protein is not detected in the hearts of male mdx mice, and is reduced compared to 
WT in the hearts of mdx carrier females (n=6) (**P<0.01, ****P<0.0001). Low levels of 
endogenous DDAH1 are detected in the hearts of ntg animals, but do not significantly vary 






Figure 4.3. DDAH transgene expression reduces circulating ADMA concentration in male 
dystrophin-deficient mdx mice. (A) Serum concentration of asymmetric dimethylarginine 
(ADMA) is reduced in DDAH-transgenic (TG) versus non-transgenic (ntg) male dystrophin-
deficient mdx mice (n=6) (***P<0.001). Serum concentrations of monomethylarginine (L-
NMMA) (B) and symmetric dimethylarginine (SDMA) (C) do not differ between ntg and TG male 
mdx mice (n=6). Serum concentrations of ADMA (D), L-NMMA (E), and SDMA (F) do not differ 






Figure 4.4. Validation of exercise assays and assessment of exercise tolerance in male mdx 
mice. (A) Sequence of open-field measurement sessions and treadmill exercise sessions used to 
assess exercise-induced fatigue. (B) Progressive increase of treadmill running speed in 
exhaustion assay. (C) Voluntary ambulatory activity decreases more over successive open field 
monitoring sessions in exercised than in mock-exercised male wild-type (WT) mice (*P<0.05, 
**P<0.01). (D) Voluntary ambulatory activity decreases more over successive open field 
monitoring sessions in exercised than in mock-exercised male dystrophin-deficient mdx mice 
(**P<0.01, ***P<0.001, ****P<0.0001). (E) Exercised male mdx mice exhibit a greater decrease 
in voluntary activity over successive open field monitoring sessions than exercised male WT 
mice (*P<0.05). (F) The decrease in voluntary ambulatory activity over successive open field 
monitoring sessions is similar in mock-exercised male WT and mdx mice. Male mdx mice run a 







Figure 4.5. Validation of exercise assays and assessment of exercise tolerance in female mdx 
carrier mice. (A) Voluntary ambulatory activity decreases more over successive open field 
monitoring sessions in exercised than in mock-exercised female wild-type (WT) mice (*P<0.05). 
(B) Voluntary ambulatory activity decreases more over successive open field monitoring 
sessions in exercised than in mock-exercised female dystrophin-heterozygous mdx carrier mice 
(**P<0.01). (C) Voluntary ambulatory activity decreases more over successive open field 
monitoring sessions in exercised than in mock-exercised female dystrophin-deficient  mdx mice 
(**P<0.01, ***P<0.001, ****P<0.0001). (D) Exercised female mdx mice exhibit a greater 
decrease in voluntary ambulatory activity over successive open field monitoring sessions than 
exercised female WT  and mdx carrier mice (*P<0.05, ***P<0.001, ****<P<0.0001, WT vs. mdx; 
^P<0.05, ^^^P<0.001, ^^^^P<0.0001 mdx carrier vs. mdx). (E) The decrease in voluntary 
ambulatory activity over successive open field monitoring sessions is similar in mock-exercised 
female WT, mdx carrier, and mdx mice. Female mdx carrier mice run a shorter time (F) and 
distance (G) before reaching exhaustion than female WT mice; this impairment  is further 






Figure 4.6. DDAH transgene expression does not affect exercise-induced fatigue or exercise 
capacity in male dystrophin-deficient mdx mice. (A) The absolute voluntary ambulatory activity 
over successive open field monitoring sessions does not differ between exercised DDAH-
transgenic (TG) and non-transgenic (ntg) male mdx mice. (B) The relative decrease in voluntary 
ambulatory activity over successive open field monitoring sessions does not differ between 
exercised TG and ntg male mdx mice. Male TG and ntg mdx mice do not differ in the time (C) or 









Figure 4.7. DDAH transgene expression attenuates exercise-induced fatigue in female 
dystrophin-heterozygous mdx carrier mice. (A) The absolute voluntary activity in open field 
sessions following successive bouts of treadmill exercise is greater in DDAH-transgenic (TG) 
than non-transgenic (ntg) female dystrophin-heterozygous mdx carrier mice (*P<0.05). (B) The 
relative decrease in voluntary ambulatory activity over successive open field monitoring 
sessions is attenuated in exercised TG versus ntg female mdx carrier mice (**P<0.05). Female 
TG and ntg mdx carrier mice do not differ in the time (C) or distance (D) that they are able to 







Figure 4.8. DDAH transgene expression does not significantly affect total body NO production 
or overall creatine kinase release in dystrophin-deficient mdx males or dystrophin-
heterozygous mdx carrier females. (A) Urine nitrite + nitrate (NOx) concentration in 
dystrophin-deficient mdx males is not significantly altered by DDAH transgene expression (n=12 
for WT; n=16 for ntg and TG mdx) (**P<0.01). (B) Urine NOx concentration is elevated in female 
dystrophin-heterozygous mdx carriers compared to wild-type (WT) but is not altered by DDAH 
transgene expression (n=12 for WT; n=16 for ntg and TG mdxhets) (**P<0.01). (C) Plasma 
creatine kinase concentration is elevated in ntg male mdx mice compared to WT, but is not 
significantly altered by DDAH transgene expression (n=12 for WT, n=16 for ntg and TG mdx) 
(**P<0.01). (D) Plasma creatine kinase concentration is slightly but not significantly elevated in 
female mdx carriers compared to WT, and is not significantly altered by DDAH transgene 






Figure 4.9. DDAH transgene expression reduces heart size in female dystrophin-heterozygous 
mdx carrier mice. The heart weight to body weight ratio (A) and heart weight to tibia length 
ratio (B) do not differ between non-transgenic (ntg) and DDAH-transgenic (TG) dystrophin-
deficient male mdx mice (n=16). Both the heart weight to body weight ratio (C) and heart 
weight to tibia length ratio (D) are reduced in TG versus ntg female dystrophin-heterozygous 
mdx carriers (n=16) (*P<0.05, **P<0.01). (E) The percent area of the heart staining positive for 
collagen does not differ between ntg and TG male mdx mice (n=6) (Scale bar = 200μm). (F) The 
percent area of the heart staining positive for collagen does not differ between ntg and TG 






Figure 4.10. DDAH transgene expression does not alter skeletal muscle pathology in female 
dystrophin-heterozygous mdx carrier mice. (A) The percentage of centrally-nucleated fibers 
(CNF) is reduced in the gastrocnemius muscle of DDAH-transgenic (TG) versus non-transgenic 
(ntg) male dystrophin-deficient mdx mice (*P<0.05). Fiber cross-sectional area (CSA) (B) and 
fiber CSA variance (C) do not differ between the gastrocnemius of ntg and TG male mdx mice. 
The percentage of CNF (D), fiber CSA (E), and fiber CSA variance (F) do not differ between the 
soleus muscle of ntg and TG male mdx mice. (G) The percent area of the gastrocnemius and 
soleus muscles staining positive for collagen does not differ between ntg and TG male mdx 
mice. The percentage of CNF, fiber CSA, and fiber CSA variance do not differ between the 
gastrocnemius muscle (H-J) or soleus muscle (K-M) of ntg and TG female dystrophin-
heterozygous mdx carrier mice. (N) The percent area of the gastrocnemius and soleus muscles 







Figure 4.11. DDAH transgene expression improves contractile performance and restores 
cardiac functional reserve in female mdx carriers. (A) Stroke volume is increased in DDAH-
transgenic (TG) compared to non-transgenic (ntg) female dystrophin-heterozygous mdx carriers 
(n=12) (*P<0.05). (B) Basal heart rate is reduced in TG mdx carriers (n=12) (**P<0.01). (C) 
Cardiac output is similar between ntg and TG mdx carriers (n=12). (D) The left ventricular 
myocardial performance index is reduced in TG versus ntg mdx carriers (n=12) (*P<0.05). (E) 
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Conclusions and future directions. 
 
SUMMARY OF THESIS WORK 
 
 The most striking phenotype of the muscular dystrophies is the characteristic 
progressive weakening and wasting of the skeletal muscles that first caught the attention of the 
physicians in the mid-1800s(1, 2). A defect in muscle plasma membrane integrity was described 
in these and other early works, and the eventual identification of causative mutations in 
components of the sarcolemmal dystrophin-glycoprotein complex (DGC)(3) support a 
fundamental role for this structure in preventing mechanical injury of the membrane. While a 
primary defect in sarcolemmal stability can explain the increased susceptibility of dystrophic 
muscle cells to damage when subjected to mechanical stress, sarcolemmal instability does not 
offer a ready explanation for all the phenotypes observed in muscular dystrophy patients. For 
example, muscular dystrophy patients are easily fatigued by even mild physical activity such as 
walking that does not place undue strain on the muscles, a phenomenon noted in early case 
studies by Duchenne(2). The discovery that the enzyme neuronal nitric oxide synthase (nNOS) is 
retained near the skeletal muscle sarcolemma by interactions with the DGC, but is mislocalized 
to the cytosol when the DGC is disrupted and is no longer activated appropriately during 
exercise(4-12), suggested an additional signaling function for the complex. The loss of DGC-
dependent regulation of muscle nitric oxide (NO) production is thought to contribute to 
impaired exercise tolerance in muscular dystrophy patients because muscle NO production is 
critical for the local maintenance of blood flow to the muscle during exercise(13, 14). Despite 
the potential relevance of this signaling pathway to disability in Duchenne muscular dystrophy 
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and related diseases, the molecular mechanisms by which dystrophin and the DGC regulate 
nNOS activity are poorly understood. Therefore, the goal of this project was to dissect the 
molecular pathways leading from the loss of dystrophin to impaired striated muscle nitric oxide 
production. 
A live-cell imaging assay was developed to monitor NO production directly while wild-
type and dystrophin-deficient cardiomyocytes were stretched in vitro. The strength of this assay 
was the ability to monitor acute activation of NO synthesis in combination with standard 
biochemical analyses in order to explore the contribution of intracellular mechanosensitive 
signaling pathways to the regulation of nNOS activity, and how these pathways are affected by 
the loss of dystrophin (Chapter 2). These experiments identified dystrophin-dependent 
mechanoactivation of AMP-activated protein kinase (AMPK) as an upstream regulator of 
mechanosensitive NO production in muscle cells. Furthermore, these studies showed that 
direct pharmacologic activation of AMPK could restore acute nitric oxide production in 
dystrophin-deficient cardiomyocytes (Chapter 2). To expand these studies, further experiments 
outlined in Chapter 3 showed that acute AMPK activation could activate skeletal muscle NOS 
activity and improve exercise tolerance in vivo in the dystrophin-deficient mdx mouse model of 
Duchenne muscular dystrophy (DMD). In addition to changes in intrinsic signaling cascades 
within individual dystrophin-deficient muscle cells, muscular dystrophy patients display 
dramatic alterations in the composition of the extracellular fluid that reflect the high degree of 
cell damage and degeneration within their striated muscle(15, 16). Chapter 4 showed the 
significance of elevated circulating levels of endogenous nitric oxide synthase inhibitors to 
impaired NO production and exercise intolerance in dystrophin-deficient mdx mice and 
dystrophin-heterozygous mdx carrier mice, a model for female carriers of DMD mutations. 
Collectively, the experiments presented in the preceding chapters demonstrated the 
contributions of muscle cell-intrinsic and -extrinsic alterations on impaired striated muscle nitric 
oxide production and exercise intolerance observed in dystrophinopathies. Importantly, these 
experiments have identified new therapeutic targets to improve exercise tolerance in 
Duchenne and potentially other DGC-related muscular dystrophies. The findings described in 
the previous chapters are summarized in the following sections to demonstrate how they 
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support the hypothesis that both the mechanosignaling and the structural, membrane-
stabilizing functions of the DGC are essential for normal striated muscle nitric oxide signaling 
and a normal ability to withstand exercise. The next sections will also discuss how the relative 
contribution of these two mechanisms to nitric oxide synthase impairment and exercise 
intolerance may vary between the fully dystrophin-deficient and dystrophin-heterozygous state 
(Fig. 5.1). It is important to note that the relative contribution of these mechanisms to NO 
production and exercise phenotypes may differ between species as well, a consideration that 
will be important for the planning and interpretation of future pre-clinical translational studies 
relying on animal models of muscular dystrophy.  
 
DGC-dependent mechano-AMPK signaling stimulates striated muscle NO production. 
 Chapter 2 described the consequences of dystrophin deficiency for mechanically-
activated signaling pathways that regulate nNOS activity within adult mouse cardiomyocytes. 
Whereas in vitro passive stretch stimulated NO production and a downstream increase in 
cellular cGMP content in wild-type (WT) cells, these effects were abrogated in dystrophin-
deficient mdx cells, suggesting that impaired nNOS function in dystrophin-deficient muscle may 
be a direct result of disrupted mechanotransduction. nNOS-specific inhibition partially 
attenuated stretch-induced NO production in WT cardiomyocytes, verifying that this particular 
nitric oxide synthase isoform is activated by mechanical stimulation of this tissue. Western 
blotting revealed that this impaired mechano-NO production in mdx cardiomyocytes was 
associated with attenuation of mechanically-activated phosphorylation of nNOS at the 
stimulatory residue serine 1412, along with impaired activating phosphorylation of a kinase 
that targets this residue, AMP-activated protein kinase (AMPK). Pharmacologic AMPK inhibition 
inhibited the stretch-induced NO production observed in WT cardiomyocytes, and the 
endogenous level of nNOS serine 1412 phosphorylation was reduced in vivo in mdx mouse 
hearts. Together, these findings support the idea that dystrophin-dependent 
mechanoactivation of AMPK contributes to the mechanically-induced stimulation of nNOS 
enzymatic activity, and that impaired mechanoactivation of AMPK contributes to defective 
regulation of nNOS activity and phosphorylation state within the beating dystrophin-deficient 
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heart. Neither nNOS nor the catalytic α-subunit of AMPK were specifically enriched at the 
sarcolemma of WT or dystrophin-deficient cardiomyocytes under basal conditions, and were 
not recruited to the plasma membrane during acute mechanical stretch of the cells. This work 
identifies AMPK as a mediator of dystrophin-dependent nNOS regulation in striated muscle, 
and, importantly, demonstrates that dystrophin can influence striated muscle nNOS activity 
even in the absence of a direct physical interaction between nNOS and the DGC. Thus, 
scaffolding interactions between the DGC and nNOS in skeletal muscle may primarily be 
important for targeting nNOS to physiologically-important sites of action, rather than for direct 
regulation of nNOS activity. 
 
Acute pharmacologic stimulation of AMPK improves exercise tolerance of dystrophin-
deficient mice. 
 The final experiments described in Chapter 2 tested whether direct pharmacologic 
stimulation of AMPK-nNOS signaling could stimulate nitric oxide production in dystrophin-
deficient cardiomyocytes. Indeed, acute treatment of mdx cardiomyocytes either with the 
AMP-analog AICAR or with the aspirin metabolite salicylate caused increased activating 
phosphorylation of AMPK, increased stimulatory phosphorylation of nNOS-serine 1412, and 
increased nNOS-dependent cellular NO production. The magnitude of these effects were similar 
between wild-type and dystrophin-deficient cardiomyocytes, suggesting that apart from 
uncoupling AMPK activation from mechanical stimuli, the loss of dystrophin does not otherwise 
negatively impact the functional capacity of downstream components of the AMPK-nNOS 
signaling pathway in cardiac muscle.  
 The investigations described in Chapter 3 started by testing if pharmacologic AMPK 
activation could also stimulate nitric oxide synthesis in dystrophin-deficient skeletal muscle 
cells. In these experiments, acute salicylate treatment increased cellular NO production in 
isolated WT and mdx flexor digitorum brevis fibers, but AICAR did not stimulate fiber NO 
production in fibers of either genotype. Taken with the findings from the analogous 
experiments in cardiomyocytes, this result suggests that AMPK activation is sufficient to 
stimulate NO production across both types of striated muscle, but that the AMPK heterotrimers 
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that are expressed and that functionally target NOS likely differ in their composition of AICAR-
sensitive subunits between these two types of muscle. Importantly, the observation that 
salicylate treatment increased NO production even in dystrophin-deficient skeletal muscle 
fibers suggests that nNOS within these cells can still be activated and is not completely 
defective as a result of the loss of nNOS-DGC binding. Thus, this finding provides further 
support to the notion that physical interactions between nNOS and the DGC are not strictly 
required for striated muscle nNOS activity. Collectively, the in vitro drug experiments of 
Chapters 2 and 3 provide foundational evidence for acute pharmacologic AMPK activation as a 
therapeutic strategy to increase NO production by dystrophin-deficient striated muscle.  
 The second part of Chapter 3 expanded upon these in vitro results to test the hypothesis 
that acute pharmacologic AMPK activation improves exercise tolerance in dystrophin-deficient 
mdx mice. Two separate models of treadmill running were first validated for their ability to 
detect distinct components of exercise intolerance observed in muscular dystrophy: 
exaggerated exercise-induced fatigue and a diminished total exercise capacity. In control 
experiments, treatment of mdx mice with the phosphodiesterase 5 (PDE5) inhibitor sildenafil, a 
drug that has been previously shown to increase muscle blood flow and alleviate exercise-
induced fatigue in this model,  attenuated the decrease in the animals’ voluntary ambulatory 
activity following exercise. This result indicates that PDE5 inhibition does indeed alleviate post-
exercise fatigue in dystrophic animals, as has been reported by others(17), and verified that the 
fatigue assay used in this study was sensitive enough to detect an improvement in fatigue 
resistance following pharmacologic intervention. In contrast, sildenafil treatment did not affect 
the time or distance that mdx mice were able to run before reaching exhaustion, suggesting 
that inhibiting the breakdown of cGMP and improving muscle blood flow does not significantly 
affect the maximal exercise capacity of dystrophin-deficient mice. Acute treatment of mdx mice 
with pharmacologic AMPK activators yielded effects that were distinct from those of PDE5 
inhibition. Both AICAR and salicylate increased the time and distance that mdx mice ran before 
reaching exhaustion, demonstrating that AMPK activation increases the exercise capacity of 
dystrophin-deficient animals. These data represent intriguing proof-of-concept evidence for the 
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therapeutic potential of acute pharmacologic AMPK activation to improve exercise tolerance in 
Duchenne muscular dystrophy. 
 
Endogenous nitric oxide inhibitors released following sarcolemmal injury of dystrophin-
deficient cells may contribute to exercise intolerance in subjects with mosaic dystrophin 
expression.  
 Finally, Chapter 4 discusses experiments designed to understand the contribution of 
endogenous nitric oxide synthase inhibitors to impaired exercise tolerance in DMD. Initial 
studies showed that circulating concentrations of the methylated arginines asymmetric 
dimethylarginine (ADMA) and monomethylarginine (L-NMMA) are elevated in dystrophin-
deficient mdx mice, a finding consistent with the observation of excessive urinary ADMA 
concentrations in human muscular dystrophy patients(18, 19). Induction of acute degenerative 
muscle injury with cardiotoxin increased circulating methylated arginine concentrations in wild-
type mice, and infusion of exogenous ADMA into WT mice was sufficient to impair exercise 
performance on voluntary running wheels. Collectively, these findings suggest that the elevated 
circulating methylated arginine concentrations in DMD results from the increased amount of 
cell damage and necrotic cell death in dystrophin-deficient muscle, and that excessive ADMA 
may contribute to reduced exercise tolerance in dystrophin-deficient subjects. Therefore, 
dystrophin-deficient male mdx and dystrophin-heterozygous female mdx carrier mice 
expressing a transgene encoding dimethylarginine dimethylaminohydrolase (DDAH), the 
enzyme that degrades ADMA, were generated in order to test the effects of excessive ADMA on 
exercise tolerance in DMD and DMD carriers.  
DDAH transgene expression attenuated the drop in voluntary ambulatory activity 
following treadmill exercise in dystrophin-heterozygous female mice, but not in dystrophin-
deficient male mice. The beneficial effect of DDAH transgene expression on the exercise 
phenotype of female mdx carriers was associated with reduced heart mass, a lower resting 
heart rate, and an increased stroke volume in transgenic mdx carriers. Echocardiography 
revealed that DDAH transgene expression lowered the left ventricular myocardial performance 
index in female mdx carriers, indicating that it improved the heart’s systolic and/or diastolic 
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function. Finally, the chronotropic response to acute β-adrenergic stimulation was lost in 
female mdx carriers, but was restored with expression of the DDAH transgene. Together, these 
data support the idea that endogenous methylated arginines promote pathological remodeling 
and impair the function of the dystrophin-heterozygous heart. They further suggest that 
dystrophin-heterozygous subjects adapt to impaired contractile function with a compensatory 
increase in basal heart rate. A diminished chronotropic reserve may mean that dystrophin-
heterozygous hearts have less functional reserve available to increase cardiac output during 
exercise, possibly contributing to exercise-induced fatigue in mdx carriers.  
 
 The findings presented in this thesis expand our understanding of the mechanisms by 
which disruption of the dystrophin-glycoprotein complex alters physiologically-relevant 
signaling pathways within striated muscle and thus may contribute to disability in the muscular 
dystrophies. Because these results support a role for both the signaling and structural functions 
of the DGC in the regulation of muscle nitric oxide production and exercise performance, they 
have important implications for both for muscular dystrophies in which sarcolemmal integrity is 
compromised, as well in instances where DGC-dependent signaling is perturbed even though 
sarcolemmal stability is maintained(9, 10, 20). The implications of these findings and their 
relevance to muscular dystrophy therapies will be addressed in more depth in the remainder of 
this chapter. The rest of the chapter will also outline future experiments to determine the 
mechanisms by which the DGC regulates AMPK activity, as well as the role of ADMA in cardiac 
remodeling. 
 
IMPLICATIONS AND FUTURE DIRECTIONS 
 
Towards an integrated model for the mechanosignaling and structural functions of the 
dystrophin-glycoprotein complex in the regulation of striated muscle nitric oxide production. 
 The dystrophin-glycoprotein complex is critical for the protection of the sarcolemma 
from mechanical injury during muscle contraction. This membrane-stabilizing function of the 
DGC is mediated by its structural linkage of the muscle cell cytoskeleton and the extracellular 
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matrix, and disruption of this physical connection between the interior and exterior of the 
muscle cell is a primary factor contributing to muscle cell injury, muscle death, and the 
progressive weakening and disability that is seen in many forms of muscular dystrophy. Recent 
studies have suggested an additional role for the DGC in regulating cell signaling(4, 5, 21-31), 
although how disruption of this signaling capacity affects muscle function and contributes to 
the overall disease phenotype in muscular dystrophy patients is not fully understood. 
Considered together, the results discussed above support a model in which both the signaling 
and structural functions of the DGC have important consequences for the mechanical 
regulation of nitric oxide production by striated muscle cells (Fig. 5.1).  
 The findings from Chapter 2 indicate that the loss of dystrophin disrupts mechanically-
induced activation of AMPK-nNOS signaling, resulting in impaired mechanical activation of 
cellular NO production. These data demonstrate that a direct function for dystrophin and the 
DGC, possibly as a mechanotransducer, is critical for the activation of intrinsic, biochemical 
signaling cascades that stimulate the enzymatic activity of nNOS. It is important to note that for 
technical reasons relating to the ease with which they can be passively stretched in bulk in 
tissue culture systems, these experiments were conducted using cardiomyocytes as a general 
model for striated muscle mechano-NO signaling. Thus, it remains to be determined whether 
DGC-dependent activation of AMPK similarly regulates nNOS activity within skeletal muscle. 
Previous investigations have shown that skeletal muscle contraction is associated with the 
concurrent activation of nNOS and AMPK(32); that genetic disruption of AMPK activity is 
associated with reduced nNOS phosphorylation in vivo(33); and that pharmacologic stimulation 
of AMPK with AICAR is sufficient to stimulate nNOS phosphorylation and NO production in 
skeletal muscle myotubes in vitro(33, 34). These data suggest that AMPK does play some role in 
the regulation of nNOS activity in skeletal muscle. Future studies could modify the approach 
used in Chapter 2 and use electrical field stimulation to stimulate contraction or carbon micro-
fibers(35, 36) to stretch isolated mature skeletal muscle fibers in vitro in combination with 
genetic knockout or pharmacologic inhibition of AMPK in order to determine the specific 
contribution of AMPK to mechanically-activated NO production in this tissue.  
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 The research presented in Chapter 4 indicates that the structural function of the DGC to 
stabilize the sarcolemma may also play an indirect role in regulating striated muscle NO 
production. The finding that acute degenerative muscle injury with cardiotoxin was sufficient to 
cause elevated circulating levels of methylated arginines in wild-type mice suggests that in 
dystrophin-deficient mdx mice and DMD patients, elevated circulating levels of the endogenous 
NOS inhibitors are a direct result of increased sarcolemmal instability and necrosis of injured 
dystrophin-deficient muscle cells. In the model proposed here, the lack of an effect of DDAH 
expression and subsequent lowering of ADMA levels in male mdx mice to significantly alter 
exercise-induced fatigue, a phenotype that is related to impaired striated muscle NO 
production, can be explained by the observation from Chapter 2 that the normal activation of 
muscle nNOS activity is already disrupted due to the impairment of mechanosensitive AMPK 
signaling within dystrophin-deficient muscle cells (Fig. 5.1 A and B). In other words, relieving 
any ADMA-dependent inhibition of nNOS may do little to increase striated muscle NO 
production in dystrophin-deficient subjects, because this process is still impaired due to cell-
intrinsic defects in DGC-dependent mechanosignaling. Because monomethylarginine (L-NMMA) 
can also inhibit NOS(37) and its circulating concentration was elevated in dystrophin-deficient 
animals but not significantly reduced by DDAH transgene expression in the studies described in 
Chapter 4, it is also possible that this compound exerts an additional layer of nNOS inhibition 
that could help to explain the lack of improved NO production and fatigue resistance in DDAH-
transgenic dystrophin-deficient animals.  
Furthermore, the proposed model would predict that in dystrophin-deficient subjects, in 
vivo pharmacologic stimulation of AMPK in an attempt to stimulate NOS activity within the 
striated muscle may ultimately do little on its own to increase cellular NO production because 
nNOS would still be subject to inhibition by excessive methylated arginines. Indeed, attenuated 
nNOS activity as combined result of impaired mechanosignaling and inhibition by methylated 
arginines could help to explain why cellular NO production is only slightly increased (~0.2-fold) 
in nNOS-transgenic dystrophin-deficient skeletal and cardiac muscle despite robust 
overexpression of nNOS in these tissues(38, 39). Experiments measuring indices of in vivo 
muscle cell NO production, like protein nitrosylation or tissue nitrite + nitrate (NOx) content, in 
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mdx mice treated with AMPK-activating drugs that stimulate nNOS in vitro could shed light on 
whether nNOS inhibition by excessive methylated arginines may override normal endogenous 
stimulation of muscle NO production. Another way to test this question could be to use in situ 
fluorescence imaging of mdx skeletal muscles loaded with NO-sensitive dyes in order to 
measure their NO production following acute administration of AMPK-activating drugs. If 
elevated concentrations of methylated arginines do inhibit NOS in intact dystrophin-deficient 
striated muscle, pharmacologic AMPK activation should fail to stimulate muscle NO production 
in non-transgenic mdx mice. However, pharmacologic AMPK activation may be sufficient to 
stimulate muscle NO production in DDAH-transgenic mdx mice in which any NOS inhibition by 
AMDA should be minimized. Studies like these would also help to clarify whether the beneficial 
effects of acute pharmacologic AMPK activation on the exercise tolerance of dystrophin-
deficient animals are mediated by increased striated muscle NO production. 
 A model incorporating both the cell-intrinsic functions of the DGC in mechanosignaling 
and its structural role to prevent membrane damage and the excessive release of methylated 
arginines to the extracellular fluid on striated muscle NO production also has interesting 
implications for cases of mosaic dystrophin expression. This pattern of expression occurs in the 
cardiac muscle of female DMD carriers, and could also arise in male DMD patients treated with 
gene-delivery, exon skipping, or stem-cell based therapies that may restore dystrophin 
expression to only a subset of skeletal muscle fibers or cardiomyocytes(40-43). In these 
instances, populations of dystrophin-positive or wild-type cells and dystrophin-mutant or -null 
cells would be distributed throughout the muscle tissue (Fig. 5.1C). In dystrophin-positive cells, 
intact mechano-DGC-AMPK signaling would allow for normal phosphorylation of nNOS by 
AMPK under periods of increased mechanical stress. However, when placed under mechanical 
stress, the population of dystrophin-null cells would be susceptible to sarcolemmal lesion and 
subsequent necrotic cell death, resulting in the local release of methylated arginines. These 
compounds could then inhibit NO production by nNOS in neighboring dystrophin-positive cells, 
despite intact mechanically-regulated phosphorylation of nNOS by AMPK within that 
population (Fig. 5.1C). This model may explain why DDAH transgene expression had a beneficial 
effect in the hearts of mdx carriers: in non-transgenic carriers, there were dystrophin-positive 
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cardiomyocytes with intact mechano-AMPK signaling, but whose nNOS activity was inhibited by 
ADMA released from nearby damaged, dystrophin-null cardiomyocytes. Expression of the 
DDAH transgene would likely have reduced ADMA concentration in the local 
microenvironment, thus relieving nNOS inhibition and restoring the capacity for NO production 
in dystrophin-expressing cells, ultimately leading to positive effects on cardiac function. The 
unexpected finding that mdx and mdx carrier mice show increased urinary NOx levels consistent 
with increased total body iNOS activity suggests that any effects of extracellular ADMA to 
inhibit muscle nNOS likely occur on a very localized level within muscle tissue, with NOS 
inhibition by ADMA being the most pronounced within intact cells in the immediate vicinity of 
degenerating cells (Fig. 5.1C). Thus, the structural function of the DGC to stabilize the plasma 
membrane seems to play an important, indirect role in maintaining a local extracellular milieu 
that is permissive for striated muscle nitric oxide signaling. 
 The proposed model predicts that nNOS activity would be impaired in both dystrophin-
positive and dystrophin-null cell populations within mosaic muscle, albeit by distinct 
mechanisms. Accordingly, nNOS activity in muscle with mosaic dystrophin expression should be 
impaired as it is in fully dystrophin-deficient muscle, although the extent of impairment would 
likely vary with the degree of muscle damage and local methylated arginine release, and thus 
may be more pronounced following physical activity involving eccentric exercise. While 
restoration of dystrophin expression can restore nNOS sarcolemmal localization in DMD 
skeletal muscle fibers(41, 44), the effect of mosaic dystrophin expression on NO production in 
the hearts of DMD carriers or in partially-corrected DMD skeletal muscle has not yet been 
reported in the literature. Therefore, it would be interesting for future investigations to explore 
the effect of mosaic dystrophin expression on muscle nNOS activity. Mechanosensitive NO 
production in dystrophin-mosaic tissue could be assessed by increasing the frequency of 
electrical pacing of working hearts isolated from dystrophin-heterozygous female mdx carrier 
mice or by stimulating contraction in situ in skeletal muscles of wild-type/mdx chimeric mice 
generated by the injection of wild-type embryonic stem cells into mdx blastocysts(45). If both 
dystrophin-positive and dystrophin-null cells in these dystrophin-mosaic tissues have impaired 
NO production due to the combined effects of disrupted mechanosignaling and inhibition of 
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nNOS by the local release of ADMA from damaged cells, then the total mechanosensitive NO 
production by these intact preparations should be reduced compared to wild-type to an extent 
approaching the degree of impairment observed in fully dystrophin-deficient muscle. Critically, 
if the proposed model is correct, in vitro examination of heterogeneous populations of 
enzymatically dissociated cardiomyocytes or skeletal muscle fibers that are surrounded by a 
relatively large volume of media should minimize the local accumulation of methylated 
arginines at high concentrations surrounding any damaged cells. In this setup, measurement of 
cellular NO production during mechanical stimulation by passive stretch or electrical field 
stimulation of contraction should, in contrast to studies of intact muscle tissue where 
methylated arginines can accumulate locally, reveal discrete populations of cells that respond 
to mechanical perturbation with increased NO production and cells that do not respond to 
mechanical perturbation with increased NO production. Fixing the cells and performing 
immunofluorescence staining for dystrophin expression following completion of the mechanical 
stimulation protocol could verify that the mechano-responsive population was indeed 
comprised of dystrophin-positive cells, and that the non-responsive population contained the 
dystrophin-null cells. 
 
The mechanical regulation of AMPK by the dystrophin-glycoprotein complex. 
 In addition to direct allosteric regulation by adenine nucleotides and glycogen that allow 
AMPK to sense cellular energy and nutrient status(46-48), several studies suggest that AMPK is 
also subject to regulation by the mechanical activity of a given cell. Experiments in contracting 
skeletal muscle or beating hearts support the idea for mechanical activation of AMPK that can 
even be graded according to the mechanical load against which the tissue must work(32, 49). 
However, interpretation of the direct consequences of mechanical stimulation as opposed to 
metabolic stress on AMPK activation in this context is confounded by the potential for 
increased contractile activity of muscle to accelerate cellular turnover of ATP. Models of passive 
muscle stretch, which impose less metabolic demand than muscle contraction, indicate that 
this mode of mechanical stimulation also activates AMPK(50, 51), supporting the idea that 
there may be unique mechanisms for mechanical regulation of this enzyme separate from its 
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metabolic regulation. The activation of AMPK by passive stretch also occurs in non-muscle 
tissue, and in lung epithelial cells has been shown to depend on the expression of dystroglycan, 
a core component of the dystrophin-glycoprotein complex within muscle(52). Taken with the 
findings presented in Chapter 2, this observation supports a role for the DGC in the mechanical 
regulation of AMPK.  
How, then, might the DGC regulate mechanically-induced AMPK activation? A number 
of targets known to regulate AMPK activity across a wide range of tissues could be activated 
downstream of the intact DGC and couple DGC-dependent mechanosensation to the 
stimulation of striated muscle AMPK activity (Fig. 5.2). The upstream kinases liver kinase B1 
(LKB1) and Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) phosphorylate the 
catalytic alpha subunit of AMPK at threonine 172 and thereby increase its enzymatic 
activity(53-57). Whether either of these two kinases is specifically activated by mechanical 
stimulation, and whether dystrophin plays any direct role in this process, remains to be 
determined. However, since CaMKKβ can be activated by calcium, the cytosolic levels of which 
are increased by muscle contraction or stretch(58-60), this protein is a promising candidate for 
mechanically-induced AMPK activation. The phosphatases PP2A and PP2C oppose the actions of 
LKB1 and CaMKKβ and dephosphorylate AMPKα-Thr172(61-63), and thus represent another 
signaling pathway regulating AMPK activity. The observation that PP2A activity is increased by 
calcium(61) could help to explain why increased cytosolic calcium flux with stretch or eccentric 
contraction of dystrophin-deficient muscle cells(36, 64) is not associated with increased AMPK 
activation, as might be expected based on the ability for calcium to stimulate CaMKKβ. In this 
scenario, dystrophin and the DGC may serve a permissive rather than a direct role in AMPK 
regulation, by preventing stretch-induced calcium overload and excessive phosphatase activity 
in the muscle cell. Activation of phosphatases in dystrophin-deficient muscle cells that occurs 
specifically under periods of mechanical stress may also help to explain why application of 
AICAR or salicylate to non-stretched mdx cardiomyocytes increased AMPKα-Thr172 
phosphorylation to an extent similar to that observed in treated WT cardiomyocytes. 
Alternatively, the discrepancy between the efficacy of mechanical versus AICAR- or salicylate-
induced AMPKα-Thr172 phosphorylation and stimulation of kinase activity in dystrophin-
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deficient cells may reflect distinct roles for the different upstream AMPK kinases in 
phosphorylating AMPK under these different conditions. 
In addition to stimulatory phosphorylation of AMPKα-Thr172, a number of other post-
translational modifications of AMPK may be mechanically regulated and altered by dystrophin 
expression. Phosphorylation of AMPKα-Thr479 by glycogen synthase kinase (GSK) increases the 
access of phosphatases to AMPKα-Thr172, thus favoring Thr172 dephosphorylation and tending 
to decrease AMPK activity(65). GSK’s kinase activity towards AMPK can be activated by AKT, 
which can also phosphorylate AMPKα-Ser485 leading to reduced Thr172 phosphorylation(65, 
66). Notably, the mechanical activation of AKT is increased in dystrophin-deficient muscle(23). 
This effect may be mediated by increased mechanosensitive production of reactive oxygen 
species (ROS) in the absence of dystrophin(58), as increased ROS can activate AKT(67). Thus, a 
second permissive role for the DGC in the appropriate mechanoregulation of AMPK may be the 
prevention of excessive ROS generation and subsequent activation of AKT and GSK during 
periods of mechanical stress. Furthermore, excess mechano-ROS production could also oppose 
mechano-AMPK activation in dystrophin-deficient muscle cells directly via the inhibitory 
oxidation of cysteine residues in the alpha subunits of AMPK(68). 
Additional levels of allosteric control may also play direct or permissive roles in DGC-
dependent AMPK regulation. Glycogen inhibits AMPK through interaction with the glycogen-
binding domain of the beta subunits(69). Increased muscle glycogen content reported in 
dystrophin-deficient mdx mice(70) and in some human DMD patients(71) may therefore 
attenuate any mechanically-induced activation of AMPK. The cytoskeleton of dystrophin-
deficient muscle cells could also affect the allosteric regulation of AMPK. The cytoskeletal 
protein plectin binds to AMPKγ1 subunits in differentiated muscle and has been shown to 
reduce the AMP-sensitive activity of γ1-containing AMPK heterotrimers, possibly by stabilizing 
the expression of the less responsive α1 subunit over the more responsive α2 subunit(72). 
Several reports indicate that plectin expression is increased in dystrophin-deficient skeletal 
muscle(73, 74), and, consistent with this model, a recent study demonstrated a decrease in 
AMPKα2 expression in the gastrocnemius muscle of dystrophin-deficient dogs(75). Thus, 
alteration of the cytoskeleton in dystrophin-deficient muscle cells may influence the subunit 
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composition of AMPK heterotrimers in a manner that ultimately reduces the sensitivity of their 
kinase activity to regulation by normal allosteric regulators, such as increased cellular AMP 
content during stretch or contraction. 
Distinct from such a permissive role of the DGC in allowing mechanosensitive AMPK 
activation is the particularly intriguing idea that dystrophin or the DGC directly binds to and 
mechanically regulates conformational changes in the regulatory γ- or β-AMPK subunits, which 
are then translated to the α-subunit to favor the phosphorylation of AMPKα-Thr172 and 
promote AMPK kinase activity. A recent study demonstrated that inhibition of contraction with 
myosin inhibitors attenuated the increase in phosphorylation of AMPKα-Thr172 in electrically-
stimulated isolated muscles(76). This observation could be explained either by attenuation of 
the mechanical forces normally exerted on the sarcolemma by contraction of the muscle, 
resulting in less mechanical stimulation of DGC-dependent signaling; or by the fact that 
inhibiting cross-bridge cycling will result in reduced cellular consumption of ATP, thus placing 
less metabolic stress on the electrically-stimulated muscle cells. Interestingly, though, the 
attenuation of AMPKα phosphorylation was associated with a specific and potent inhibition of 
the kinase activity of AMPK heterotrimers composed of α2β2γ3 subunits. The authors also 
reported a distinct increase in the kinase activity of AMPK heterotrimers containing γ1 subunits, 
which presumably was correlated to the observed net increase  in AMPKα phosphorylation in 
stimulated muscles(76). The different AMPK γ-subunits do differ in their overall sensitivity to 
regulation by adenine nucleotides, with AMPK trimers containing the γ-3 subunit being the 
least sensitive to activation by AMP(77).The observations by Jensen et al.(76) would further 
indicate that the γ-AMPK subunits also differ in their sensitivity to mechanical stimulation, 
suggesting that different AMPK subunits may play specific roles in distinct metabolically- or 
mechanically-regulated signaling pathways. While striated muscle expresses a variety of AMPK 
subunits (Fig. 5.2), whether any of the γ-AMPK subunits, or even the β-AMPK subunits, are 
specifically associated with the DGC in skeletal or cardiac muscle, and whether disruption of the 
DGC affects their function, is currently unknown.  
Answering this question would help to clarify the mechanism by which loss of 
dystrophin-dependent mechanosensation perturbs striated muscle AMPK signaling. Studies to 
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this end could use cardiomyocytes or skeletal muscle fibers from mice with subunit-specific 
knockout of AMPK, starting with γ3(78). In such experiments, it would be important to 
quantitatively assess how the loss of specific individual AMPK subunits affects stretch-induced 
increases in AMPK activation, measured by stimulatory phosphorylation of AMPKα-Thr172 in 
addition to AMPK kinase activity, as indicated by phosphorylation of validated endogenous 
AMPK targets like acetyl-CoA carboxylase within cells or in vitro phosphorylation of the artificial 
SAMS peptide by AMPK heterotrimers isolated from mechanically-stimulated muscle cells or 
tissue. It would also be interesting to monitor changes in cellular respiration and ATP content 
under these conditions, in order to understand how specific AMPK subunits contribute to 
metabolic responses to mechanical stress. This general approach could also be modified to 
measure mechanically-induced nNOS activation in order to identify the subunit composition of 
AMPK trimeric complexes that participate in the mechanical regulation of nNOS. Finally, the 
effect of dystrophin deficiency on the localization of AMPK heterotrimers of different subunit 
composition could be assessed using immunofluorescence labelling of wild-type and mdx 
muscle fibers and cardiomyocytes, and its effect on mechanoactivation of different AMPK 
heterotrimers could be measured biochemically following immunoprecipitation of specific 
AMPK complexes from lysates of stretched wild-type and mdx cells. If these experiments 
provided evidence of direct, dystrophin-dependent mechanical regulation of a particular subset 
of AMPK subunits, they could help establish a role for dystrophin and the DGC in the coupling of 
mechanosensation and metabolic regulation within striated muscle. 
  
ADMA and cardiac hypertrophy in DMD carriers. 
Increased circulating levels of asymmetric dimethylarginine have been correlated with 
cardiovascular disease and cardiac hypertrophy for some time(79, 80). However, since 
excessive ADMA inhibits endothelial cell nitric oxide production and can increase blood 
pressure(81, 82), it is difficult to know whether the association between ADMA levels and 
cardiac hypertrophy is a direct result of ADMA actions within the cardiomyocytes, or rather is  a 
secondary consequence of hypertension. As DDAH transgene expression was associated with 
reduced cardiac size and improved cardiac performance in dystrophin-heterozygous mdx carrier 
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mice in Chapter 4, a deeper understanding of the mechanisms by which ADMA affects cardiac 
function and remodeling could have important implications for attempts to mitigate the risk of 
cardiomyopathy in carriers of DMD mutations. A recent study reported elevated systolic blood 
pressure in Duchenne muscular dystrophy carriers who exhibit late gadolinium enhancement 
on cardiac MRI, indicative of increased cardiac fibrosis(83). This association between cardiac 
fibrosis and increased blood pressure could perhaps reflect increased angiotensin II signaling in 
DMD carriers(84), but an interesting alternative explanation is that the DMD carriers who 
present with the most cardiac fibrosis are those who have had the most focal cardiomyocyte 
damage and therefore the greatest release of methylated arginines from dying cells. This 
excessive methylated arginine release from the heart could impair NO production in the 
vascular endothelium and lead to elevated blood pressure that may exacerbate cardiac 
remodeling. It could also have direct effects on cardiac function by altering nitic oxide signaling 
within dystrophin-positive cardiomyocytes (Fig. 5.1C). 
The results presented in Chapter 4 support the notion that local methylated arginine 
signaling affects cardiac remodeling and heart function. However, whether excessive 
methylated arginine levels directly affect cardiomyocyte remodeling or contractile function, and 
the interplay between cellular remodeling and contractile function in vivo, remains unclear. The 
observation that ADMA can stimulate hypertrophic growth of cultured adipocytes(85) supports 
the idea that this compound may promote cardiac hypertrophy, even independent of effects on 
hemodynamic load. The hypothesis that local elevation of ADMA has direct effects on both 
hypertrophic remodeling and the contractile function of cardiomyocytes could be tested using 
in vitro approaches. For instance, isolated rat cardiomyocytes or human induced pluripotent 
stem cell-derived cardiomyocytes could be maintained in culture in media with or without 
exogenous ADMA, and after several days the cardiomyocyte size and protein content of these 
two groups could be compared. If these initial experiments suggested an effect of ADMA to 
promote cell hypertrophy, gene expression could be assessed using microarrays in order to 
identify candidate genes responsible for this effect. Furthermore, comparison of changes in 
gene expression between wild-type cardiomyocytes treated with ADMA versus alternative nitric 
oxide synthase inhibitors, or between ADMA-treated wild-type and ADMA-treated NOS-
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deficient cardiomyocytes, could help to distinguish any NO-dependent versus NO-independent 
effects of ADMA(86) on hypertrophic gene expression. To establish a causative role for any 
identified genes in ADMA-induced hypertrophy, candidate genes could be individually disrupted 
in cultured cells using the CRISPR/Cas9 system(87). The ability of sustained ADMA exposure to 
induce hypertrophy could then be compared in modified cells and unmodified controls. 
The contractile function of isolated cardiomyocytes treated acutely with ADMA in vitro 
could also be assessed using measurements of sarcomere shortening and calcium transients in 
electrically-stimulated cells(88). Such experiments could indicate whether ADMA has direct 
effects on cardiac function that are independent of changes in cardiac remodeling. Assessment 
of effects of acute ADMA exposure on mouse nNOS- or eNOS- knockout cardiomyocytes(89-91) 
in these studies could clarify whether any effects of ADMA on contractile function depend on 
its function as a NO synthase inhibitor, or might act through NO-independent mechanisms. 
 
DGC-dependent regulation of muscle nitric oxide production: therapeutic implications. 
 The restoration of NO/cGMP signaling in dystrophin-deficient striated muscle has 
received considerable attention as a therapeutic goal for the improvement of muscle blood 
flow during exercise, cardiac function, and exercise tolerance in Duchenne and Becker muscular 
dystrophy. Although phosphodiesterase 5 inhibition, currently the only pharmacologic strategy 
available for this purpose, yielded promising results in studies of mdx mice(17, 92), translation 
to human patients so far has had only limited success(93-96). The in vitro data presented in 
Chapters 2 and 3 of this thesis suggest that an alternative strategy, direct pharmacologic 
stimulation of AMPK activity, is effective at stimulating nNOS activity and boosting NO 
production in dystrophin-deficient striated muscle. This represents the first pharmacologic 
approach that has the potential to restore both the cGMP-dependent and cGMP-independent 
downstream effects of nNOS within dystrophic muscle. The demonstration that pharmacologic 
AMPK activation can stimulate NO production in dystrophin-deficient striated muscle also 
offers a new mechanistic explanation for how chronic treatment with AMPK activators 
improved muscle pathology in mdx mice in previous pre-clinical studies(97-99). Indeed, several 
of the improved phenotypes in these studies, including reduced muscle fiber damage and 
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improved force generation(97-99), could be explained by improved perfusion of the dystrophin-
deficient muscle with increased local NO signaling or by improved NO-dependent control of 
calcium handling within the muscle fibers(100-102). The in vivo experiments discussed in 
Chapter 3 further indicate that pharmacologic AMPK activation has acute beneficial effects on 
exercise capacity in the mdx mouse model of Duchenne muscular dystrophy. This work 
represents an important advance from earlier translational studies in which chronic AMPK 
activation showed little long-acting improvements in the exercise performance of dystrophin-
deficient animals(103). However, the overall model for the regulation of striated muscle NO 
production supported by the work in Chapters 2 and 4 of this thesis (Fig. 5.1) raises a puzzling 
question: if nNOS activity in dystrophin-deficient muscle is still subject to inhibition by elevated 
levels of endogenous methylated arginines, how does acute treatment with AICAR or salicylate 
improve exercise tolerance in dystrophin-deficient mice? 
 The discrepancy between the in vitro findings of Chapters 2 and 3 and the predictions of 
the model likely reflect the fact that in in vitro experiments, cardiomyocytes and skeletal 
muscle fibers are dissociated from neighboring cells and surrounded by a volume of media that 
is infinitely greater than that of the extracellular fluid immediately surrounding each cell in vivo. 
Thus, any methylated arginines released by damaged muscle cells in culture are likely diluted to 
a concentration much lower than in the microenvironment surrounding a necrotic cell in intact 
tissue. This would tend to minimize any inhibitory effect of methylated arginines on nNOS 
activity, allowing for AMPK-stimulated cellular NO production when dystrophin-deficient cells 
are treated with AICAR or salicylate in vitro. If correct, this reasoning would imply that a 
substantial component of the effect of acute pharmacologic AMPK activation on the exercise 
capacity of mdx mice is attributable to AMPK targets other than striated muscle nNOS, because 
nNOS would still be subject to inhibition by methylated arginines in intact dystrophin-deficient 
muscle. Generation of dystrophin-deficient mice lacking nNOS specifically within the heart and 
skeletal muscle would allow for direct testing of whether the beneficial effects of 
pharmacologic AMPK activation on exercise capacity require striated muscle nNOS activation. 
Interestingly, improved muscle blood flow may still contribute to the observed effects of AMPK 
activation on exercise, even independent of increased muscle nNOS activity, since eNOS is a 
144 
 
known AMPK target and has been shown to function in sympatholysis(14, 104). A contribution 
of vascular eNOS to sympatholysis may help to reconcile the reported benefits of PDE5 
inhibition on muscle blood flow and exercise tolerance in mdx mice and Duchenne/Becker 
muscular dystrophy patients and the effects of AMPK activation on exercise tolerance in mdx 
mice reported here with the proposed working model’s inhibition of muscle nNOS activity in 
dystrophin-deficient muscle. Thus, the findings of this thesis still support the therapeutic 
potential for acute AMPK activation to improve exercise tolerance in Duchenne muscular 
dystrophy, although it may ultimately do so through mechanisms independent of the 




 The ability for striated muscle to withstand the mechanical and metabolic stress of 
contraction requires endogenous mechanisms to protect the integrity of the sarcolemma, and 
to sense changes in mechanical activity and couple them to the regulation of local oxygen and 
nutrient delivery. Both of these mechanisms can be disrupted in muscular dystrophy, resulting 
in progressive loss of muscle cells as well as impaired vasoregulation within the muscle tissue. 
The goal of this thesis was to understand the mechanisms by which dystrophin and the 
dystrophin-glycoprotein complex, a structure that is essential for the maintenance of 
sarcolemmal integrity, regulate striated muscle nitric oxide production, a phenomenon that is 
critical for contraction-induced regulation of the muscle vasculature. 
The findings presented in this thesis demonstrate that dystrophin expression is required 
for the normal mechanical activation of AMPK and nNOS within cardiomyocytes, and that direct 
pharmacologic stimulation of AMPK activity can rescue nitric oxide production in dystrophin-
deficient striated muscle cells in vitro and improve exercise tolerance in dystrophin-deficient 
mice. Additional work suggests that methylated arginines released following sarcolemmal injury 
of dystrophin-deficient muscle cells also impair muscle nNOS activity, an effect whose 
functional consequences are best appreciated in muscle with mosaic dystrophin expression. 
Collectively, these findings support a model in which both the structural and signaling functions 
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of the DGC are indispensable for the normal mechanical regulation of striated muscle NO 
production. As nitric oxide production is critical for the contractile function of the striated 
muscle and is necessary for its functional adaptations to increased work demands during 
exercise, the model proposed here will be useful in guiding the development of new therapies 













Figure 5.1. Proposed model integrating the signaling and structural functions of the 
dystrophin-glycoprotein complex in the mechanical regulation of striated muscle nitric oxide 
production. (A) In wild-type striated muscle, the dystrophin-glycoprotein complex is intact 
(indicated by filled text) and maintains the structural integrity of the sarcolemma while also 
mediating the mechanical activation of AMPK-nNOS signaling that allows cells to respond to 
mechanical stress with an increase in nitric oxide (NO) production. (B) In dystrophin-deficient 
muscle, the DGC is disrupted (indicated by open text). This results in loss of DGC-dependent 
mechanoactivation of AMPK and subsequent loss of the ability for cells to increase nNOS 
activity in response to mechanical stress. DGC disruption also results in sarcolemmal instability, 
leading to increased injury of the muscle cells under periods of mechanical stress, and the 
release of methylated arginines such as ADMA from necrotic muscle cells. Locally-elevated 
concentrations of methylated arginines can further inhibit nNOS activity within the muscle cells, 
distinct from disruptions in AMPK signaling. (C) In muscle displaying mosaic dystrophin 
expression, both dystrophin-deficient and dystrophin-positive cells exist side by side. In this 
instance, methylated arginines released from damaged, dystrophin-deficient cells may inhibit 
nNOS activity in neighboring dystrophin-positive cells, even though DGC-dependent 
mechanoregulation of AMPK remains intact within this population. Inhibitory effects of 
methylated arginines released by necrotic muscle cells may be spatially confined and have little 
influence on NO production in distant dystrophin-positive cells. While this model is largely 
informed by experiments conducted in cardiac muscle, it may hold true for the regulation of NO 






Figure 5.2. Regulation and subunit expression of AMPK in striated muscle. AMPK is subject to 
multiple layers of regulation by kinases, phosphatases, reactive oxygen species (ROS), allosteric 
regulators, and components of the cytoskeleton. Arrows depict the subunit at which regulators 
exert their effects, with pointed arrowheads representing regulation that stimulates AMPK 
enzymatic activity, and blunt arrowheads representing regulation that inhibits AMPK activity. 
Phosphorylation at AMPKα-Thr172 increases kinase activity(53-57), and allosteric activators 
such as AMP and ADP induce conformational changes that are translated to the alpha subunit, 
protecting this site from dephosphorylation by phosphatases(105). Phosphorylation at AMPKα-
Thr479 or AMPKα-Ser485 or the binding of allosteric inhibitors such as glycogen increases the 
accessibility of Thr172 to phosphatases, resulting in decreased AMPK activity(65, 66, 69). 
Oxidation of AMPKα-Cys130/174 causes aggregation of AMPK that prevents stimulatory 
phosphorylation of Thr172(68). Possible crosstalk between these different regulatory 
mechanisms is highlighted with grey arrows. ATP can also inhibit AMPK activity by competing 
with AMP and ADP for binding to regulatory Bateman domains in the gamma subunit(106). The 
cytoskeletal protein plectin binds to AMPKγ subunits and attenuates maximal nucleotide-
sensitive AMPK catalytic activity by selectively stabilizing the expression of α1 subunits over α2 
subunits(72). Any direct role for dystrophin or the dystrophin-glycoprotein complex (DGC) in 
regulating AMPK activity or subunit expression remains to be determined. Potential 
mechanisms by which dystrophin or the DGC may affect established AMPK-regulatory pathways 
to control the mechanical activation of AMPK are discussed in the text. The unique array of 
AMPK subunits that are expressed in cardiac and in skeletal muscle(105, 107) raises the 






1. Meryon E (1852) On Granular and Fatty Degeneration of the Voluntary Muscles. Medico-
chirurgical transactions 35:73-84 71. 
2. Duchenne de Boulogne G-B-A (1867) The Pathology Of Paralysis With Muscular 
Degeneration (Paralysie Myosclerotique), Or Paralysis With Apparent Hypertrophy. The 
British Medical Journal 2(363):541-542. 
3. Kanagawa M & Toda T (2006) The genetic and molecular basis of muscular dystrophy: 
roles of cell-matrix linkage in the pathogenesis. Journal of human genetics 51(11):915-
926. 
4. Brenman JE, Chao DS, Xia H, Aldape K, & Bredt DS (1995) Nitric oxide synthase 
complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne 
muscular dystrophy. Cell 82(5):743-752. 
5. Chang WJ, et al. (1996) Neuronal nitric oxide synthase and dystrophin-deficient 
muscular dystrophy. Proceedings of the National Academy of Sciences of the United 
States of America 93(17):9142-9147. 
6. Chao DS, et al. (1996) Selective loss of sarcolemmal nitric oxide synthase in Becker 
muscular dystrophy. The Journal of experimental medicine 184(2):609-618. 
7. Cohn RD, et al. (2002) Disruption of DAG1 in differentiated skeletal muscle reveals a role 
for dystroglycan in muscle regeneration. Cell 110(5):639-648. 
8. Crosbie RH, Barresi R, & Campbell KP (2002) Loss of sarcolemma nNOS in sarcoglycan-
deficient muscle. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 16(13):1786-1791. 
9. Kameya S, et al. (1999) alpha1-syntrophin gene disruption results in the absence of 
neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle 
degeneration. The Journal of biological chemistry 274(4):2193-2200. 
10. Grady RM, et al. (1999) Role for alpha-dystrobrevin in the pathogenesis of dystrophin-
dependent muscular dystrophies. Nature cell biology 1(4):215-220. 
11. Thomas GD, et al. (1998) Impaired metabolic modulation of alpha-adrenergic 
vasoconstriction in dystrophin-deficient skeletal muscle. Proceedings of the National 
Academy of Sciences of the United States of America 95(25):15090-15095. 
12. Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, & Adams ME (2003) Vasomodulation 
by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal 
localization of neuronal Nitric oxide synthase. Circulation research 92(5):554-560. 
13. Thomas GD & Victor RG (1998) Nitric oxide mediates contraction-induced attenuation of 
sympathetic vasoconstriction in rat skeletal muscle. The Journal of physiology 506 ( Pt 
3):817-826. 
14. Jendzjowsky NG & DeLorey DS (2013) Role of neuronal nitric oxide in the inhibition of 
sympathetic vasoconstriction in resting and contracting skeletal muscle of healthy rats. 
Journal of applied physiology 115(1):97-106. 
15. Yasmineh WG, Ibrahim GA, Abbasnezhad M, & Awad EA (1978) Isoenzyme distribution 
of creatine kinase and lactate dehydrogenase in serum and skeletal muscle in Duchenne 




16. Hathout Y, et al. (2015) Large-scale serum protein biomarker discovery in Duchenne 
muscular dystrophy. Proceedings of the National Academy of Sciences of the United 
States of America 112(23):7153-7158. 
17. Kobayashi YM, et al. (2008) Sarcolemma-localized nNOS is required to maintain activity 
after mild exercise. Nature 456(7221):511-515. 
18. Inoue R, Miyake M, Kanazawa A, Sato M, & Kakimoto Y (1979) Decrease of 3-
methylhistidine and increase of NG,NG-dimethylarginine in the urine of patients with 
muscular dystrophy. Metabolism 28(8):801-804. 
19. Lou MF (1979) Human muscular dystrophy: elevation of urinary dimethylarginines. 
Science 203(4381):668-670. 
20. Hack AA, et al. (1999) Muscle degeneration without mechanical injury in sarcoglycan 
deficiency. Proceedings of the National Academy of Sciences of the United States of 
America 96(19):10723-10728. 
21. Kumar A, Khandelwal N, Malya R, Reid MB, & Boriek AM (2004) Loss of dystrophin 
causes aberrant mechanotransduction in skeletal muscle fibers. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 18(1):102-
113. 
22. Teichmann MD, et al. (2008) Inhibitory control over Ca(2+) sparks via mechanosensitive 
channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin 
expression. PloS one 3(11):e3644. 
23. Dogra C, Changotra H, Wergedal JE, & Kumar A (2006) Regulation of 
phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways 
in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 
208(3):575-585. 
24. Vandebrouck A, et al. (2007) Regulation of capacitative calcium entries by alpha1-
syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of 
alpha1-syntrophin. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 21(2):608-617. 
25. Sabourin J, et al. (2009) Regulation of TRPC1 and TRPC4 cation channels requires an 
alpha1-syntrophin-dependent complex in skeletal mouse myotubes. The Journal of 
biological chemistry 284(52):36248-36261. 
26. Spence HJ, Dhillon AS, James M, & Winder SJ (2004) Dystroglycan, a scaffold for the ERK-
MAP kinase cascade. EMBO Rep 5(5):484-489. 
27. Spinazzola JM, Smith TC, Liu M, Luna EJ, & Barton ER (2015) Gamma-sarcoglycan is 
required for the response of archvillin to mechanical stimulation in skeletal muscle. 
Human molecular genetics 24(9):2470-2481. 
28. Russo K, et al. (2000) Characterization of the beta-dystroglycan-growth factor receptor 2 
(Grb2) interaction. Biochemical and biophysical research communications 274(1):93-98. 
29. Oak SA, Zhou YW, & Jarrett HW (2003) Skeletal muscle signaling pathway through the 
dystrophin glycoprotein complex and Rac1. The Journal of biological chemistry 
278(41):39287-39295. 
30. Zhou YW, Oak SA, Senogles SE, & Jarrett HW (2005) Laminin-alpha1 globular domains 3 
and 4 induce heterotrimeric G protein binding to alpha-syntrophin's PDZ domain and 
alter intracellular Ca2+ in muscle. Am J Physiol Cell Physiol 288(2):C377-388. 
150 
 
31. Okumura A, Nagai K, & Okumura N (2008) Interaction of alpha1-syntrophin with 
multiple isoforms of heterotrimeric G protein alpha subunits. FEBS J 275(1):22-33. 
32. Chen ZP, et al. (2000) AMPK signaling in contracting human skeletal muscle: acetyl-CoA 
carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 
279(5):E1202-1206. 
33. Thomas MM, et al. (2014) Muscle-specific AMPK beta1beta2-null mice display a 
myopathy due to loss of capillary density in nonpostural muscles. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 28(5):2098-
2107. 
34. Lira VA, et al. (2010) Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal 
muscle cells. The Journal of physiology 588(Pt 18):3551-3566. 
35. Yeung EW, Head SI, & Allen DG (2003) Gadolinium reduces short-term stretch-induced 
muscle damage in isolated mdx mouse muscle fibres. The Journal of physiology 552(Pt 
2):449-458. 
36. Yasuda S, et al. (2005) Dystrophic heart failure blocked by membrane sealant 
poloxamer. Nature 436(7053):1025-1029. 
37. Bedford MT & Clarke SG (2009) Protein arginine methylation in mammals: who, what, 
and why. Molecular cell 33(1):1-13. 
38. Wehling M, Spencer MJ, & Tidball JG (2001) A nitric oxide synthase transgene 
ameliorates muscular dystrophy in mdx mice. The Journal of cell biology 155(1):123-131. 
39. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, & Tidball JG (2005) Cardiomyopathy 
in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide 
synthase transgene in the myocardium. Human molecular genetics 14(14):1921-1933. 
40. Sienkiewicz D, Kulak W, Okurowska-Zawada B, Paszko-Patej G, & Kawnik K (2015) 
Duchenne muscular dystrophy: current cell therapies. Therapeutic advances in 
neurological disorders 8(4):166-177. 
41. Echigoya Y, et al. (2015) Long-term efficacy of systemic multiexon skipping targeting 
dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Molecular 
therapy. Nucleic acids 4:e225. 
42. Harper SQ, et al. (2002) Modular flexibility of dystrophin: implications for gene therapy 
of Duchenne muscular dystrophy. Nature medicine 8(3):253-261. 
43. Park J, Wicki J, Knoblaugh SE, Chamberlain JS, & Lee D (2015) Multi-parametric MRI at 
14T for muscular dystrophy mice treated with AAV vector-mediated gene therapy. PloS 
one 10(4):e0124914. 
44. Xu L, et al. (2016) CRISPR-mediated Genome Editing Restores Dystrophin Expression and 
Function in mdx Mice. Molecular therapy : the journal of the American Society of Gene 
Therapy 24(3):564-569. 
45. Stillwell E, et al. (2009) Blastocyst injection of wild type embryonic stem cells induces 
global corrections in mdx mice. PloS one 4(3):e4759. 
46. Li X, et al. (2015) Structural basis of AMPK regulation by adenine nucleotides and 
glycogen. Cell research 25(1):50-66. 




48. Xiao B, et al. (2011) Structure of mammalian AMPK and its regulation by ADP. Nature 
472(7342):230-233. 
49. Coven DL, et al. (2003) Physiological role of AMP-activated protein kinase in the heart: 
graded activation during exercise. Am J Physiol Endocrinol Metab 285(3):E629-636. 
50. Hao J, et al. (2010) Mechanical Stretch-Induced Protection against Myocardial Ischemia-
Reperfusion Injury Involves AMP-Activated Protein Kinase. Korean J Physiol Pharmacol 
14(1):1-9. 
51. Nakai N, Kawano F, & Nakata K (2015) Mechanical stretch activates mammalian target 
of rapamycin and AMP-activated protein kinase pathways in skeletal muscle cells. 
Molecular and cellular biochemistry 406(1-2):285-292. 
52. Budinger GR, et al. (2008) Stretch-induced activation of AMP kinase in the lung requires 
dystroglycan. Am J Respir Cell Mol Biol 39(6):666-672. 
53. Hawley SA, et al. (2003) Complexes between the LKB1 tumor suppressor, STRAD 
alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein 
kinase cascade. Journal of biology 2(4):28. 
54. Woods A, et al. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase 
cascade. Current biology : CB 13(22):2004-2008. 
55. Hawley SA, et al. (2005) Calmodulin-dependent protein kinase kinase-beta is an 
alternative upstream kinase for AMP-activated protein kinase. Cell metabolism 2(1):9-
19. 
56. Hurley RL, et al. (2005) The Ca2+/calmodulin-dependent protein kinase kinases are 
AMP-activated protein kinase kinases. The Journal of biological chemistry 
280(32):29060-29066. 
57. Woods A, et al. (2005) Ca2+/calmodulin-dependent protein kinase kinase-beta acts 
upstream of AMP-activated protein kinase in mammalian cells. Cell metabolism 2(1):21-
33. 
58. Prosser BL, Ward CW, & Lederer WJ (2011) X-ROS signaling: rapid mechano-chemo 
transduction in heart. Science 333(6048):1440-1445. 
59. Khairallah RJ, et al. (2012) Microtubules underlie dysfunction in duchenne muscular 
dystrophy. Sci Signal 5(236):ra56. 
60. Prosser BL, Ward CW, & Lederer WJ (2013) X-ROS signalling is enhanced and graded by 
cyclic cardiomyocyte stretch. Cardiovascular research 98(2):307-314. 
61. Park S, Scheffler TL, Rossie SS, & Gerrard DE (2013) AMPK activity is regulated by 
calcium-mediated protein phosphatase 2A activity. Cell calcium 53(3):217-223. 
62. Ingebritsen TS, Stewart AA, & Cohen P (1983) The protein phosphatases involved in 
cellular regulation. 6. Measurement of type-1 and type-2 protein phosphatases in 
extracts of mammalian tissues; an assessment of their physiological roles. European 
journal of biochemistry 132(2):297-307. 
63. Ruiz A, Xu X, & Carlson M (2013) Ptc1 protein phosphatase 2C contributes to glucose 
regulation of SNF1/AMP-activated protein kinase (AMPK) in Saccharomyces cerevisiae. 
The Journal of biological chemistry 288(43):31052-31058. 
64. Allen DG, Gervasio OL, Yeung EW, & Whitehead NP (2010) Calcium and the damage 




65. Suzuki T, et al. (2013) Inhibition of AMPK catabolic action by GSK3. Molecular cell 
50(3):407-419. 
66. Horman S, et al. (2006) Insulin antagonizes ischemia-induced Thr172 phosphorylation of 
AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of 
Ser485/491. The Journal of biological chemistry 281(9):5335-5340. 
67. Ushio-Fukai M, et al. (1999) Reactive oxygen species mediate the activation of 
Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. The Journal of 
biological chemistry 274(32):22699-22704. 
68. Shao D, et al. (2014) A redox-dependent mechanism for regulation of AMPK activation 
by Thioredoxin1 during energy starvation. Cell metabolism 19(2):232-245. 
69. McBride A, Ghilagaber S, Nikolaev A, & Hardie DG (2009) The glycogen-binding domain 
on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell metabolism 
9(1):23-34. 
70. Stapleton DI, et al. (2014) Dysfunctional muscle and liver glycogen metabolism in mdx 
dystrophic mice. PloS one 9(3):e91514. 
71. Rose MR, et al. (1993) A case of myopathy associated with a dystrophin gene deletion 
and abnormal glycogen storage. Muscle & nerve 16(1):57-62. 
72. Gregor M, et al. (2006) Plectin scaffolds recruit energy-controlling AMP-activated 
protein kinase (AMPK) in differentiated myofibres. Journal of cell science 119(Pt 9):1864-
1875. 
73. Schroder R, et al. (1997) Altered distribution of plectin/HD1 in dystrophinopathies. 
European journal of cell biology 74(2):165-171. 
74. Rezniczek GA, et al. (2007) Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) 
muscle fibers through multiple interactions with beta-dystroglycan. The Journal of cell 
biology 176(7):965-977. 
75. Markham LW, et al. (2017) GRMD cardiac and skeletal muscle metabolism gene profiles 
are distinct. BMC medical genomics 10(1):21. 
76. Jensen TE, et al. (2014) Contraction-stimulated glucose transport in muscle is controlled 
by AMPK and mechanical stress but not sarcoplasmatic reticulum Ca(2+) release. 
Molecular metabolism 3(7):742-753. 
77. Scott JW, et al. (2004) CBS domains form energy-sensing modules whose binding of 
adenosine ligands is disrupted by disease mutations. The Journal of clinical investigation 
113(2):274-284. 
78. Barnes BR, et al. (2004) The 5'-AMP-activated protein kinase gamma3 isoform has a key 
role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. The Journal of 
biological chemistry 279(37):38441-38447. 
79. Sibal L, Agarwal SC, Home PD, & Boger RH (2010) The Role of Asymmetric 
Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr 
Cardiol Rev 6(2):82-90. 
80. Nemeth Z, et al. (2015) Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the 
Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. PloS one 
10(8):e0135498. 
81. Dayoub H, et al. (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide 
synthesis: genetic and physiological evidence. Circulation 108(24):3042-3047. 
153 
 
82. Achan V, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac 
dysfunction in humans and is actively metabolized by dimethylarginine 
dimethylaminohydrolase. Arteriosclerosis, thrombosis, and vascular biology 23(8):1455-
1459. 
83. Wexberg P, et al. (2016) Myocardial late gadolinium enhancement is associated with 
clinical presentation in Duchenne muscular dystrophy carriers. Journal of cardiovascular 
magnetic resonance : official journal of the Society for Cardiovascular Magnetic 
Resonance 18(1):61. 
84. Xu J, et al. (2010) Local angiotensin II aggravates cardiac remodeling in hypertension. 
American journal of physiology. Heart and circulatory physiology 299(5):H1328-1338. 
85. Dowsett LB, Boruc O, Lee B, & Leiper J (2014) Abstract 600: Asymmetric 
Dimethylarginine is a Novel Regulator of mTOR Expression in Adipocytes. 
Arteriosclerosis, thrombosis, and vascular biology 34(Suppl 1):A600-A600. 
86. Smith CL, Anthony S, Hubank M, Leiper JM, & Vallance P (2005) Effects of ADMA upon 
gene expression: an insight into the pathophysiological significance of raised plasma 
ADMA. PLoS Med 2(10):e264. 
87. Carroll KJ, et al. (2016) A mouse model for adult cardiac-specific gene deletion with 
CRISPR/Cas9. Proceedings of the National Academy of Sciences of the United States of 
America 113(2):338-343. 
88. Lang SE, et al. (2013) Myofilament incorporation and contractile function after gene 
transfer of cardiac troponin I Ser43/45Ala. Archives of biochemistry and biophysics 
535(1):49-55. 
89. Huang PL, Dawson TM, Bredt DS, Snyder SH, & Fishman MC (1993) Targeted disruption 
of the neuronal nitric oxide synthase gene. Cell 75(7):1273-1286. 
90. Gyurko R, Leupen S, & Huang PL (2002) Deletion of exon 6 of the neuronal nitric oxide 
synthase gene in mice results in hypogonadism and infertility. Endocrinology 
143(7):2767-2774. 
91. Shesely EG, et al. (1996) Elevated blood pressures in mice lacking endothelial nitric oxide 
synthase. Proceedings of the National Academy of Sciences of the United States of 
America 93(23):13176-13181. 
92. Adamo CM, et al. (2010) Sildenafil reverses cardiac dysfunction in the mdx mouse model 
of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of 
the United States of America 107(44):19079-19083. 
93. Witting N, et al. (2014) Effect of sildenafil on skeletal and cardiac muscle in Becker 
muscular dystrophy. Ann Neurol 76(4):550-557. 
94. Nelson MD, et al. (2014) PDE5 inhibition alleviates functional muscle ischemia in boys 
with Duchenne muscular dystrophy. Neurology 82(23):2085-2091. 
95. Leung DG, et al. (2014) Sildenafil does not improve cardiomyopathy in Duchenne/Becker 
muscular dystrophy. Ann Neurol 76(4):541-549. 
96. Martin EA, et al. (2012) Tadalafil alleviates muscle ischemia in patients with Becker 
muscular dystrophy. Sci Transl Med 4(162):162ra155. 
97. Ljubicic V, et al. (2011) Chronic AMPK activation evokes the slow, oxidative myogenic 
program and triggers beneficial adaptations in mdx mouse skeletal muscle. Human 
molecular genetics 20(17):3478-3493. 
154 
 
98. Pauly M, et al. (2012) AMPK activation stimulates autophagy and ameliorates muscular 
dystrophy in the mdx mouse diaphragm. The American journal of pathology 181(2):583-
592. 
99. Jahnke VE, et al. (2012) Metabolic remodeling agents show beneficial effects in the 
dystrophin-deficient mdx mouse model. Skelet Muscle 2(1):16. 
100. Thomas GD (2013) Functional muscle ischemia in Duchenne and Becker muscular 
dystrophy. Front Physiol 4:381. 
101. Percival JM, Anderson KN, Huang P, Adams ME, & Froehner SC (2010) Golgi and 
sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and 
vasoconstriction in exercising mouse skeletal muscle. The Journal of clinical investigation 
120(3):816-826. 
102. Stoyanovsky D, Murphy T, Anno PR, Kim YM, & Salama G (1997) Nitric oxide activates 
skeletal and cardiac ryanodine receptors. Cell calcium 21(1):19-29. 
103. Ljubicic V, Khogali S, Renaud JM, & Jasmin BJ (2012) Chronic AMPK stimulation 
attenuates adaptive signaling in dystrophic skeletal muscle. Am J Physiol Cell Physiol 
302(1):C110-121. 
104. Chen ZP, et al. (1999) AMP-activated protein kinase phosphorylation of endothelial NO 
synthase. FEBS Lett 443(3):285-289. 
105. Viollet B, et al. (2010) AMPK inhibition in health and disease. Critical reviews in 
biochemistry and molecular biology 45(4):276-295. 
106. Corton JM, Gillespie JG, Hawley SA, & Hardie DG (1995) 5-aminoimidazole-4-
carboxamide ribonucleoside. A specific method for activating AMP-activated protein 
kinase in intact cells? European journal of biochemistry 229(2):558-565. 
107. Arad M, Seidman CE, & Seidman JG (2007) AMP-activated protein kinase in the heart: 
role during health and disease. Circulation research 100(4):474-488. 
 
